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ABSTRACT 
Background: Colorado became the first state to legalize and implement recreational cannabis 
sales in the United States. Research is needed to understand the public health implications of 
recreational cannabis legalization as other state follow suit. Emergency department (ED) visit 
data and cannabis diagnosis coding provide an opportunity to track the impacts of these policy 
changes. We aimed to characterize the performance of cannabis diagnosis codes in predicting 
ED visits attributed to cannabis. 
Methods: This study used one year of ED visit from the University of Colorado Hospital to 
perform three analyses characterizing the performance of cannabis diagnostic codes. First, 
positive predictive values (PPVs) for the codes were calculated. Second, supporting data to 
improve PPVs were explored. Finally, a novel text mining and prioritization approach was used 
to review ED visit without cannabis diagnosis codes for cannabis attribution and the negative 
predictive value was calculated. 
Results: Cannabis poisoning or intoxication diagnosis codes predicted ED visits attributable to 
cannabis well (PPV=89%), but were rare (14.4%). Cannabis abuse and use diagnosis codes 
were more common (94.4%) but performed poorly in predicting ED visits attributed to cannabis 
(PPVs: 31%-45%). Supporting information like coding position, absence of other substance 
codes, and presence of cannabis-related outcome codes improved PPVs. Cannabis codes 
missed approximately one third (38.1%) of ED visits attributed to cannabis and the negative 
predictive value for cannabis codes was 99.4%. 
Conclusions: Cannabis diagnosis codes alone may not be ideal for measuring true numbers of 
ED visits attributable to cannabis, but could be used to measure trends in ED visits attributed to 
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cannabis over time. These studies provide the first comprehensive characterization of the 
performance of cannabis diagnostic codes. This work is the foundation for future development 
of a standardized administrative case definition for ED visits attributed to cannabis use. 
The form and content of this abstract are approved. I recommend its publication.  
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CHAPTER I:  
INTRODUCTION 
Background and Significance 
Colorado became the first state to legalize and implement recreational cannabis sales in 
the United States after a thirteen year history of medical cannabis legalization.1–3 Research is 
needed to understand the public health implications of recreational cannabis legalization. It is 
unclear if these policy changes will lead to an increase in adverse health events like cannabis 
poisonings. Emergency department (ED) visit data provide a data source for tracking the impact 
of policy changes; however, public health officials and researchers are challenged by the lack of 
funding for cannabis research as well as no standardized method for surveillance of cannabis 
adverse health events. Our study will aid in providing performance measures of cannabis 
diagnostic codes. These measures can inform the future development of a standardized case 
definition for surveillance of ED visits attributable to cannabis to measure the public health 
impact of cannabis legalization.  
Current State of Cannabis Legalization and Access in Colorado 
Colorado legalized the use of cannabis for specific medical conditions in 2000.1 At this 
time legal access to cannabis required a registered medical marijuana card for patients whose 
doctors recommended the use of cannabis for debilitating conditions. Patients or caregivers 
were allowed to possess up to two ounces of cannabis or grow up to six plants.4 In October 
2009, the Ogden Memorandum assured states that federal resources would not be used on 
individuals in compliance with state laws on the medical use of cannabis.5 This allowed for the 
development of medical cannabis dispensaries operating as caregivers. In response to the 
Ogden memo the Colorado General Assembly created the structure for a medical cannabis 
market with HB 10-1284.2,4 In 2012, Colorado and Washington were the first states to legalize 
recreational cannabis.3,6 Colorado became the first state to allow legalized recreational sales of 
cannabis in January 2014.7 This began the development of a booming and diverse recreational 
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cannabis industry in Colorado where sales in 2016 topped $1 billion and have continue to rise 
each year with $1,747,990,628 sold in 2019.8–10 As of December 2019, the Marijuana 
Enforcement Division reported 1,147 licensed medical cannabis businesses and 1,562 licensed 
adult use (retail) cannabis establishments in the state of Colorado. Also by the end of 2019, 
350,429 pounds of cannabis flower/bud, 14,313,361 units of edibles, and 1,137,349 units of 
non-edibles were sold in Colorado (Figure 1).9,11,12 The amount of cannabis products sold is of 
public health concern as it is an indicator of the true exposure or use of cannabis in Colorado.  
Figure 1. Cannabis salesa in Colorado 2014-2019. 
 
aSales data collected by the Colorado Department of Revenue Marijuana Enforcement Division (MED). 
 
Current State of Cannabis Use in Colorado 
In 2009, the National Survey on Drug Use and Health (NSDUH) estimated past 30 day 
cannabis use at 9.72% of Colorado adults compared to 6.33% in the US.13,14 After one year of 
full legalization, in 2015 NSDUH estimated 17.12% of Colorado adults used cannabis in the past 
30 days. This was a significant increase compared to the 2009 estimate (p<0.0001) (Figure 
2).13–15 NSDUH is the only available data source for Colorado estimates of adult cannabis use 
prior to the legalization of recreational cannabis. Colorado began collecting adult cannabis use 












































System (BRFSS).16 BRFSS reported past 30 day adult cannabis use to be 13.6% (95% CI: 
12.4%, 14.8%) in 2014 and 13.4% (95% CI: 12.3%, 14.5%) in 2015 (Figure 2).16,17 Reported 
past 30 day adult cannabis use remained stable until 2017 when it significantly increased from 
13.6% (95% CI: 12.7%, 14.5%) in 2016 to 15.5% (95% CI: 14.4%,16.5%) (p=0.0096) in 2017. In 
2018 reported past 30 day adult cannabis use increased again to 17.5% (95% CI: 16.4%, 
18.7%) (Figure 2).16 In 2017, BRFSS indicated that among adults that reported past 30 day 
cannabis use, 49.4% (95% CI: 45.6%, 53.3%) reported daily to near daily (20-30 days in the 
past 30 days) cannabis use, 50.0% (95% CI: 46.2%, 53.8%) reported using multiple methods of 
cannabis (smoking, vaping, eating, or dabbing), and 38.7% (95% CI: 35.0%, 42.4%) reported 
only smoking in the past 30 days.16,18 The trends observed in the cannabis use data along with 
the cannabis sales indicate a possible increase in cannabis consumption in the Colorado 
population which could lead to increases in cannabis adverse health effects among Coloradans. 
Figure 2. Adult (18+ years) past 30 day cannabis use in Colorado compared to national 
estimates. 
 
Unintentional Consequences of Cannabis Legalization in Colorado 
Most non-fatal adverse health events result in emergency department (ED) visits or 
























trends in adverse health events. Specifically, the International Classification of Diseases, 9th or 
10th Revision, Clinical Modification (ICD-9/10-CM) coding system allows for the standardization 
of adverse health events within administrative discharge data. In Colorado, after the legalization 
of medical cannabis in 2001, increases in healthcare encounters from pediatric unintentional 
cannabis poisonings and unintentional cannabis exposures reported to the poison center were 
documented.19–21 These trends have continued in increases in childhood cannabis exposures 
reported to the poison control center and hospitalizations or ED visits with cannabis discharge 
coding after the legalization of recreational marijuana.18,22,23 Additionally, new unintentional 
consequences like deaths caused by overdose with cannabis infused edible products have 
emerged.24  
The rate of hospitalizations with at least one cannabis ICD-9/10-CM code has increased 
since the legalization of medical cannabis with the highest rate in 2016 at 3,517 per 100,000 
hospitalizations (Figure 3). That year there were 16,669 (3.5%) hospitalizations with cannabis 
abuse, dependence, or use discharge codes and 238 (0.05%) hospitalizations with cannabis 
poisoning codes. ED visits followed a similar trend, where the highest rate of ED visits with at 
least one cannabis ICD-9/10-CM code was in 2017 at 1,139 per 100,000 ED visits. That year 
there were 21,010 (1.1%) ED visits with cannabis abuse, dependence, or use discharge codes 
and 756 (0.04%) ED visits with cannabis poisoning codes (Figure 3).17,18 When examined by 
age categories in 2017 the rates of ED visits and hospitalizations with cannabis discharge codes 
were higher in young adults aged 18-25 at 2,352 and 9,852 per 100,000 ED visits and 
hospitalizations respectively. This age group also had the highest rate of ED visits and 
hospitalizations with cannabis poisoning codes in 2017 at 80 and 110 per 100,000 ED visits and 
hospitalizations respectively.18,25 
The Colorado Child Health Survey estimated in 2017 that 11.2% (95% CI: 8.2%-14.3%) 
of homes with children ages 1-14 had cannabis stored in the home. This was significantly higher 
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than 2014 where it was estimated 6.9% (95% CI: 4.9%-8.9%) of homes with children had 
cannabis stored in the home (p=0.0178). Along with increases of cannabis in homes with  
Figure 3. Rate of hospitalizations and emergency department visits with cannabis codes 
in Colorado by type of cannabis codes.  
 
 
a Cannabis ICD-9/10-CM codes included: E854.1, 969.6, 305.2, 304.3, F12, and T40.7 
b Cannabis poisoning ICD-9/10-CM codes included: E854.1, 969.6, and T40.7 
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children, there were increases in potentially unsafe storage of cannabis in the home from an 
estimated 14.0% (95% CI: 4.4%-23.6%) of Colorado homes with children in 2014 to 22.4% 
(95% CI:10.1%-34.7%) of Colorado homes with children in 2017; however, this increase 
was not statistically significant. Based on this survey, it was approximated that in 2017 in 
Colorado there were 23,009 homes with children under the age of 14 in which cannabis was 
stored unsafely.18,26  
The number of reported cannabis exposures to the poison center has been stable from 
2014 to 2018 ranging from 222 to 265 reports. However, in children ages 0 to 8 years old the 
number of calls has increased each year since 2012 with 89 reported cannabis exposures in 
2018. Also, there were more reported cannabis exposures in children 0-8 in 2018 than any other 
age category. Most exposures in children were unintentional (N=88, 98.9%), involved only 
cannabis (N=80, 89.9%), and were from cannabis edible products (N=54, 60.7%). Reported 
edible cannabis exposures in children increased from 25 in 2015 to 54 in 2018.18,27 
These unintentional consequences of cannabis legalization make monitoring adverse 
health events related to cannabis within ED visits a public health necessity. 
Health Concerns of Cannabis Use 
The literature supports associations with cannabis and mental health disorders such as 
acute psychotic symptoms, depression, and impaired memory as well as respiratory disorders 
similar to tobacco smoking such as chronic bronchitis, precancerous airway lesions, and 
cardiovascular disease.28–46 Cannabis use in adolescents has been linked with increased 
addiction to other substances such as alcohol, tobacco, and other illicit substances as well as 
impaired cognitive abilities and decreased academic performance.39,47–74 Furthermore, 
decreased growth, cognitive functioning, academic abilities, and attention deficit disorders have 
been described in children of mothers who use cannabis during pregnancy.75–85 The trends in 
cannabis use coupled with outcomes associated with cannabis use raise concern for both the 
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short- and long-term consequences of recreational cannabis legalization on the health of 
Coloradans.  
Need for Standardization of Cannabis Surveillance 
State public health departments are encouraged by the Centers for Disease Control 
(CDC), Safe States, and Council of State and Territorial Epidemiologist (CSTE) to conduct 
regular surveillance of drug poisonings and overdoses within administrative emergency 
department and hospital data in order to identify trends early.86,87 In 2016 the CSTE Cross 
Cutting committee identified four key challenges that public health was facing in states with 
legalized cannabis: 1) Lack of funding for research and surveillance surrounding cannabis use, 
2) Lack of standard methods and coordination of data collection in states and jurisdictions that 
have embarked on enhanced cannabis surveillance related to legalization, 3) Lack of uniform 
guidance for data analysis and reporting and 4) Lack of research on cannabis-related health 
outcomes.87 These challenges become particularly concerning considering the documented 
unintentional consequences of cannabis legalization, amounts of cannabis products being 
consumed, and the health outcomes associated with short- and long-term cannabis use. In a 
resource-limited setting ED visit data provide a population level data source to monitor 
unintentional consequences of cannabis legalization that most state health departments already 
monitor for other outcomes.88,89 However, to date there is no standardized case definition for ED 
visits attributed to cannabis. Currently there are ICD code based case definitions for overall 
drugs, opioids, cocaine, or alcohol poisonings and are monitored within state ED visit and 
hospitalization surveillance systems nationwide.86,90–92 ICD code based case definitions for 
opioids have been validated with up to 84% sensitivity within ED visit data.90,93,94 The challenge 
with developing an ICD code based cannabis case definition has largely been due to the 
structure of the ICD-9-CM discharge diagnosis coding system. ICD-9-CM discharge diagnosis 
codes indicating cannabis poisoning could not be separated from psychodysleptics which 
includes cannabis derivatives, lysergide (LSD), marijuana (derivatives), mescaline, psilocin, and 
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psilocybin.95,96 However, the ICD-10-CM coding system mitigates this challenge by expanding 
the cannabis codes within ICD-9-CM. This expansion separated cannabis from 
psychodysleptics within ICD-9-CM into codes specific to cannabis poisonings within ICD-10-CM. 
Furthermore, ICD-10-CM specifies codes for cannabis poisonings, adverse effects of cannabis, 
cannabis dependence, and cannabis use or abuse with intoxication, psychotic disorder, or other 
cannabis use-related symptoms.97 However, in order to quantify rates of ED visits attributed to 
cannabis in an administrative case definition, the performance of these new cannabis ICD-10-
CM codes must be validated. Positive and negative predictive values along with sensitivity and 
specificity of these codes are necessary to develop an ICD-10-CM based case definition to 
monitor adverse health effect of cannabis use in a cannabis legal environment. 
KNOWLEDGE AND GAPS 
To develop an administrative case definition that uses ICD-10-CM coding, first the 
performance of the ICD-10-CM codes to be used in the definition must be examined. After 
measuring the performance of the ICD-10-CM codes a case definition can be built that will 
maximize the sensitivity and specificity. 
Current Literature on the Performance of Cannabis ICD-10-CM Codes 
PubMed was searched for peer reviewed literature on the performance of cannabis ICD-
10-CM codes and thirteen articles were found. The search terms used can be found in Appendix 
A. There were seven articles published before 2015 that were excluded because ICD-10-CM 
was implemented in 2015. Thus one relevant peer reviewed article (Marx et al. 2019) was left. 
Google Scholar was also searched for peer reviewed and gray literature using the search terms 
“cannabis PPV OR NPV OR sensitivity OR specificity "ICD-10-CM””. Two hundred and seventy 
eight citations were found and all but 2 were excluded after a title review: DeYoung et al. 2017 





Figure 4. Literature review for performance of cannabis ICD-10-CM codes. 
 
DeYoung et al. (2017) examined a cannabis syndromic case definition to identify ED 
visits potentially related to cannabis in Denver metropolitan hospitals reporting syndromic data 
to BioSense 2.0. The case definition utilized structured data in the diagnosis codes and 
diagnosis text as well as unstructured free-text in the chief complaint, triage notes, and clinical 
impression. The definition included a combination of cannabis scientific and colloquial terms, 
ICD-9-CM and ICD-10-CM cannabis codes, and ICD-9/10-CM cannabis code without periods 
that may have appeared in the free-text data. To confirm the ED visits as potentially related to 
cannabis, an epidemiologist, DeYoung, reviewed the data reported to BioSense 2.0 and 
classified the visit as potentially related (true positives), unrelated, or unclear if related to 
cannabis. There was not a manual review of electronic medical records performed nor were 
these data double reviewed for inter-rater reliability. Then positive predictive values were 
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DeYoung el at. (2017) performed this process, calculated PPVs, and used the results to refine 
the cannabis syndromic case definition. They then applied the refined case definition to a new 
set of ED visits and calculate the final PPVs. There were 698 ED visits in the final analysis and 
36.1% had a cannabis use code, 36.2% had a cannabis abuse code, 3.3% had a cannabis 
poisoning code, and 3.0% had a cannabis dependence code. Not all records had a cannabis 
diagnosis code. DeYoung reported that cannabis use unspecified (F129/F12.9), cannabis 
poisoning (T407/T40.7), and cannabis dependence (F122/F12.2) identified 100.0% of ED visits 
potentially related to cannabis and cannabis abuse (F121/F12.1) captured 98.8%.98 
Marx et al. (2019) performed a similar study to DeYoung et al. (2017); however, true 
positives were validated by electronic medical records (EMRs) abstraction by a physician. Their 
objective was to determine the validity of using Electronic Surveillance System for the Early 
Notification of Community- Based Epidemics (ESSENCE) to identify ED visits related to acute 
adverse effects of marijuana termed AAEM in three hospitals in the Denver metropolitan area. 
Marx et al. developed queries that included combinations of cannabis ICD-10-CM codes and 
text and examined their performance with positive predictive values.  They reported at least one 
cannabis ICD-10-CM diagnosis code predicted 60% of ED related to AAEM. The PPVs 
improved when cannabis ICD-10-CM codes were combined with chief complaints and triage 
notes (PPVs range: 89%-100%); however, few ED visits met these queries (N range: 2-63 ED 
visits). Predictive values of individual cannabis codes ranged from 48% to 100% in identifying 
ED visits related to AAEM. Cannabis poisoning ICD-10-CM codes had the highest PPV at 
100%, but were relatively rare (N=10) across the three hospitals. Marx et al. concluded that the 
best query identified captured ED visits related to AAEM about half of the time, but insisted that 
this query could be useful in detecting events or outbreaks of cannabis adverse health effects 
that would require ED visits.99 
The dissertation completed by Close et al. (2019) aimed to assess the validity of 
cannabis ICD-9/10-CM codes for identifying cannabis related hospitalizations reported in an 
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administrative discharge dataset and to see if the performance of these codes changed across 
legalization time points in Washington state. Close et al. included the most rigorous and detailed 
analysis of the performance of cannabis ICD-10-CM codes to date. Records from the 
Washington State hospital discharge dataset were probabilistically matched to the Washington 
State Trauma Registry where positive toxicology screens for cannabis were used as the gold 
standard to determine true positives or true marijuana involvement. Cannabis ICD-9/10-CM 
codes and groupings of codes were used to predict positives. Positive predictive value, negative 
predictive value, sensitivity, and specificity were calculated. Kappa statistics were also 
calculated to determine concordance between the state hospitalizations discharge diagnoses 
(cannabis ICD-10-CM code) and the trauma registry toxicology test results. The total sample 
size included 210,258 hospitalizations with a matched trauma registry record. Among those 
4,832 had a cannabis diagnosis and 2,031 (PPV=42.0%) of those were determined true 
positives with a positive toxicology result for cannabis. Limiting the analysis to years coded in 
ICD-10-CM, PPV of at least one cannabis ICD-10-CM code was improved to 68.3%. 
Performance of individual cannabis codes varied from 64.5% to 100.0% with cannabis 
dependence and poisoning codes having the highest performance at 100.0%. All cannabis ICD-
10-CM had high specificity (range: 95.5%-100.0%) but low sensitivity (range: 0.1%-17.8%). 
Sensitivity was maximized with the presence of at least one cannabis ICD-10-CM code at 
27.7%. No cannabis ICD-10-CM codes or combination of codes achieved area under the 
receiver operator characteristic curve greater than 61%. Performance of the cannabis ICD-10-
CM codes varied across cannabis legalization time periods; however, these differences were 
not tested for statistical significance. Close et al. examined improvement of performance 
measures by the position of the cannabis ICD-10-CM codes. They found the positive predictive 
value of the codes was improved with codes listed in the first 10 diagnosis code positions, but 
other performance measures were not affected. None of these improvements were tested for 
statistical significance. Close et al. concluded that cannabis ICD-10-CM codes from 
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administrative discharge datasets may not be best at identifying the true count of cannabis-
related hospitalizations but may be useful for monitoring trends across time.100 
Preliminary Data 
Pilot Study Identifying ED as Visits Partially Attributed to Cannabis 
In a pilot study all University of Colorado Hospital ED visits (UCH ED) from January 1, 
2012 through December 31, 2014 with at least one cannabis related International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code were abstracted by three 
trained research assistants. Cannabis related codes included accidental poisoning by 
psychodysleptics (E854.1)96, poisoning by psychodysleptics (969.6)95, nondependent cannabis 
abuse (codes 305.20-305.23)101, and cannabis dependence (codes 304.30-304.33)102. 
Psychodysleptics included cannabis derivatives, lysergide (LSD), marijuana (derivatives), 
mescaline, psilocin, and psilocybin.95,96 The abstracters determined if each index ED visit was 
partially attributable to cannabis if 1) the ED physician identified cannabis as likely precipitating 
or contributing to the condition bringing the patient to the ED, 2) if the patient was admitted to 
the hospital and the inpatient provider identified cannabis as likely precipitating or contributing to 
the condition, or 3) the urine toxicology screen was positive AND there was a temporally related 
cannabis exposure documented in a condition known to be associated with marijuana use (for 
example, motor vehicle collisions103–106, or acute panic attack107,108). Both urine toxicology 
screening and temporal use were necessary in these cases, otherwise the visit was considered 
not partially attributable to cannabis. Visits that were questionable were arbitrated by a medical 
toxicologist. The term partially attributed to cannabis was used because there is not a formal 
clinical definition for ED visits being attributable to cannabis and therefore it can only be 
speculated that the visits were partially attributed to cannabis. From 2012 to 2014 there were 
253,360 total ED visits at the UCH ED. Two thousand six hundred and three (1.03%) visits 
contained at least one cannabis ICD-9-CM code. Of these, 975 (PPV: 37.5%) were deemed 
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partially attributed to cannabis on individual chart reviews (Table 1). The Cohen’s Kappa 
statistic was 0.91 indicating excellent inter-rater agreement.  
Table 1. University of Colorado Hospital Emergency Department Visits, January 1, 2012 
to December 31, 2014 (N=253,360). 
Clinical Variable 






Partially Attributed to 
Cannabis 
N=975 
Age (IQR) 52 (26, 79) 34 (25, 47) 30 (23, 40) 
Male Gender, N (%) 107,569 (42.46) 1,701 (65.35) 631 (64.72) 
Race, N (%)    
  AI and ANa 1,415 (0.56) 9 (0.35) 1 (0.10) 
  Asian 6,785 (2.68) 23 (0.88) 13 (1.33) 
  African American 69,916 (27.60) 1,002 (38.49) 364 (37.33) 
  NH and Other PIa 642 (0.25) 7 (0.27) 4 (0.41) 
  White 116,523 (45.99) 1,187 (45.60) 421 (43.18) 
  Mixed race 56,851 (22.39) 369 (14.18) 169 (17.33) 
  Unknown 1,228 (0.48) 6 (0.23) 3 (0.31) 
Hispanic ethnicity, N (%) 55,868 (22.05) 387 (14.87) 177 (18.15) 
Disposition, N (%)    
  Admit/Transfer 46,167 (18.22) 1,362 (52.32) 221 (22.67) 
Discharge/ED 
observation/Expired 200,221 (79.03) 1,128 (43.33) 703 (72.10) 
AMA/Left before visit 
complete 6,972 (2.75) 19 (0.73) 11 (1.13) 
a AI: American Indian, AN: Alaska Native, NH: Native Hawaiian, PI: Pacific Islander 
bInternational Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code. accidental poisoning by 
psychodysleptics (E854.1), poisoning by psychodysleptics (969.6), nondependent cannabis abuse (codes 305.20-305.23), and 
cannabis dependence (codes 304.30-304.33). 
 
Prevalence of ED Visits with at Least One Cannabis ICD-9/10-CM Code Overtime 
The Colorado Department of Public Health and Environment (CDPHE) has monitored 
Colorado ED visits with at least one cannabis ICD-9/10-CM code present from 2000 to 2018. 
The cannabis related ICD-9-CM codes include accidental poisoning by psychodysleptics 
(E854.1)96, poisoning by psychodysleptics (969.6)95, nondependent cannabis abuse (codes 
305.20-305.23)101, and cannabis dependence (codes 304.30-304.33).102 With the transition to 
ICD-10-CM, CDPHE included the ICD-10-CM codes for cannabis abuse, dependence, or use to 
the third character (F12) and poisoning by, adverse effects of, and underdosing of cannabis to 
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the fourth character (T40.7).97 Crude rates of ED visits were calculated by dividing the number 
of ED visits with cannabis related diagnosis codes in a time period by the total number of ED 
visits during that same time period. This proportion was multiplied by 100,000 to obtain a rate. 
Rates of ED visits were compared across years and a percent change was calculated by each 
year to compare the trends across time. Rates were examined over time using a Pearson Χ2. A 
Bonferroni correction was used to adjust for multiple comparisons and the p-values required for 
significance were less than or equal to 0.001. Rates of ED visits with cannabis-related diagnosis 
codes have showed a steadily increasing trend since 2011 (Figure 3). When examining the 
cannabis codes over time separated by cannabis poisonings and cannabis abuse, dependence, 
or use (Figure 3), there is a wide gap between the two trends. This gap may indicate that 
cannabis abuse, dependence, and use ICD-10-CM codes could over count ED visits attributed 
to cannabis because they may include visits where patients report cannabis use but the visit is 
due to unrelated outcomes. However, limiting a case definition to only cannabis poisoning ICD-
10-CM codes may undercount ED visits attributable to cannabis as there is not a standardized 
clinical definition for cannabis poisonings. The true rates of ED visits attributed to cannabis are 
likely in between these two indicators. 
Gaps in Knowledge of the Performance of Cannabis ICD-10-CM Codes 
DeYoung (2017) and Marx et al. (2019) both evaluated cannabis ICD-10-CM coding in 
ED visit discharge data captured through syndromic surveillance reporting systems. These data 
systems are intended to be used for real-time monitoring of ED visits most commonly for 
communicable disease outbreaks or influenza like illness. Unfortunately, in Colorado only 
hospitals in the Denver metropolitan area participate in these programs and the system does 
not have coverage of the state of Colorado. Additionally, not all states participate in syndromic 
surveillance. CSTE recommends drug poisoning or overdose surveillance to be monitored in 
administrative emergency department and inpatient datasets. Close et al. (2019) examined 
cannabis ICD-10-CM codes in hospital administrative discharge data, but validated true 
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positives in a trauma registry. This limited these findings to hospitalizations with trauma, and not 
hospitalization in general. Also, discharge data from hospitalizations may have different 
underlying coding practices or documentation from providers due to the extended inpatient 
stays in the hospital and increased contacts with providers. Therefore, findings from inpatient 
discharges may not be generalizable to emergency department visits.  
DeYoung and Marx et al. did not use robust methods to validate a true positive. 
DeYoung et al. (2017) used an epidemiologist’s review of the syndromic data to determine 
cannabis involvement and did not review medical records. Marx et al. (2019) used a physician’s 
review of the electronic medical records to determine true positives, but this review was not 
evaluated with inter-rater reliability through a double review and may be biased. Close et al. 
(2019) did not manually review any records to determine true positives, but relied on positive 
urine or blood toxicology screens from the linked trauma registry. A chronic cannabis user can 
have positive toxicology results without experiencing intoxication or adverse effects. Therefore, 
validation of a true positive by toxicology results alone would likely overestimate the number of 
hospitalizations attributed to cannabis.  
DeYoung and Marx et al. focused on positive predictability and did not evaluate false 
negatives or the negative predictive value of the cannabis ICD-10-CM codes. Close et al. (2019) 
did examine the negative predictive value of cannabis ICD-10-CM codes, but their analysis was 
done in hospitalizations linked to a trauma registry and may not be generalizable to ED visit 
discharge data. 
The currently adopted method by CDPHE of measuring emergency department visits 
with at least one cannabis code may be overestimating the true number of ED visits attributed to 
cannabis. CDPHE interprets this indicator as ED visits involving cannabis and not as ED visits 
attributed to cannabis. However, their data are often misinterpreted by media and policy makers 
as measuring the burden or impact of cannabis legalization, which further highlights the 
importance of measuring in the performance of these codes. Indicators like the ones utilized by 
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CDPHE are likely to be relatively good indicators of changes in trends over time, but the 
performance measures for the cannabis ICD-10-CM codes are required to accurately quantify 
the number of ED visits attributed to cannabis. 
To date the performance of cannabis ICD-10-CM codes has not been evaluated in 
administrative emergency department discharge data. The positive predictive value, negative 
predictive value, sensitivity, and specificity of cannabis ICD-10-CM codes in identifying ED visits 
attributed to cannabis is unknown. Additionally, determination of true positive conditions for 
these codes have not been done through robust manual review of electronic medical records 
with a double review for inter-rater reliability. 
INNOVATION 
This project aims to fill gaps in the literature surrounding the performance of cannabis 
ICD-10-CM codes in their ability to identify ED visit attributable to cannabis. First, this project will 
apply robust methods for determining true positives or ED visits attributed to cannabis. Second, 
we will evaluate the use of supporting information within the discharge records to maximize the 
predictive value of the cannabis codes. Finally, we will use time- and cost-efficient novel 
methods for measuring false negatives to calculate the negative predictive value of cannabis 
codes. All this work will inform future research to develop a nationally standardized case 
definition for ED visits attributed to cannabis. 
The Performance of Cannabis ICD-10-CM Codes has Never been Quantified 
This project is novel in that it will be the first attempt at quantifying the performance of 
cannabis ICD-10-CM codes to predict ED visits attributed to cannabis within a cannabis legal 
environment. Until the implementation of ICD-10-CM, parsing cannabis poisonings or 
intoxications from psychodysleptics was impossible without an extensive medical records 
review. ED visits with poisonings by psychodysleptics and regional poison center calls for 
cannabis exposures have been used as proxy indicators for cannabis adverse health events. 
However, using coding for psychodysleptics potentially overestimates, while regional poison 
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center calls likely underestimates the burden of cannabis adverse health events. This project 
will describe the performance of cannabis ICD-10-CM codes through positive predictive value 
and negative predictive value so that this information can be used in future development of a 
case definition for identifying ED visits attributed to cannabis.  
New Application for Established Methods 
It is well established that when leveraging ED visit data to monitor a condition, an 
administrative case definition must be developed and validated.86,93,94,109–117 The first step 
towards developing an administrative case definition for ED visits attributable to cannabis is to 
evaluate how well cannabis ICD-10-CM discharge diagnosis codes identify ED visits attributable 
to cannabis. The individual performance of these codes can then inform a case definition with 
maximized sensitivity and specificity. This project will examine the positive and negative 
predictive value of cannabis ICD-10-CM discharge diagnosis codes. To determine positive 
predictive value of the cannabis ICD-10-CM codes this project will perform a traditional manual 
records review of all EMRs with at least one cannabis ICD-10-CM code as the gold standard for 
cannabis attribution. For negative predictive value of the cannabis ICD-10-CM a novel 
application of EMRs reviews will be applied to reduce the time and cost associated with a large 
records review.  This project will pilot a text mining approach to make EMRs reviews for false 
negatives (or ED visits without cannabis ICD-10-CM codes that were attributed to cannabis) 
more efficient. These methods will provide public health with performance measures for the 
cannabis ICD-10-CM codes that can be used to inform a standardized administrative case 
definition for ED visits attributed to cannabis.  
Colorado Presents an Optimal Environment for this Study 
Colorado was the first state to implement legalize recreational cannabis in January 2014 
with distribution in private dispensaries after two stages of cannabis legalization: medical 
cannabis legalization (2001-2009) and medical cannabis commercialization (2010-2013).1–3 This 
history of cannabis legalization and development of the privatized cannabis industry in Colorado 
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presents a culture where cannabis de-stigmatization has been taking place for many years. This 
presents an innovative environment to validate cannabis ICD-10-CM codes’ performance in 
identifying ED visits attributed to cannabis within a cannabis legal environment because it 
minimizes reporting bias from patients and detection bias from medical providers. Any hospital 
changes in cannabis screening because of legalization should be established by the start of this 
project (2016). No other state in the United States would be able to minimize reporting and 
screening biases like Colorado because of the privatized history of the cannabis industry. 
Colorado presents an innovative opportunity to examine the performance of cannabis ICD-10-
CM codes in ED visits with minimal bias. 
GOALS 
This project will be the first comprehensive evaluation of the performance of cannabis 
ICD-10-CM codes in identifying ED visits attributed to cannabis. It will be the foundation of 
future research to develop a nationally standardized case definition to quantify ED visits 
attributed to cannabis to measure the public health impacts of cannabis legalization. 
Additionally, these performance measures will help to quantify the true number of ED visits 
partially attributed to cannabis in Colorado. This project will fill a gap identified by CSTE and aid 
public health with tools for cannabis surveillance within states at any stage of cannabis 
legalization. Findings from this study will aid in evaluating public health cannabis policies and 
legislation and fill recognized gaps in cannabis surveillance and research.  
In the short term this project will provide time- and cost- efficient methods for validating 
ICD-10-CM codes through electronic records reviews. It will be the first study to apply an 
objective and systematic determination of partial cannabis attribution to evaluate the 
performance of cannabis ICD-10-CM codes.118 It will also provide positive predictive value and 
negative predictive value for cannabis ICD-10-CM codes to predict ED visit partially attributed to 
cannabis in a sample of ED visit from a large, urban, academic hospital. The short terms goals 




Aim 1: Determine the positive predictive value for cannabis ICD-10-CM codes to predict 
ED visits partially attributed to cannabis: 
1.1) with at least one cannabis code 
1.2) with a cannabis code and no other substance codes vs. with a cannabis code 
and other substance codes 
For Aim 1.1, we will use manual records reviews of electronic medical records (EMRs) 
for all ED visits from the University of Colorado Hospital with at least one cannabis ICD-10-CM 
codes (Table 2) from 2016. Manual records reviews for full or partial cannabis attribution will be 
used as the “gold standard”. ED visits partially attributed to cannabis will be determined by 
documentation in the EMR of 1) the ED or inpatient physician identifying cannabis as likely 
precipitating or contributing to the condition bringing the patient to the ED, or 2) a positive urine 
toxicology screen for delta-9-tetrahydrocannabinol (THC) AND a temporally related cannabis 
exposure documented in a condition known to be associated with cannabis use (i.e., motor 
vehicle collisions103–106, or acute panic attack107,108). True positives and false positives will be 
determined by meeting the criteria for cannabis attribution in the manual records review (Figure 
5). We will calculate positive predictive values (PPV) for cannabis specific ICD-10-CM codes to 
predict meeting the criteria of partially attributable to cannabis (Table 2).  
For Aim 1.2, we will group ED visits into those that included cannabis codes (Table 2) 
but no other substance codes and those that included both cannabis codes and other substance 
codes. Substance codes will include at least one of the following codes in any discharge 
position: opioid related disorders (F11); sedative, hypnotic, or anxiolytic related disorders (F13); 
cocaine related disorders (F14); other stimulant related disorders (F15); hallucinogen related 
disorders (F16); nicotine dependence (F17); inhalant related disorders (F18); other 
psychoactive substance related disorders (F19); poisoning by, adverse effect of and 
underdosing of drugs, medicaments and biological substances (T36-T50); and alcohol related 
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codes (E24.4, F10, G31.2, G62.1, G72.1, I42.6, K29.2, K70, K85.2, K86.0, O35.4, O99.31, 
P04.3, Q86.0, T51.0, Y90.4-Y90.8). 
Figure 5. Conceptual model for calculating the positive predictive value for cannabis ICD-
10-CM codes (Aim 1). 
    
 
Outcome 1.1: Estimate positive predictive values (PPVs) with 95% confidence for each 
cannabis ICD-10-CM code to predict ED visits partially attributed to cannabis.  
Outcome 1.2: Estimate positive predictive values (PPVs) with 95% confidence for each 
cannabis ICD-10-CM code without other substance codes to predict ED visits partially attributed 
to cannabis and for each cannabis code with other substance codes to predict ED visits partially 
attributed to cannabis.  
Hypothesis 1.2: Positive predictive values (PPVs) for individual cannabis codes ability to 
predict attribution to cannabis will be increased in ED visits with cannabis codes and no other 























Table 2. Cannabis ICD-10-CM codes evaluated for positive and negative predictive values 













Cannabis abuse with intoxication (uncomplicated, with 
delirium, with perceptual disturbance, and unspecified) 
[PPV] 
F12.22,-0,-1,-2,-9 
Cannabis dependence with intoxication (uncomplicated, with 
delirium, with perceptual disturbance, and unspecified) 
[PPV] 
F12.92,-0,-1,-2,-9 
Cannabis use, unspecified with intoxication (uncomplicated, 
with delirium, with perceptual disturbance, and unspecified) 
[PPV] 
T40.7X1-.7X5 
Poisoning by adverse effect of and underdosing of cannabis 




Use, and Abuse 
Cannabis 
Codes 
F12.22, -0, -1 Cannabis dependence (uncomplicated, in remission) [PPV] 
F12.25, -0, -1, -9 
Cannabis dependence with psychotic disorder (with 
delusions, with hallucinations, unspecified) 
[PPV] 
F12.28, -0, -8 
Cannabis dependence with other cannabis-induced disorder 




Cannabis dependence with unspecified cannabis-induced 
disorder) 
[PPV] 
F12.1, -0 Cannabis abuse (uncomplicated) [PPV] 
F12.15, -0, -1, -9  
Cannabis abuse with psychotic disorder (with delusions, 
with hallucinations, unspecified) 
[PPV] 
F12.18, -0, -8 
Cannabis abuse with other cannabis-induced disorder 
(cannabis-induced anxiety disorder, cannabis-induced 
disorder) 
[PPV] 
F12.19 Cannabis abuse with unspecified cannabis-induced disorder [PPV] 
F12.9, -0  Cannabis use, unspecified (uncomplicated) [PPV] 
F12.95, -0, -1, -9  
Cannabis use, unspecified with psychotic disorder (with 
delusions, with hallucinations, unspecified) 
[PPV] 
F12.98, -0, -8,  
Cannabis use, unspecified with other cannabis-induced 
disorder (with anxiety disorder, with cannabis-induced 
disorder) 
[PPV] 














Aim 2: Improve the positive predictive value for cannabis abuse, use, and dependence 
ICD-10-CM codes to predict ED visits partially attributed to cannabis by examining them: 
2.1) with codes of outcomes related to cannabis 
2.2) by the position of the cannabis code 
For Aim 2.1 we will group ED visits with cannabis codes into those with codes of 
outcome related to cannabis (Table 3) and those without outcomes related to cannabis. For Aim 
2.2 we will examine cannabis codes’ positions at increasing cut points away from the primary 
diagnosis: 1st, 2nd-5th, 6th-10th, 11th-15th, and 16th-30th positions. All records with cannabis codes 
will have been reviewed for Aim 1. True positives and false positives will be determined by 
meeting the criteria in the manual records reviews. We will calculate individual positive 
predictive values (PPV) for individual cannabis codes with and without codes of outcomes 
related to cannabis use (Aim 2.1) (Table 3), and for cannabis code positions at the described 
cut points (Aim 2.2).  
Hypothesis 2.1: Positive predictive values (PPVs) for individual cannabis codes ability to 
predict attribution to cannabis will be improved in ED visits with cannabis codes and codes of 
outcomes related to cannabis.  
Hypothesis 2.2: Positive predictive values (PPVs) for individual cannabis codes ability to 
predict attribution to cannabis will be improved in ED visits with cannabis codes in the primary 









Table 3. ICD-10-CM codes of outcomes related to cannabis with cannabis ICD-10-CM 
codes evaluated for positive predictive values to predict emergency department 









V87, V88, V89 Motor vehicle collision103–106 
S00-T32 Injury  
G43.A, -0, -1, R11 Cyclic vomiting119–123 
G45.8, -.9 
Ischemic Stroke in individuals younger than 55 years 
old124–129 
J40-J42, R05, R06.2, R09.3 Chronic bronchitis with cough/wheeze/ sputum 130–136 
F22, F23, F28, F29, F30.2, 
F31.2, F32.3, F33.3 Psychotic symptoms or disorders34,57,137–139 
F41.0 Acute panic attack107,108 
F19.93 Withdrawal symptoms 
 
Aim 3: Determine the negative predictive value for ED visits without cannabis ICD-10-CM 
codes to predict ED visits not attributable to cannabis.  
We will select all ED visits without cannabis ICD-10-CM codes (Table 2) from 2016 and 
search the history and physical, chief complaint, physician or nurses notes, and laboratory 
records for cannabis text strings140 (Table 4). Records with at least one cannabis text strings will 
be manually reviewed using the criteria for partially attributed to cannabis described in Aim 1 to 
determine false negatives (Figure 6). We will calculated the negative predictive value for the 
absence of cannabis codes to predict ED visits not partially attributed to cannabis.  
Outcome 3.1: Estimate the negative predictive value (NPV) with 95% confidence for ED visits 
without cannabis ICD-10-CM codes for predicting ED visits not partially attributed to cannabis.  
Table 4. Cannabis text strings to select ED visits for manual records review without 
cannabis ICD-10-CM codes. 
Text Strings Included Text Strings Excluded 
“ marijuana ” or “ mj ” “ not marijuana ” or “ not m j” 
“ THC ” or “ tetrahydrocannabinol ” 
or “ cannabinoids “ 
“ not THC ” or “ synthetic THC ” or “ synthetic 
tetrahydrocannabinol “or “ not cannabinoids “ or “ not synthetic 
cannabinoids “ 
“ cannabis ” “ not cannabis ’ 
“ edibles “ “ not edibles “ 
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Figure 6. Conceptual model for calculating the negative predictive value for ED 
discharges not having cannabis ICD-10-CM codes (Aim 3). 
 
The following three chapters are publishable papers addressing these aims. Chapter II 
examines aims 1.1 and 1.2 describing the positive predictive value of the cannabis ICD-10-CM 
codes and improvement of the PPVs by limiting to ED visits without other substance use 
diagnosis codes other than cannabis. Chapter III further examines methods for improving the 
PPVs of cannabis abuse, dependence, and use ICD-10-CM codes by limiting to ED visits with 
cannabis codes and codes of outcomes related to cannabis (aim 2.1), or by limited to certain 
positions of the cannabis codes in the list of discharge diagnoses (aim 2.2). Chapter IV applies 
a novel method for false negative reviews and examines the negative predictive value of the 
cannabis ICD-10-CM codes (aim 3). Chapter V discusses the findings from the three papers, 
their limitations, next steps, and conclusions from the project. These three papers support the 
specific goal of determining the performance of the cannabis ICD-10-CM codes in determining 
ED visits attributable to cannabis. This project fits into the larger goal of developing a 
standardized case definition for surveillance of ED visits attributed to cannabis by providing the 
foundation of a successful administrative case definition, the performance measure of the 






Positive Predictive Value of Cannabis ICD-10-Cm Codes in Emergency Discharges 
Abstract 
Introduction: The new ICD-10-CM coding system has expanded cannabis discharge 
diagnosis codes to be more specific. However, positive predictive values (PPVs) of cannabis 
ICD-10-CM codes have not been validated with chart reviews. We aimed to characterize 
cannabis ICD-10-CM coding and predictive value for determining emergency department (ED) 
visits attributable to cannabis. 
Methods: All emergency department visits at the University of Colorado Hospital 
between January 1, 2016 and December 31, 2016 with a cannabis ICD-10-CM code were 
included. The presence of a cannabis ICD-10-CM code indicated the predicted positive 
condition. The true positive condition was confirmed with chart review for cannabis attribution. 
We described the types of cannabis codes in this sample and calculated their PPVs. 
Additionally, we examined co-occurring substance codes’ utility to improve the PPVs. PPVs 
were compared with a generalized score statistic proposed by Kosinski (2013) and significance 
set at an alpha 0.05.  
Results: There were 942 (PPV: 0.37, 95% CI: 0.35-0.39) ED visits determined attributed 
to cannabis with a cannabis code. Ninety percent (PPV: 0.90, 95% CI: 0.82-0.95) of ED visits 
with a cannabis poisoning or intoxication code were attributed to cannabis but 14.4% of all ED 
visits attributed to cannabis included a cannabis poisoning or intoxication codes. PPVs for 
cannabis ICD-10-CM codes improved when limited to ED visits that did not have additional 
substance discharge codes. 
Conclusion: Cannabis poisoning and intoxication codes perform well independently or 
combined in identifying ED visits attributable to cannabis. However, these codes are rare and 
underestimate the true number of ED discharges attributed to cannabis. More research is 
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needed on improving the PPVs of cannabis abuse, dependence, and use codes because they 
comprise 86.9% of ED visits attributed to cannabis, however, overestimated the true number of 
ED visits attributed to cannabis. 
Introduction 
Colorado became the first US state to legalize and implement recreational cannabis 
sales after a long history of medical cannabis legalizaiton.1–3 Currently at least 10 states have 
recreational cannabis sales and more than 30 have some form of legalized or decriminalized 
cannabis.141,142 Six states with legalized cannabis are monitoring adverse health outcomes 
associated with cannabis use to inform regulation and legislators.142 The Centers for Disease 
Control (CDC), Safe States, and Council for State and Territorial Epidemiologist (CSTE) 
recommend state-level surveillance of drug poisonings and overdoses within administrative data 
to identify trends in adverse health outcomes early.86,87 Emergency department (ED) discharge 
data provide a population level data source to monitor public health impacts of cannabis 
legalization that can be accessed daily through data reported to the National Syndromic 
Surveillance Program (NSSP).99,143 However, there is little national public health guidance on 
how to use discharge coding to identify ED visits with cannabis involvement. In 2016 the Council 
for State and Territorial Epidemiologist identified the lack of standardized methods for cannabis 
surveillance as a key challenge that public health in states with legalized cannabis are facing.87   
Despite lacking a standard definition, studies are using discharge coding in 
administrative discharge data systems to examine trends in healthcare encounters involving 
cannabis to measure impacts of recreational cannabis legalization. The International 
Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD-9/10-CM) 
included diagnosis codes for cannabis. ICD-10-CM expanded all diagnosis codes from ~14,000 
to ~68,000 and expanded cannabis codes from 10 to 53 codes.97,144 The newly added cannabis 
codes are more specific to cannabis poisonings, intoxication, and use. Both cannabis ICD-9-CM 
and ICD-10-CM coding has been used to track prevalence of hospitalizations and ED 
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discharges across legalization periods and to examine impacts of legalization.145–151 There have 
been numerous approaches to count cannabis discharge codes, however, without validated 
cannabis codes that capture ED visits attributed to cannabis, these methods are at risk for over- 
or underestimating cannabis related adverse health outcomes. 
Currently there is no national guidance on surveillance of ED discharges involving 
cannabis using ICD-10-CM. Two studies examined ICD-10-CM cannabis coding within 
syndromic surveillance data and found, when supplemented with text from physicians 
describing the chief complaint, cannabis coding can be used to track ED visits attributed to 
cannabis.99,140 Marx et al. described positive predictive values (PPVs) for the four cannabis ICD-
10-CM code categories and found PPVs as high as 100% for cannabis poisoning codes (n=10) 
and as low as 48% for cannabis use (n=110) in identifying ED visits attributed to cannabis.99 
The chief complaint is not available in statewide administrative ED discharge datasets.25 To 
date cannabis ICD-10-CM coding has not been validated as an indicator for ED discharges 
attributed to cannabis in administrative ED discharge datasets. 
A lack of a clinical definition for healthcare encounters due to cannabis limits the ability 
to fully attribute ED visits to cannabis. In this study we described ED visits with cannabis codes 
by ‘partial’ attribution to cannabis through electronic medical records reviews relying on the 
medical interpretation of the attending physician. We aimed to 1) determine the positive 
predictive value (PPV) for cannabis ICD-10-CM codes to predict ED discharges at least partially 
attributed to cannabis and 2) improve the PPVs for cannabis ICD-10-CM codes to predict ED 
discharges partially attributed to cannabis by examining them with and without other substance 
use codes. We hypothesized PPVs for determining attribution to cannabis would be improved in 
ED visits with cannabis codes and no other substance codes compared to ED visits with 
cannabis codes and other substance use codes. In other words, ED visits with cannabis codes 




Materials and Methods 
Study Design and Population 
We utilized a retrospective cohort study design and selected all ED visits discharged 
from January 1, 2016 00:00 to December 31, 2016 23:59 and had at least one cannabis ICD-
10-CM code in the up to 30 listed diagnosis codes from the University of Colorado Hospital 
Emergency Department (UCHED) an urban, academic, Level 2 Trauma center (Figure 7). 
Records without discharge diagnosis codes were excluded from the sample. We looked at 
encounter-level data instead of patient-level data, so individuals may have had multiple visits to 
the ED during this time period.  
Figure 7. Sampling strategy for calculating positive predictive values for cannabis ICD-
10-CM codes to predict ED discharges partially attributable to cannabis. 
 
 
Verification of Cannabis Attribution 
It was not feasible to review the entire sample of ED visits in 2016 for partial attribution 
to cannabis (N=98,521). Therefore, reviews were limited to ED visit with cannabis ICD-10-CM 
codes (Figure 8). Partial attribution to cannabis was determined through manual review of 
electronic medical records (EMRs) by three trained abstracters blinded to the study objective. 
UCH ED visits discharged in 2016 
N=98,521 














ED visits with cannabis coding were determined at least partially attributable to cannabis if at 
least one of the following criteria were met: 1) the ED physician identified cannabis as likely 
precipitating or contributing to the condition bringing the patient to the ED, 2) the patient was 
admitted to the hospital, and the inpatient provider identified cannabis as likely precipitating or 
contributing to the condition, or 3) the urine toxicology screen was positive for delta-9-
tetrahydrocannabinol AND there was a temporally related cannabis exposure documented in 
the medical record (within 24 hours) with a condition known to be associated with cannabis use. 
Conditions know to be associated with cannabis use included unintentional marijuana 
exposures20,24,152, cannabis poisonings or overdoses, motor vehicle collision103–106, injury due to 
impairment, cyclic vomiting119–123,153,154, ischemic stroke in individuals younger than 55 years 
old124,126,127,155,156, chronic bronchitis with cough/wheeze/sputum130,131,133,136,157–159, psychotic 
symptoms or disorders54,57,59,138,160, acute panic attack107,108, and withdrawal symptoms. Both 
urine toxicology screening and documentation of temporal cannabis use were necessary in 
these cases otherwise, the visit was considered not attributable to cannabis. Assessment of 
cannabis use was included in the drug use section of the standard nursing assessment 
questionnaire performed on every patient seen in the UCHED (Table 5).118  
To assess the accuracy of the chart review, a sample of 10% UCHED charts with at 
least one cannabis ICD-10-CM code were abstracted by both a medical toxicologist and the 
trained abstractors. Abstractors were retrained on any discrepancies during initial training. Visits 
with questionable cannabis attribution were arbitrated by a single medical toxicologist (AAM). 
For quality control, a 7.7% (N=195) random sample was double reviewed by the same medical 
toxicologist. A Cohen’s Kappa statistic was evaluated for inter-rater agreement. The kappa 
statistic for the electronic medical records review for cannabis attribution was 0.91 (95% CI: 
0.85-0.97) indicating acceptable inter-rater reliability. The full instrument used for manual 




Table 5. Criteria to determine partially attributed to marijuana within the electronic 
medical record (EMR). 
Criteria  
1) ED physician identified marijuana as likely precipitating or contributing to the condition 
bringing the patient to the ED 
OR  
2) If the patient was admitted to the hospital, and the inpatient provider identified marijuana 
as likely precipitating or contributing to the condition 
OR  
3) The urine toxicology screen was positive for delta-9-tetrahydrocannabinol AND there 
was a temporally related marijuana exposure documented in a condition known to be 
associated with marijuana use 
Outcomes related to 
marijuana use 
Unintentional marijuana exposures20,24,152 
Marijuana poisonings or overdoses 
Motor vehicle collision103–106 
Injury due to impairment 
Cyclic vomiting119–123,153,154 
Ischemic Stroke in individuals younger than 55 
years old124,126,127,155,156 
Chronic bronchitis with cough/wheeze/ sputum 
130,131,133,136,157–159 
Mental health outcomes 
related to marijuana use 
Psychotic symptoms or disorders54,57,59,138,160 
Acute panic attack107,108 
Withdrawal symptoms (only marijuana use 
indicated) 
Demographics 
Age in years was recorded continuously. Gender (male/female) and race/ethnicity (non-
Hispanic White, non-Hispanic African American, Hispanic, and non-Hispanic Other race) were 
coded as categorical variables. Colorado resident status was determined using billing address 
and coded as resident or non-resident. 
Visit Characteristics 
Health insurance was categorized as private, public (state insurance, Medicare, or 
Medicaid), military, and other (indigent or other) insurance provider. To account for patients with 
more than one ED discharge in 2016, the median number of visits per patient (in 2016) was 
calculated. Urine toxicology screening performed at any time during the visit was determined 
and length of stay was calculated as number of hours in ED and separately days in inpatient 
care for those admitted from the ED. Visit disposition was classified as discharge to home, 
admitted, transferred to psychiatric unit, or other. 
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Substance Use Characteristics 
Information on urine drug screens was collected during the electronic medical records 
review. The abstractor indicated if a urine toxicology screen was performed and if so then 
indicated if it was positive for THC, opioids, benzodiazepines, barbiturates, amphetamines, 
cocaine, other, or negative. Positive urine toxicology screening for THC was categorized as 
THC only and THC with other substances. THC with other substances were categorized by THC 
with opioids, benzodiazepines, barbiturates, amphetamines, cocaine, or other substances and 
were not mutually exclusive. Blood alcohol levels were collected during electronic medical 
records review and categorized as greater than or equal to 80 milligrams/deciliter (mg/dL) or 
less than 80 mg/dL.  
Predicted Cannabis Attributed ED Discharge  
The primary objective was to evaluate the predictive value of cannabis ICD-10-CM 
codes. For this objective all ED visits with a cannabis ICD-10-CM code were predicted to be 
attributable to cannabis. Cannabis codes included cannabis abuse (F12.1), cannabis 
dependence (F12.2), cannabis use, unspecified (F12.9), and cannabis poisoning (T40.7) 
(Appendix C) and PPVs were calculated for each.161 When evaluating the secondary objective 
of improving the PPVs of cannabis ICD-10-CM codes based on the presence of additional 
substance codes, the ED discharges were stratified into those with cannabis ICD-10-CM codes 
and no additional substance codes and those with cannabis and substance ICD-10-CM codes. 
Other substance codes included were: opioid related disorders (F11); sedative, hypnotic, or 
anxiolytic related disorders (F13); cocaine related disorders (F14); other stimulant related 
disorders (F15); hallucinogen related disorders (F16); nicotine dependence (F17); inhalant 
related disorders (F18); other psychoactive substance related disorders (F19); poisoning by, 
adverse effect of and underdosing of drugs, medicaments and biological substances (T36-T50); 
and alcohol related codes (E24.4, F10, G31.2, G62.1, G72.1, I42.6, K29.2, K70, K85.2, K86.0, 
O35.4, O99.31, P04.3, Q86.0, T51.0, Y90.4-Y90.8).161,162 Poisoning by, adverse effect of and 
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underdosing of cannabis (T40.7) was excluded in the T36-T50 codes. ED discharges were 
predicted positive if there were both cannabis ICD-10-CM codes and substance ICD-10-CM 
codes and PPVs were calculated. Then to examine improvement of PPVs, ED discharges were 
predicted positive if there were cannabis ICD-10-CM codes and no additional substance ICD-
10-CM codes and PPVs were compared to those with both cannabis and other substance 
codes. 
Statistical Analysis 
All analyses were completed using SAS version 9.4 (SAS Institute Inc., Cary, NC). 
Demographics, clinical characteristics, and substance use characteristics for ED discharges 
with a cannabis code were examined by cannabis attribution and tested using a Pearson chi 
squared test for categorical comparisons and an ANOVA for continuous comparisons. We 
calculated PPV for each cannabis ICD-10-CM code chapter’s (cannabis abuse, cannabis 
dependence, cannabis use, and poisoning by cannabis) and groups of code’s abilities to predict 
partial attribution to cannabis using Equation 2.1.163 Visits with multiple cannabis code chapters  
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2.1: 𝑃𝑃𝑉 = 𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 
were included in multiple PPV calculations. PPVs were calculated across the total sample and 
stratified by cannabis ICD-10-CM codes and no additional substance ICD-10-CM codes and 
cannabis with additional substance ICD-10-CM codes. True positives were ED visits with a 
cannabis ICD-10-CM code (predicted attributable to cannabis) that met the criteria for partially 
attributed to cannabis. False positives were ED visits with a cannabis ICD-10-CM code but did 
NOT meet the criteria for partially attributed to cannabis. We calculated binomial 95% 
confidence intervals (95% CI) using the Clopper-Pearson exact method for each PPV using the 
binomial option in SAS FREQ procedure.164 To test our hypothesis that limiting our predictive 
positives to ED discharges with cannabis ICD-10-CM codes and no additional substances 
codes we used the generalized score statistic proposed by Kosinski (2013) (Equation 2.2) and 
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There were 98,521 emergency department (ED) discharges at the UCH main campus 
emergency department in 2016. Of those, 2,528 (2.6%) had at least one cannabis ICD-10-CM 
code in the discharge diagnoses and 2,528 (100.0%) were reviewed for attribution to cannabis. 
There were 12 (0.5%) ED discharges missing race/ethnicity, 3 (0.1%) missing health insurance 
and 19 (0.8%) missing disposition. 
There were 942 (37.3%) ED discharges determined partially attributed to cannabis 
through manual review of EMRs. ED discharges determined partially attributable to cannabis 
were on average 4.3 years younger (34.2 years, p<0.05), majority male (67.0%, p<0.05), and a 
higher percent had private (15.5% vs 10.3%) or other health insurance (15.3% vs 11.2%). There 
was a higher percentage of non-Colorado residents among ED discharges attributed to 
cannabis (13.8%) compared to ED discharges not attributable to cannabis (5.6%) (p<0.05). 
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Among ED discharges attributed to cannabis 397 (42.4%) were White, non-Hispanic, 319 
(34.0%) were African American, non-Hispanic, 176 (18.8%) were Hispanic, and 45 (4.8%) were 
other race. There were 69 (8.3%) ED discharges partially attributed to cannabis had at least one 
other discharge within 2016 which was not significantly difference from the 129 (9.2%) ED 
discharges not attributed to cannabis than had an additional discharge in 2016 (p=0.51). 
However, the range of number of visits within 2016 was larger in ED visits attributed to cannabis 
(1-16 visits) compared to those not attributed (1-11 visits). The average length of emergency 
department stay for ED discharges attributed to cannabis was 2.8 (SE=4.7) hours compared to 
2.4 (SE=3.3) for those not attributed to cannabis (p=0.02). There were 273 (29.1%) ED 
discharges attributed to cannabis admitted to inpatient. The average length of inpatient stay 
among ED discharges attributed to cannabis was 3.8 (SE=5.8) days compared to 4.7 (SE=6.3) 
days among ED discharges not attributed to cannabis (p=0.05). Among ED visits attributed to 
cannabis 602 (64.2%) were discharged to home, 273 (29.1%) were admitted, 27 (2.9%) were 
transferred to psychiatric unit, and 36 (3.8%) had other dispositions compared to 708 (45.1%), 
800 (50.9%), 20 (1.3%), and 43 (2.7%) among ED discharges not attributable to cannabis 
respectively (p<0.05) (Table 6). 
Among the 942 ED visit partially attributed to cannabis, 727 (77.2%) were determined 
attributable by the ED physician, 114 (12.1%) were determined attributable by the inpatient 
physician, 56 (5.9%) were determined attributable by a positive toxicology screen for THC, a 
temporal exposure, and a condition related to cannabis use, 43 (4.6%) met multiple criteria, and 
2 (0.2%) were missing criteria. Most diagnoses documented for ED visits attributable to 
cannabis were gastrointestinal (28.9%), intoxication (27.8%), psychiatric (24.8%), altered mental 
status (9.2%), neurologic (8.3), and respiratory (7.5%). Other diagnoses included cardiovascular 






Urine toxicology screens were performed in 5,788 ED visits (5.9%) in 2016. There were 
2,365 (93.6%) of the ED discharges with at least one cannabis ICD-10-CM code that had a 
urine toxicology screen performed. This comprised 40.9% of the total number of urine toxicology 
screens performed in ED visits in 2016. Among those 2,207 (93.3%) discharges had a positive 
urine toxicology screen. A higher percent of ED visits with cannabis codes received a urine 
toxicology screen in those attributed to cannabis (96.9%) compared to those not attributed to 
cannabis (91.6%) (p<0.05). There were 2,180 (92.1%) ED discharges positive for THC. Among 
those attributed to cannabis 820 (99.4%) discharges were positive for THC compared to 1,360 
(98.4%) in discharges not attributed to cannabis (p=0.04). A smaller proportion of ED 
discharges attributed to cannabis were positive for THC only (62.9%) compared to ED 
discharges not attributed to cannabis (69.9%); however, a higher proportion of ED discharges 
attributed to cannabis were positive for THC with other substances (37.1%) compared to ED 
discharges not attributable (p<0.05). Toxicology screens positive for THC and other substances 
were similar between discharges attributed and not attributed to cannabis, except discharges 
attributed to cannabis had a higher proportion of positive screens for THC and benzodiazepine 
(25.7%, p=0.01) and THC and other substances (26.3%, p<0.05) compared to discharges not 
attributed to cannabis (18.1% and 17.9% respectively). Blood alcohol levels were tested in 349 
(13.8%) ED visits with cannabis codes and in 102 (29.2%) visits the patient tested above 80 
mg/dL. This was similar by cannabis attribution.  
ICD-10-CM Coding Results 
There were 1,539 (60.9%) ED discharges with a cannabis use code (F12.9), 918 
(36.3%) with a cannabis abuse code (F12.1), 47 (1.9%) with a poisoning by, adverse effect of, 
or underdosing of cannabis code (T40.7), and 42 (1.7%) with a cannabis dependence code  
(F12.2). There were 18 (0.7%) ED visits with two cannabis codes and no ED visits with 
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Table 6. Demographics of emergency department visits that received a cannabis ICD-10-
CM code at UCH in 2016 by attribution to cannabis or not (N=2,528). 
 Attributed to Cannabis  
N (%) Yes (N=942) No (N=1,586) P Value 
Age, mean (SE) 34.2 (13.3) 38.5 (14.1) <0.05 
Male 631 (67.0) 961 (60.6) <0.05 
Race   <0.05 
White, Non-Hispanic 397 (42.4) 742 (47.0)  
African American, Non-Hispanic 319 (34.0) 558 (35.3)  
Hispanic 176 (18.8) 214 (13.6)  
Other, Non-Hispanic 45 (4.8) 65 (4.1)  
Resident Status   <0.05 
Colorado Resident 812 (86.2) 1,497 (94.4)  
Nonresident 130 (13.8) 89 (5.6)  
Health Insurance   <0.05 
Private 146 (15.5) 163 (10.3)  
Public 622 (66.0) 1,215 (76.8)  
Military 30 (3.2) 27 (1.7)  
Other 144 (15.3) 178 (11.2)  
More than one visit in 2016 69 (8.3) 129 (9.2) 0.51 
Number of visits in 2016, median (range) 1.0 (1-16) 1.0 (1-11)  
Toxicology Tested 913 (96.9) 1,452 (91.6) <0.05 
Positive Urine Toxicology 825 (87.6) 1,382 (87.1) 0.75 
THC 820 (99.4) 1,360 (98.4) 0.04 
THC Only 516 (62.9) 951 (69.9) <0.05 
THC with Other Subs. 304 (37.1) 409 (30.1)  
Opioids 66 (21.7) 107 (26.2) 0.17 
Benzodiazepines 78 (25.7) 74 (18.1) 0.01 
Barbiturates 1 (0.3) 2 (0.5) 0.74 
Amphetamines 112 (36.8) 139 (34.0) 0.43 
Cocaine 110 (36.2) 158 (38.6) 0.50 
Other 80 (26.3) 73 (17.9) <0.05 
Blood Alcohol ≥ 80 mg/dL 42 (4.5) 60 (3.8) 0.59 
ED Length of Stay, mean (SE) (hours)a 2.8 (4.7) 2.4 (3.3) 0.02 
Hospital Length of Stay, mean (SE) (days)b 3.8 (5.8) 4.7 (6.3) 0.05 
Disposition   <0.05 
Discharge to Home 602 (64.2) 708 (45.1)  
Admit 273 (29.1) 800 (50.9)  
Transfer to psych 27 (2.9) 20 (1.3)  
Other 36 (3.8) 43 (2.7)  
a Excluding those admitted to the hospital. 
b Only those admitted to the hospital. 
 
more than 2 cannabis codes. Among all ED discharges in 2016 cannabis use and abuse codes 
were the most prevalent. Discharges attributed to cannabis had a higher prevalence of 
poisoning by cannabis codes at 4.5% (n=42) compared to 0.3% (n=5) of discharges not 
attributed to cannabis (Table 8). Cannabis dependence codes were also more prevalent among 
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Table 7. Criteria for determination of partial cannabis attribution and diagnoses of 
emergency department visits determined partially attributed to cannabis (N=942). 
Criteria Met for Attribution to cannabis N (%) 
1. ED physician identified cannabis as likely precipitating or contributing to the 
condition bringing the patient to the ED  727 (77.2) 
2. The patient was admitted to the hospital and the inpatient physician identified 
cannabis as likely precipitating or contributing to the condition  114 (12.1) 
3. The urine toxicology screen was positive AND there was a documented 
temporal (within ~24 hours) relationship between cannabis exposure and a 
condition or event known to be associated with cannabisa 56 (5.9) 
4. Met multiple criteria 43 (4.6) 
Missing 2 (0.2%) 
Diagnosis  
Altered mental status 87 (9.2) 
Cardiovascular 46 (4.9) 
Dermatologic 4 (0.4) 
Gastrointestinal 272 (28.9) 
Intoxication 262 (27.8) 
Motor vehicle collision 12 (1.3) 
Neurologic 78 (8.3) 
Psychiatric 232 (24.8) 
Respiratory 71 (7.5) 
Trauma 33 (3.5) 
Other 35 (3.7) 
a Conditions known to be associated with cannabis exposure included: (unintentional marijuana exposures, cannabis poisonings 
or overdoses, motor vehicle collision, injury due to impairment, cyclic vomiting, ischemic stroke in individuals younger than 55 
years old, chronic bronchitis with cough/wheeze/sputum, psychotic symptoms or disorders, acute panic attack, and withdrawal 
symptoms. 
discharges attributed to cannabis (2.8%) compared to those not (1.0%) (Table 8). Among 
poisoning by cannabis codes 22 (46.8%) were accidental, 2 (4.3%) were self-harm, 9 (19.1%) 
were undetermined, and 14 (29.8%) were adverse effect of cannabis. There were no poisoning 
by cannabis assaults or underdosing of cannabis codes present in our study. 
PPV Results 
Cannabis ICD-10-CM PPVs 
Among ED discharges with a cannabis code, 37% (PPV: 0.37, 95% CI: 0.35-0.39) were 
attributed to cannabis. Among ED discharges with a cannabis use, abuse, or dependence code 
(excluding intoxication), 34% (PPV: 0.34, 95% CI: 0.32-0.36) were attributed to cannabis and 
captured 86.9% of all ED discharges attributed to cannabis. Ninety percent (PPV: 0.90, 95% CI: 
0.82-0.95) of ED visits with a cannabis poisoning or intoxication code were attributed to 
cannabis and captured 14.4% of all ED discharges attributed to cannabis. Examination of PPVs 
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in cannabis code chapters showed that poisoning by, adverse effect of, or underdosing of 
cannabis (T40.7) performed the best (PPV: 0.89, 95% CI: 0.77-0.96), followed by cannabis 
dependence (PPV: 0.62, 95% CI: 0.47-0.76), cannabis abuse (PPV: 0.45, 95% CI: 0.42-0.48), 
and cannabis use (PPV: 0.31, 95% CI: 0.29-0.33) (Table 8). 
Table 8. Positive predictive values for cannabis specific ICD-10-CM codes evaluated for 






Positives PPV (95% CI) 
Cannabis abuse (F12.1)a 413 918 0.45 (0.42-0.48) 
Cannabis dependence (F12.2)b 26 42 0.62 (0.47-0.76) 
Cannabis use (F12.9)c 476 1539 0.31 (0.29-0.33) 
Poisoning by, adverse effect of cannabis (T40.7)d 42 47 0.89 (0.77-0.96) 
Cannabis Intoxication (F12.12, F12.22, or F12.92) 94 105 0.90 (0.82-0.95) 
Cannabis Poisoning or Intoxication (T40.7, F12.12, F12.22, or 
F12.92) 
136 152 0.89 (0.83-0.94) 
Cannabis Use, Abuse, or Dependence (without intoxication) 
(F12.1, F12.2, or F12.9, but not F12.12, F12.22, or F12.92) 
819 2388 0.34 (0.32-0.36) 
At least one cannabis code (F12 or T40.7) 942 2528 0.37 (0.35-0.39) 
aIncludes truncated or incomplete codes starting with (F12.1). 
bIncludes truncated or incomplete codes starting with (F12.2). 
c Includes truncated or incomplete codes starting with (F12.9). 
dIncludes truncated or incomplete codes starting with (T40.7). 
 
Cannabis ICD-10-CM Codes alone vs with Other Substance Codes PPVs 
The presence of a cannabis code without additional substance codes improved the PPV 
from 0.37 (95% CI: 0.35-0.39) to 0.41 (95% CI: 0.38-0.45) (p value=0.0028). There was 
marginally significant improvement of the PPV for cannabis use, abuse, or dependence codes 
(excluding intoxication) from 0.34 (95% CI: 0.32-0.36) to 0.37 (95% CI: 0.34-0.40) (p 
value=0.0524). Cannabis intoxication codes improved with the highest PPV at 0.96 (95% CI: 
0.85-0.99) compared to 0.90 (95% CI: 0.82-0.95) (p value=0.0483), but still captured a small 
percent (12.8%) of ED visits attributed to cannabis. Among the cannabis code chapters, limiting 
to cannabis abuse codes without additional substances codes improved the PPV from 0.42 
(95% CI: 0.38-0.46) to 0.52 (95% CI: 0.46-0.57) (p value=0.0048), however, cannabis 
dependence, use, or poisoning codes were not significantly improved (Table 9). 
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Table 9. Positive predictive values for cannabis specific ICD-10-CM codes evaluated for 
determining emergency department visits attributed to cannabis at UCH in 2016 by 
records with cannabis codes and those with cannabis codes and other substances. 
 
Cannabis - Substance Codes 
(N=849) 
 Cannabis + Substance Codes 
(N=1,679) 
 
Code Descriptions TPe APf PPV (95% CI)  TP AP PPV (95% CI) p Value 
Cannabis abuse (F12.1)a 156 302 0.52 (0.46-0.57)  257 616 0.42 (0.38-0.46) <0.05 
Cannabis dependence 
(F12.2)b 10 15 0.67 (0.38-0.88)  16 27 0.59 (0.39-0.78) 0.23 
Cannabis use (F12.9)c 170 517 0.33 (0.29-0.37)  306 1022 0.30 (0.27-0.33) 0.24 
Poisoning by, adverse effect 
of cannabis (T40.7)d 20 22 0.91 (0.71-0.99)  22 25 0.88 (0.69-0.97) 0.75 
Cannabis Intoxication 
(F12.12, F12.22, or F12.92) 45 47 0.96 (0.85-0.99)  49 58 0.84 (0.73-0.93) 0.05 
Cannabis Poisoning or 
Intoxication (T40.7, F12.12, 
F12.22, or F12.92) 65 69 0.94 (0.89-1)  71 83 0.86 (0.76-0.92) 0.07 
Cannabis Use, Abuse, or 
Dependence (without 
intoxication) (F12.1, F12.2, or 
F12.9, but not F12.12, F12.22, 
or F12.92) 290 784 0.37 (0.34-0.4)  529 1604 0.33 (0.31-0.35) 0.05 
At least one cannabis code 
(F12 or T40.7) 351 849 0.41 (0.38-0.45)  591 1679 0.35 (0.33-0.38) <0.05 
aIncludes truncated or incomplete codes starting with (F12.1). 
bIncludes truncated or incomplete codes starting with (F12.2). 
c Includes truncated or incomplete codes starting with (F12.9). 
dIncludes truncated or incomplete codes starting with (T40.7). 
eTP: True Positives or ED visits with cannabis ICD-10-CM codes and determined attributed to cannabis. 
fAP: All Positive or all ED visits with cannabis ICD-10-CM codes 
 
Discussion 
We found that cannabis intoxication and poisoning ICD-10-CM codes have the highest 
probabilities of predicting ED discharges attributed to cannabis, but these codes were rare and 
captured only 14.4% of the true positives. Limiting to ED discharges with a cannabis code and 
no additional substance codes improved the prediction for ED discharges attributable to 
cannabis; however, this improvement resulted in a PPV of 41% and therefore a large proportion 
of ED discharges attributable to cannabis were missed. The presence of at least one cannabis 
code captured all ED discharges attributable to cannabis but 63% of those captured were not 
attributable to cannabis. 
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Our finding are consistent with national drug overdose guidance from the Council for 
State and Territorial Epidemiologist and CDC in using drug poisoning codes to identify ED 
discharges caused by drug poisoning or overdose.162 However, this study shows that applying 
those guidelines to cannabis may lead to an underestimation of ED discharges attributed to 
cannabis by 85.6%. Additionally, this guidance recommends excluding adverse effects codes 
from poisoning definitions.162 In our study adverse effect of cannabis codes comprised 29.8% of 
all poisoning by cannabis codes and performed well with a PPV at 86%. In 2018 statewide ED 
discharges, the cannabis adverse effect codes were 34.6% of all poisoning by cannabis codes 
(data not published).25 It is possible that the use of the adverse effects code is due to physicians 
becoming familiar with the new coding system and the new chapter for cannabis poisonings. 
Conversations with local coders have revealed that at some facilities physicians do not 
recognize that documentation of “adverse effects of cannabis” results in a different ICD-10-CM 
code than “poisoning by cannabis”. It is also possible in the context of legal medical cannabis 
use, adverse effects would be a description for proper use of recommended medical cannabis 
from a physician and a patient experiencing an adverse effect. Other federally illicit substance 
codes, like heroin, do not have an option for adverse effects which makes adverse effects of 
cannabis more challenging to interpret. Nevertheless, excluding these codes could 
underestimate the true number of ED discharges attributed to cannabis and induce an 
increasing trend as providers adopt documentation to be more in line with national guidance 
overtime.  
Alternatively, including all cannabis ICD-10-CM codes in a case definition to capture ED 
visits attributable to cannabis would overestimate cannabis attribution by 63% and 59% when 
excluding ED visits with cannabis codes and other substance codes. Cannabis codes that have 
high predictive value like cannabis poisoning, intoxication, or dependence, were rare and 
missed a large proportion of ED visits attributable to cannabis while cannabis codes that 
captured large proportions of ED visits attributable to cannabis, like cannabis abuse and use, 
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were predictive less than 50%. More research is needed on cannabis abuse and use codes to 
find characteristics that may improve their predictive value in a case definition for ED visits 
partially attributed to cannabis.  
If other characteristics in the administrative data cannot improve PPVs for cannabis 
codes then alternative data sources that capture contentment around cannabis terms should be 
considered. Syndromic surveillance through the National Syndromic Surveillance program 
includes chief complaint text along with diagnostic codes which could be used to improve the 
PPV of a case definition for cannabis attribution. The predictive value of cannabis related text 
strings in the chief complaint with or without cannabis coding should be explored. It is possible 
that an administrative case definition that relies on cannabis ICD-10-CM coding to determine ED 
visits attributed to cannabis cannot achieve high predictive values. In that case public health 
should explore other routes for accurately surveilling ED visits attributable to cannabis. One 
option may include review random samples of ED visits with cannabis codes annually in the 
jurisdictions to estimate over counting and then adjust rates according. Another more accurate, 
but costly option may include establishing a clinical definition for cannabis attribution and 
requiring reporting of that condition to health departments. 
Limitations 
These data are limited in that they are subject to reporting bias of cannabis use to 
healthcare providers and/or providers screening for cannabis use. With Colorado’s history of 
cannabis legalization, we expect that reporting bias was minimized in this sample. Though it is 
possible that ED visits may have not received a cannabis codes as a result of reporting or 
screening biases. 
There are not standardized clinical definitions for adverse health conditions caused by 
cannabis. Furthermore, research on high potency cannabis and concentrates sold in Colorado’s 
markets is limited due to the Schedule I status of cannabis federally. Some conditions like 
cannabinoid hyperemesis have been described in literature but others like cannabis induced 
42 
 
psychosis remain vague and difficult to diagnose. For this reason, our chart abstractions in this 
study may be biased. We attempted to mitigate this bias by using a medical toxicologist to 
arbitrate questionable ED discharges and by minimizing discharges counted as attributable 
when an attending physician did not document cannabis as a contributing factor to the visits. 
Though our approach was conservative in assigning attribution to cannabis, some ED visits may 
have been misclassified as not attributable to cannabis due to lack of standard clinical 
guidelines for cannabis adverse health conditions. This may have biased our findings by 
lowering the PPVs. 
 A large percent (85.6%) of ED discharges attributed to cannabis received a cannabis 
use, abuse, or dependence code. Many of these codes did not include symptoms coding and 
were coded more generally like cannabis abuse uncomplicated (F12.10) instead of Cannabis 
abuse with psychotic disorder with delusions (F12.150). Sensitivity analyses showed that 
cannabis coding indicating symptoms (i.e. with delirium, with perceptual disturbance, with 
psychotic disorder) improved the PPVs of these codes. However, this study was underpowered 
to provide reliable PPV estimates for these codes. Further research on a larger sample of ED 
discharges should examine the improvement of PPVs in cannabis use, abuse, and dependence 
codes described with symptoms (6th character) compared to more general coding.  
The attending ED physician determined cannabis attribution in 77.2% of true positives. 
For the 273 (29.1%) of ED visits attributed to cannabis that were admitted it was not always 
documented if the attending ED physician and inpatient physician agreed on cannabis 
attribution. During the chart abstraction process once cannabis attribution was established by 
the attending ED physician no more abstraction was required even if the patient was admitted 
and therefore agreement with the inpatient physician was not always captured. An additional 
review of the inpatient records for agreement between the two physicians would strengthen the 
determination of attributable to cannabis. 
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It was determined a priori that at least 1,200 ED visits would need at least one cannabis 
ICD-10-CM code from January 1, 2016 to December 31, 2016 to detect PPVs as high as 93% 
with 95% confidence, 80% power, at a 1% prevalence, and with sensitivities and specificities as 
low as 88% and 85% respectively. Our sample included 2,528 ED visits with at least one 
cannabis ICD-10-CM code (Appendix E). While we were likely powered to detect high PPVs 
with at least one cannabis code, we may have been underpowered to detect high PPVs in the 
individual cannabis chapters cannabis abuse, cannabis dependence, cannabis use, and 
poisoning by cannabis codes.  
Conclusions 
 Cannabis poisoning and intoxication codes perform well independently or combined in 
identifying ED discharges attributable to cannabis. However, these codes are rare and 
underestimate the true number of ED discharges attributed to cannabis. The absence of an 
additional substance code can improve the predictive value of cannabis codes but captures less 
than half of ED discharges attributable to cannabis. More research is needed on possible 






IMPROVING POSITIVE PREDICTIVE VALUES OF CANNABIS ABUSE, DEPENDENCE, AND 
USE ICD-10-CM CODES WITH CODE POSITIONS AND CO-OCURRING CODES 
Abstract 
Introduction: Cannabis poisoning and intoxication ICD-10-CM codes had positive 
predictive values as high as 90% at identifying emergency department (ED) visits attributable to 
cannabis, but captured 14% of total ED visits attributed to cannabis. Cannabis abuse, 
dependence, and use codes were in 86% of ED visits attributed to cannabis, but had low 
positive predictive values ranging 30%-67% in predicting cannabis attribution. It is possible that 
other characteristics in the record, like diagnostic code position, may improve the positive 
predictive value (PPV) of these codes. We aimed to increase cannabis abuse, dependence, and 
use ICD-10-CM codes’ PPV by examining the position of the cannabis code in the up to 30 
diagnosis codes for each record and examining co-occurring diagnosis codes of outcomes 
related to cannabis. 
Methods: All emergency department visits at the University of Colorado Hospital with a 
cannabis abuse, dependence, or use ICD-10-CM code between January 1, 2016 and December 
31, 2016 were included. We calculated PPVs of cannabis ICD-10-CM codes with co-occurring 
codes of outcomes related to cannabis and PPVs for cannabis ICD-10-CM codes at varying 
code position cut points. True positives were confirmed with chart review for cannabis 
attribution. PPVs were compared with a generalized score statistic proposed by Kosinski (2013) 
and significance set at an alpha 0.05. 
Results: There were 73 ED visits with cannabis abuse, dependence, or use codes in the 
primary diagnosis and 95% (95% CI: 87%-98%) of those visits were attributed to cannabis. 
Cannabis abuse, dependence, or use codes in the primary diagnosis captured 8.6% of true 
positives. PPVs for cannabis abuse, dependence, or use ICD-10-CM codes and codes of 
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outcomes related to cannabis, like codes for cyclic vomiting (52%), psychotic 
symptoms/disorders (48%), or altered mental status (58%) were significantly improved 
compared to PPVs of cannabis abuse, dependence, or use codes (34%) (p <0.05). 
Conclusions: When cannabis codes in the primary diagnosis are included in a case 
definition with cannabis poisoning and intoxication codes, 23% of the ED visits attributed to 
cannabis would be captured at high positive predictive values ranging from 89%-96%. PPVs 
were slightly improved from codes of outcomes related to cannabis use. Other cooccurring ICD-
10-CM codes, such as codes for symptoms related to cannabis use, should be considered to 
further improve the positive predictive value of cannabis abuse, dependence, and use codes. 
Introduction 
The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-
10-CM) expanded ICD-9-CM diagnosis codes from ~14,000 to ~68,000 and expanded cannabis 
codes from 10 to 53 codes.97,144 The newly added cannabis codes are more specific to cannabis 
poisonings, intoxication, and use. Cannabis poisoning and intoxication ICD-10-CM codes 
perform well at predicting emergency department (ED) visits attributed to cannabis with positive 
predictive values (PPVs) between 89%-96%. However, these codes capture 14% of all ED visits 
attributed to cannabis. Cannabis use, abuse, and dependence codes are present in 86% of ED 
visits attributable to cannabis, but perform poorly with PPVs between 30%-62%. Limiting to 
cannabis poisoning or intoxication codes to capture ED visits attributable to cannabis could 
underestimate the true prevalence by 86% but including cannabis abuse, dependence, or 
poisoning codes could overestimate true prevalence by 63%.  
To date there is no standardized guidance on the predictive value of substance use ICD-
10-CM codes (F codes) and national surveillance efforts grouped these codes in ICD-9-CM 
together as drugs with potential for abuse.168  National guidance from the Council for State and 
Territorial Epidemiologist and CDC is limited to drug poisonings and overdose in ICD-10-CM 
which only includes ICD-10-CM for drug poisonings (T codes).87 There are two limitations to 
46 
 
measuring ED visits attributable to cannabis according to this guidance. First, cannabis does not 
have a clinical definition for poisoning or overdose; therefore, cannabis poisonings or overdoses 
are likely being coded under other cannabis ICD-10-CM codes like cannabis abuse, 
dependence, or use. Second, developing an indicator to monitor adverse health events that lead 
to ED visit as a measure of the impacts of cannabis legalization extend past overdoses and 
poisonings. Other impacts like intoxication, injuries due to impairment, and cannabinoid 
hyperemesis should also be considered.119–123,153,154 Cannabis abuse, dependence, and use 
ICD-10-CM codes poorly identify ED visits attributed to cannabis alone, but other characteristics 
in the discharge data may improve their predictive value.  
Coding guidelines from Centers for Medicare and Medicaid govern the selection of the 
primary or first listed diagnosis code as the “condition established after study to be chiefly 
responsible for occasioning the admission of the patient to the hospital for care.”169,170 A study 
by the Healthcare Cost and Utilization Project found the first listed diagnosis code in ED visits 
was descriptive for the condition in treatment. However, the study emphasized that ED visits are 
more focused on symptom treatment and more than one diagnosis code may contribute to the 
reason for the visit.170 The position of a cannabis abuse, dependence, or use code may 
influence the PPV for the ED visit being attributed to cannabis as it should indicate the reason 
for the ED visit.  
Another discharge characteristic that may improve PPVs of cannabis abuse, 
dependence, or use codes are the cooccurring diagnosis codes that further describe the reason 
for the visit. ICD-10-CM codes of outcomes related to cannabis use as documented in the 
literature, may help to indicate cannabis attribution. Codes of outcomes including motor vehicle 
collision103–106, injury due to impairment171–179, cyclic vomiting 119–123,153,154, chronic bronchitis 
with cough/wheeze/sputum130,131,133,136,157–159, psychotic symptoms or disorders54,57,59,138,160, 
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acute panic attack107,108, and withdrawal symptoms alongside cannabis abuse, dependence, or 
use codes could improve their ability to predict cannabis attribution.  
In this study we aimed to improve the PPVs for cannabis abuse, dependence, and use 
ICD-10-CM codes to predict ED visits partially attributed to cannabis by 1) examining them with 
codes of outcomes related to cannabis use and 2) examining their position in the list of 
discharge diagnosis codes. We hypothesized PPVs for cannabis abuse, dependence, and use 
codes ability to predict attribution to cannabis will be increased in ED visits with these cannabis 
codes and codes of outcomes related to cannabis use. We also hypothesized that the PPVs of 
cannabis abuse, dependence, and use ICD-10-CM codes will be improved in the primary 
diagnosis and decreased as the code position is further away from the primary diagnosis.  
Materials and Methods 
Study Design and Population 
We utilized a retrospective cohort study design and selected all ED visits discharged 
from January 1, 2016 00:00 to December 31, 2016 23:59 that had at least one cannabis abuse, 
dependence, or use ICD-10-CM code in the up to 30 listed diagnosis codes from the University 
of Colorado Hospital Emergency Department (UCHED) an urban, academic, Level 2 Trauma 
center (Figure 8). Records without discharge diagnosis codes were excluded from the sample. 
The electronic medical records (EMRs) were manually reviewed to determine if the visit was at 
least partially attributable to cannabis use. We looked at encounter-level data instead of patient-
level data, so individuals may have had multiple visits to the ED during this time period.  
Verification of Cannabis Attribution 
Partial attribution to cannabis was determined through manual review of electronic 
medical records (EMRs) by three trained abstracters blinded to the study objective. ED visits 
with cannabis coding were determined at least partially attributable to cannabis if at least one of 
48 
 
the following criteria were met: 1) the ED physician identified cannabis as likely precipitating or 
contributing to the condition bringing the patient to the ED, 2) the patient was admitted to the 
hospital, and the inpatient provider identified cannabis as likely precipitating or contributing to 
 
Figure 8. Sampling strategy for calculating positive predictive values for cannabis ICD-
10-CM codes and predicting ED visits partially attributable to cannabis. 
 
 
the condition, or 3) the urine toxicology screen was positive for delta-9-tetrahydrocannabinol 
AND there was a temporally related cannabis exposure documented in the medical record (~24 
hours) with a condition known to be associated with cannabis use. Conditions know to be 
associated with cannabis use included unintentional marijuana exposures20,24,152, cannabis 
poisonings or overdoses, motor vehicle collision103–106, injury due to impairment171–179, cyclic 
vomiting 119–123,153,154, chronic bronchitis with cough/wheeze/sputum130,131,133,136,157–159, psychotic 
symptoms or disorders54,57,59,138,160, acute panic attack107,108, and withdrawal symptoms. Both 
urine toxicology screening and documentation of temporal cannabis use were necessary in 
these cases otherwise, the visit was considered not attributable to cannabis. Assessment of 
UCH ED visits discharged in 2016 
N=98,521 










Reviewed for cannabis attribution 
N=2,376 (100.0%) 
Cannabis abuse, dependence, or use ICD-10-




cannabis use was included in the drug use section of the standard nursing assessment 
questionnaire performed on every patient seen in the UCHED (Table 10).118  
A sample of 10% UCHED charts with at least one cannabis ICD-10-CM code were 
abstracted by both a medical toxicologist and the trained abstractors. Abstractors were retrained 
on any discrepancies during initial training. Visits with questionable cannabis attribution were 
arbitrated by a single medical toxicologist (AAM). For quality control, an 8.0% random sample 
was double reviewed by the same medical toxicologist. A Cohen’s Kappa statistic was 
evaluated for inter-rater agreement. The kappa statistic for the electronic medical records review 
for cannabis attribution was 0.92 (95% CI: 0.86-0.98) indicating good inter-rater reliability. The 
full instrument used for manual records review can be found in Appendix B. 
Table 10. Criteria to determine partially attributed to marijuana within the electronic 
medical record (EMR). 
Criteria  
1) ED physician identified marijuana as likely precipitating or contributing to the condition 
bringing the patient to the ED 
OR  
2) If the patient was admitted to the hospital, and the inpatient provider identified marijuana 
as likely precipitating or contributing to the condition 
OR  
3) The urine toxicology screen was positive for delta-9-tetrahydrocannabinol AND there was 
a temporally related marijuana exposure documented in a condition known to be 
associated with marijuana use 
Outcomes related to 
marijuana use 
Unintentional marijuana exposures20,24,152 
Marijuana poisonings or overdoses 
Motor vehicle collision103–106 
Injury due to impairment171–179 
Cyclic vomiting119–123,153,154 
Chronic bronchitis with cough/wheeze/ sputum 
130,131,133,136,157–159 
Psychotic symptoms or disorders54,57,59,138,160 
Mental health outcomes 
related to marijuana use 
Acute panic attack107,108 
Withdrawal symptoms (only marijuana use indicated) 
 
Demographics 
Age in years was recorded continuously. Gender (male/female) and race/ethnicity (non-
Hispanic White, non-Hispanic African American, Hispanic and non-Hispanic) were coded as 
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categorical variables. Colorado resident status was determined using billing address and coded 
as resident or non-resident. 
Visit Characteristics 
Health insurance was categorized as private, public (state insurance, Medicare, or 
Medicaid), military, and other (indigent or other) insurance provider. To account for patients with 
more than one ED discharge in 2016, the median number of visits per patient (in 2016) was 
calculated. Urine toxicology screening performed at any time during the visit was determined 
and length of stay was calculated as number of hours in ED and separately days in inpatient 
care for those admitted from the ED. Visit disposition was classified as discharge to home, 
admitted, transferred to psychiatric unit, or other. 
Substance Use Characteristics 
Information on urine drug screens was collected during the electronic medical records 
review. Abstractor indicated if a urine toxicology screen was performed and if so then indicated 
if it was positive for THC, opioids, benzodiazepines, barbiturates, amphetamines, cocaine, 
other, or negative. Positive urine toxicology screening for THC was categorized as THC only 
and THC with other substances. THC with other substances were described individually and 
were not mutually exclusive. Blood alcohol levels were categorized as greater than or equal to 
80 milligrams/deciliter (mg/dL) or less than 80 mg/d.  
Predicted Cannabis Attributed ED Discharge 
We performed two PPV analyses. First, all ED visits included were predicted to be 
attributable to cannabis based on the presence of one cannabis abuse (F12.1), cannabis 
dependence (F12.2), or cannabis use ICD-10-CM code and the presence of at least one of the 
following ICD-10-CM codes of outcomes related to cannabis use: motor vehicle collision (V87, 
V88, V89), injury (S00-T32), cyclic vomiting (G43.A, -0, -1, R11), ischemic stroke in individuals 
younger than 55 years old (G45.8, -.9), chronic bronchitis with cough/wheeze/sputum (J40-J42, 
R05, R06.2, R09.3), psychotic symptoms or disorders (F22, F23, F28, F29, F30.2, F31.2, F32.3, 
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F33.3), acute panic attack (F41.0), withdrawal symptoms (F19.93), or altered mental status 
(unspecified) (R41.82) (Appendix F).97 Second, ED visits with one ICD-10-CM code for cannabis 
abuse, dependence, or use were predicted attributed to cannabis in the primary diagnosis 
verses any diagnosis position, in the second position verses any position, in 3-5, 6-10, 11-15, 
16-30 verses any position. Cannabis code position was assigned by scanning the discharge 
diagnosis codes from 1st position to 30th position and assigning the position of the first listed 
cannabis code. 
Statistical Analysis 
All analyses were completed using SAS version 9.4 (SAS Institute Inc., Cary, NC). 
Demographics, clinical characteristics, and substance use characteristics for ED visits with a 
cannabis abuse, dependence, or use code were examined by cannabis attribution and tested 
using a Pearson chi squared test for categorical comparisons and an ANOVA for continuous 
comparisons. We calculated PPVs using Equation 3.1. We calculated PPVs for ED visits with  
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.1: 𝑃𝑃𝑉 = 𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 
cannabis codes and codes of outcomes related to cannabis use for each cannabis code (abuse, 
dependence, and use) and compared it to the PPVs for each cannabis code without codes of 
outcomes related to cannabis use.  Visits with multiple cannabis code chapters were included in 
multiple PPV calculations. PPVs were calculated for categorized diagnostic positions (1st, 2nd, 
3rd-5th, 6th-10th, 11th-15th, and 16th-30th) of the first listed cannabis code and compared to PPVs of 
cannabis codes in any position. We stratified PPVs for cannabis code position by cannabis code 
(abuse, dependence, and use). True positives were ED visits that met the criteria for partially 
attributed to cannabis. False positives were ED visits predicted positive but did NOT meet the 
criteria for partially attributed to cannabis. We calculated binomial 95% confidence intervals 
(95% CI) using the Clopper-Pearson exact method for each PPV using the binomial option in 
SAS FREQ procedure. We compared PPVs for improvement using the generalized score 
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statistic proposed by Kosinski (2013) (Equation 3.2) and set significance at alpha 0.05.165–167 The 








There were 98,521 emergency department (ED) discharges at the UCH Anschutz 
campus emergency department in 2016. Of those, 2,528 (2.6%) ED visits had at least one 
cannabis ICD-10-CM code. There were 152 (6.0%) ED visits with cannabis poisoning or 
intoxication codes that were excluded and 14 (9.2%) of those also had a cannabis abuse, 
dependence, or use code. No ED visits had more than two cannabis codes listed. The final 
sample included 2,376 (2.4%) ED visits with at least one cannabis abuse, dependence, or use 
ICD-10-CM code in the discharge diagnoses and no cannabis poisoning or intoxication ICD-10-
CM codes. All 2,376 ED visits were reviewed for attribution to cannabis (Figure 9). There were 9 




There were 806 (33.9%) ED discharges determined partially attributed to cannabis 
through manual review of EMRs. ED discharges determined partially attributable to cannabis 
were on average 4.2 years younger (34.3 years, p<0.0001), majority male (67.7%, p=0.0006), 
and a higher percent had private (14.5% vs 10.4%) or other health insurance (14.1% vs 11.3%). 
There was a higher percentage of non-Colorado residents among ED discharges attributed to 
cannabis (12.0%) compared to ED discharges not attributable to cannabis (5.5%) (p<0.0001). 
Among ED discharges attributed to cannabis 358 (44.5%) were White, non-Hispanic, 269 
(33.5%) were African American, non-Hispanic, 146 (18.2%) were Hispanic, and 31 (3.9%) were 
other race. There were 58 (8.2%) ED discharges attributed to cannabis with more than one ED 
visit within 2016 which was not significantly difference from ED discharges not attributed to 
cannabis (N=129, 9.3%) (p=0.5064). However, the range of number of visits within 2016 was 
larger in ED visits attributed to cannabis (1-13 visits) compared to those not attributed (1-10 
visits). There was no difference in the average length of hours spent in the emergency 
department in ED discharges attributed to cannabis was compared to those not attributed to 
cannabis (2.4 hours vs 2.3 hours) (p=0.4094). There were fewer ED visits admitted to inpatient 
in those attributed to cannabis (31.4%) compared to those not attributed to cannabis (51.1%) 
(p<0.0001). On average length of inpatient stay was 0.8 days shorter in ED visits attributed to 
cannabis compared to ED visits not attributed to cannabis (3.8 days vs 4.6 days) (p=0.0361). 
Among ED discharges attributed to cannabis 61.4% were discharged to home, 31.4% were 
admitted, 3.2% were transferred to psychiatric unit, and 4.0% had other dispositions compared 
to 44.9%, 51.1%, 1.3%, and 2.8% among ED discharges not attributable to cannabis 
respectively (p<0.0001) (Table 11). 
Among the 806 ED visit partially attributed to cannabis, 605 (75.1%) were determined 
attributable by the ED physician, 105 (13.0%) were determined attributable by the inpatient 
physician, 55 (6.8%) were determined attributable by a positive toxicology screen for THC, a 
temporal exposure, and a condition related to cannabis use, 40 (5.0%) met multiple criteria, and 
54 
 
1 (0.1%) was missing criteria. Most diagnoses documented for ED visits attributable to cannabis 
were gastrointestinal (32.0%), psychiatric (25.4%), intoxication (19.5%), neurologic (8.4%), 
respiratory (8.2%), and altered mental status (7.6%). Other diagnoses included cardiovascular 
(4.7%), other (4.1%), trauma (3.1%), motor vehicle collision (1.2), and dermatologic (0.5%) 
(Table 12). 
Toxicology Results 
Urine toxicology screens were performed in 5,788 ED visits (5.9%) in 2016. There were 
2,214 (93.2%) of the ED discharges with cannabis abuse, dependence, or use ICD-10-CM 
codes that had a urine toxicology screen performed. This comprised 38.3% of the total number 
of urine toxicology screens performed in ED visits in 2016. Among those 2,115 (95.5%) 
discharges had a positive urine toxicology screen. A larger percent of ED visits received a urine 
toxicology screen in those attributed to cannabis (96.5%) compared to those not attributed to 
cannabis (91.5%) (p<0.0001) and a larger percent of ED visits had positive urine toxicology 
screen in those attributed to cannabis (92.3%) compared to those not (87.4%) (p=0.0003). 
There were 2,092 (94.5%) ED visits positive for THC. Among those attributed to cannabis 743 
(99.9%) discharges were positive for THC compared to 1,349 (98.4%) in discharges not 
attributed to cannabis (p=0.0019). A smaller proportion of ED discharges attributed to cannabis 
were positive for THC only (63.7%) compared to ED discharges not attributed to cannabis 
(70.3%) (p=0.0019). Toxicology screens positive for THC and other substances were similar 
between discharges attributed and not attributed to cannabis. Blood alcohol levels were tested 
in 336 (14.1%) ED visits with cannabis codes and in 99 (29.5%) visits the patient tested above 
80 mg/dL. This was similar by cannabis attribution (p=0.2489) (Table 11).  
Cannabis ICD-10-CM Codes with Code of Cannabis Related Outcomes PPVs 
There were 976 cannabis related outcome discharge codes among ED discharges with  
a cannabis abuse, dependence, or use code. There were not any ED visits with cannabis 
abuse, dependence, or use codes and motor vehicle collision codes or withdrawal symptoms 
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code. Codes for cyclic vomiting, psychotic symptoms or disorders, and altered mental status 
with a cannabis abuse, dependence or use code improved the PPV from 34% in cannabis 
Table 11. Demographics of emergency department visits that received a cannabis abuse, 
dependence, or use ICD-10-CM code and not a cannabis poisoning or intoxication code 
at UCH in 2016 by attribution to cannabis or not (N=2,376). 
 Attributed to Cannabis  
N (%) Yes (N=806) No (N=1,570) P Value 
Age, mean (SE) 34.3 (13.1) 38.5 (14.1) <0.05 
Male 546 (67.7) 951 (60.6) <0.05 
Race   0.03 
White, Non-Hispanic 358 (44.5) 738 (47.2)  
African American, Non-Hispanic 269 (33.5) 550 (35.2)  
Hispanic 146 (18.2) 211 (13.5)  
Other, Non-Hispanic 31 (3.9) 64 (4.1)  
Resident Status   <0.05 
Colorado Resident 709 (88.0) 1,483 (94.5)  
Nonresident 97 (12.0) 87 (5.5)  
Health Insurance   <0.05 
Private 117 (14.5) 163 (10.4)  
Public 551 (68.4) 1,202 (76.7)  
Military 24 (3.0) 25 (1.6)  
Other 114 (14.1) 177 (11.3)  
More than one visit in 2016 58 (8.2) 129 (9.3) 0.42 
Number of visits in 2016, median (range) 1.0 (1-13) 1.0 (1-10)  
Toxicology Tested 778 (96.5) 1,436 (91.5) <0.05 
Positive Urine Toxicology 744 (92.3) 1,371 (87.4) <0.05 
THC 743 (99.9) 1,349 (98.4) <0.05 
THC Only 473 (63.7) 948 (70.3) <0.05 
THC with Other Subs. 270 (36.3) 401 (29.7)  
Opioids 60 (22.2) 104 (25.9) 0.27 
Benzodiazepines 65 (24.1) 72 (18.0) 0.05 
Barbiturates 1 (0.4) 2 (0.5) 0.81 
Amphetamines 101 (37.4) 138 (34.4) 0.43 
Cocaine 96 (35.6) 154 (38.4) 0.45 
Other 65 (24.1) 72 (18.0) 0.05 
Blood Alcohol ≥ 80 mg/dL 39 (4.8) 60 (3.8) 0.25 
ED Length of Stay, mean (SE) (hours)a 2.4 (4.2) 2.3 (2.8) 0.41 
Hospital Length of Stay, mean (SE) (days)b 3.8 (5.2) 4.6 (6.1) 0.04 
Disposition   <0.05 
Discharge to Home 493 (61.4) 698 (44.9)  
Admit 252 (31.4) 794 (51.1)  
Transfer to psych 26 (3.2) 20 (1.3)  
Other 32 (4.0) 43 (2.8)  
a Excluding those admitted to the hospital. 









Table 12. Criteria for determination of partial cannabis attribution and diagnoses of 
emergency department visits determined partially attributed to cannabis (N=806). 
Criteria Met for Attribution to cannabis N (%) 
1. ED physician identified cannabis as likely precipitating or contributing to the 
condition bringing the patient to the ED  605 (75.1) 
2. The patient was admitted to the hospital and the inpatient physician identified 
cannabis as likely precipitating or contributing to the condition  105 (13.0) 
3. The urine toxicology screen was positive AND there was a documented 
temporal (within ~24 hours) relationship between cannabis exposure and a 
condition or event known to be associated with cannabisa 55 (6.8) 
4. Met multiple criteria 40 (5.0) 
Missing criteria 1 (0.1) 
Diagnosis  
Altered mental status 61 (7.6) 
Cardiovascular 38 (4.7) 
Dermatologic 4 (0.5) 
Gastrointestinal 258 (32.0) 
Intoxication 157 (19.5) 
Motor vehicle collision 10 (1.2) 
Neurologic 68 (8.4) 
Psychiatric 205 (25.4) 
Respiratory 66 (8.2) 
Trauma 25 (3.1) 
Other 33 (4.1) 
a Conditions known to be associated with cannabis exposure included: (unintentional marijuana exposures, cannabis poisonings 
or overdoses, motor vehicle collision, injury due to impairment, cyclic vomiting, ischemic stroke in individuals younger than 55 
years old, chronic bronchitis with cough/wheeze/sputum, psychotic symptoms or disorders, acute panic attack, and withdrawal 
symptoms. 
 
abuse, dependence, or use codes to 52% (p<0.0001), 48% (p=0.0093), and 58% (p=0.0033) 
respectively. There were a total of 434 (18.3%) ED visits with cannabis abuse, dependence, or 
use codes and cyclic vomiting codes. Among those, 51.8% were determined partially 
attributable to cannabis. Examining cannabis abuse, dependence, or use codes with injury, 
chronic bronchitis, or acute panic attack codes did not improve PPVs (Table 13). Stratification 
by cannabis code chapter showed that cyclic vomiting ICD-10-CM codes improved PPVs for 
cannabis abuse (67% vs 41%, p<0.0001), dependence (80% vs 60%, p=0.0360), and use (42% 
vs 29, p<0.0001). Codes for psychotic symptoms or disorders and altered mental status 
improved PPVs for cannabis use ICD-10-CM codes to 44% (p=0.0474) and 64% (p=0.0056) 
compared to 29%. No other codes of outcomes related to cannabis use improved the PPVs of 




Table 13. Positive predictive values for cannabis specific ICD-10-CM codes evaluated for 





Positives PPV (95% CI) p Value 
Cannabis Use, Abuse, or Dependence (without 
intoxication or poisoning) (F12.1, F12.2, or F12.9, but not 
F12.12, F12.22, or F12.92) 806 2,376 0.34 (0.32-0.36) (reference) 
Motor vehicle collision (V87, V88, V89) 0 0 -  
Injury (S00-T32) 87 326 0.27 (0.22-0.32) <0.05 
Cyclic vomiting (G43.A, -0, -1, R11) 225 434 0.52 (0.47-0.57) <0.05 
Chronic bronchitis with cough/wheeze/sputum (J40-
J42, R05, R06.2, R09.3) 15 51 0.29 (0.17-0.44) 0.51 
Psychotic symptoms or disorders (F22, F23, F28, 
F29, F30.2, F31.2, F32.3, F33.3) 41 85 0.48 (0.37-0.59) <0.05 
Acute panic attack (F41.0) 14 37 0.38 (0.22-0.55) 0.62 
Withdrawal symptoms (F19.93) 0 0 -  
Altered mental status (unspecified) (R41.82) 25 43 0.58 (0.42-0.73) <0.05 
Cannabis abuse (F12.1)a 348 849 0.41 (0.38-0.44) (reference) 
Injury (S00-T32 + Cannabis Code) 32 104 0.31 (0.22-0.41) <0.05 
Cyclic vomiting (G43.A, -0, -1, R11) 100 150 0.67 (0.59-0.74) <0.05 
Chronic bronchitis with cough/wheeze/sputum (J40-
J42, R05, R06.2, R09.3) 4 13 0.31 (0.09-0.61) 0.43 
Psychotic symptoms or disorders (F22, F23, F28, 
F29, F30.2, F31.2, F32.3, F33.3) 20 36 0.56 (0.38-0.72) 0.08 
Acute panic attack (F41.0) 4 7 0.57 (0.18-0.90) 0.41 
Altered mental status (unspecified) (R41.82) 12 22 0.55 (0.32-0.76) 0.21 
Cannabis dependence (F12.2)b 24 40 0.60 (0.43-0.75) (reference) 
Injury (S00-T32 + Cannabis Code) 3 5 0.60 (0.15-0.95) 1.00 
Cyclic vomiting (G43.A, -0, -1, R11) 12 15 0.80 (0.52-0.96) 0.04 
Chronic bronchitis with cough/wheeze/sputum (J40-
J42, R05, R06.2, R09.3) NA NA*   
Psychotic symptoms or disorders (F22, F23, F28, 
F29, F30.2, F31.2, F32.3, F33.3) NA NA*   
Acute panic attack (F41.0) 0 0   
Altered mental status (unspecified) (R41.82) 0 0   
Cannabis use (F12.9)c 437 1,492 0.29 (0.27-0.32) (reference) 
Injury (S00-T32 + Cannabis Code) 52 217 0.24 (0.18-0.30) 0.05 
Cyclic vomiting (G43.A, -0, -1, R11) 113 269 0.42 (0.36-0.48) <0.05 
Chronic bronchitis with cough/wheeze/sputum (J40-
J42, R05, R06.2, R09.3) 10 37 0.27 (0.14-0.44) 0.75 
Psychotic symptoms or disorders (F22, F23, F28, 
F29, F30.2, F31.2, F32.3, F33.3) 21 48 0.44 (0.29-0.59) 0.05 
Acute panic attack (F41.0) 10 30 0.33 (0.17-0.53) 0.64 
Altered mental status (unspecified) (R41.82) 14 22 0.64 (0.41-0.83) <0.05 
aIncludes truncated or incomplete codes starting with (F12.1). bIncludes truncated or incomplete codes starting with (F12.2). 
c Includes truncated or incomplete codes starting with (F12.9). *NA: suppressed due to less than 5 ED visits in the denominator. 
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First Listed Cannabis ICD-10-CM Codes Position PPVs 
We found PPVs for cannabis abuse, dependence, or use codes were most improved 
when in the primary diagnosis position (95% vs 34%, p<0.0001) and improvement was 
diminished by codes in the 6th to 30th position. Stratified analysis showed that this trend was 
similar for PPVs of cannabis abuse codes in the primary diagnosis (94% vs 41%, p<0.0001) and 
cannabis use codes in the primary diagnosis (96% vs 29%, p<0.0001). The sample size was too 
small to examine the PPV of cannabis dependence codes in the primary or secondary code 
position. First listed cannabis codes in the second position improved PPVs of cannabis abuse, 
dependence, or use codes (56% vs 34%, p<0.0001), and cannabis abuse (64% vs 41%, 
p<0.0001) and use (49% vs 29%, p<0.0001) codes individually but not as much as the primary 
diagnosis position. Cannabis abuse, dependence, or use codes in the primary diagnosis 
captured 8.6% of true positives and in the second position captured 15.6%. Cannabis codes in 
the first 5 diagnosis positions captured 65.9% of true positives; however, 45% of cannabis 
codes in positions 2-5 were attributed to cannabis. The least predictive positions were cannabis 
codes in positions 16-30 where 4.5% were attributed to cannabis (Table 14). 
Discussion 
Our findings showed that the positive predictive values for cannabis abuse, dependence, 
and use codes were improved to high probabilities of cannabis attribution when the cannabis 
codes were in the primary diagnosis. However, like the cannabis poisoning and intoxication 
codes, cannabis codes in the primary diagnosis are rare and comprise only 8.6% of the true 
positives. Cooccurring codes of cyclic vomiting improved the predictive value for cannabis 
abuse, dependence, and use codes. However, the improved PPVs were still low ranging from 
42%-67% except for cannabis dependence codes where the cooccurrence of cyclic vomiting 
codes improved the PPV to 80%. Cooccurring codes of psychotic symptoms or altered mental 
status improved the PPV for cannabis use codes to predict cannabis attribution, though the 
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improvements were low in predictive value. No other outcome codes related to cannabis use 
improved the PPVs. 
Table 14. Positive predictive values for cannabis specific ICD-10-CM codes’ position in 
determining emergency department visits attributed to cannabis at UCH in 2016. 
Code Position True positives All Positives PPV (95% CI) p Value 
Any position 806 2376 0.34 (0.32-0.36) (reference) 
1st  69 73 0.95 (0.87-0.98) <0.05 
2nd 126 227 0.56 (0.49-0.62) <0.05 
3rd-5th  304 804 0.38 (0.34-0.41) <0.05 
6th-10th  190 676 0.28 (0.25-0.32) <0.05 
11th-15th  81 345 0.23 (0.19-0.28) <0.05 
16th-30th  36 251 0.14 (0.10-0.19) <0.05 
Cannabis abuse (F12.1)a 348 849 0.41 (0.38-0.44) (reference) 
1st  44 47 0.94 (0.82-0.99) <0.05 
2nd 60 94 0.64 (0.53-0.73) <0.05 
3rd-5th 121 267 0.45 (0.39-0.52) 0.08 
6th-10th  75 226 0.33 (0.27-0.40) <0.05 
11th-15th  32 118 0.27 (0.19-0.36) <0.05 
16th-30th  16 97 0.16 (0.10-0.25) <0.05 
Cannabis dependence (F12.2)b 24 40 0.60 (0.43-0.75) (reference) 
1st NA NA   
2nd NA NA   
3rd-5th 6 11 0.55 (0.23-0.83) 0.67 
6th-10th  9 13 0.69 (0.39-0.90) 0.40 
11th-15th  3 7 0.43 (0.10-0.82) 0.33 
16th-30th  2 5 0.40 (0.05-0.85) 0.36 
Cannabis use (F12.9)c 437 1,492 0.29 (0.27-0.32) (reference) 
1st  24 25 0.96 (0.80-1.00) <0.05 
2nd 65 132 0.49 (0.40-0.58) <0.05 
3rd-5th 178 528 0.34 (0.30-0.38) <0.05 
6th-10th  106 438 0.24 (0.20-0.28) <0.05 
11th-15th  46 220 0.21 (0.16-0.27) <0.05 
16th-30th  18 149 0.12 (0.07-0.18) <0.05 
aIncludes truncated or incomplete codes starting with (F12.1). 
bIncludes truncated or incomplete codes starting with (F12.2). 
c Includes truncated or incomplete codes starting with (F12.9). 
NA: suppressed due to less than 5 ED visits in the denominator. 
 
The position of the cannabis code impacted the predictability of the codes to determine 
cannabis attribution such that the closer the codes were to the primary diagnosis the higher its 
predictability. This aligns with inpatient coding guidelines where the primary diagnosis is the 
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reason for the visit and supports studies by the Healthcare Cost and Utilization Project that 
showed the primary diagnosis in emergency department visits were reflective of the reason for 
the visit.169,170 There are scenarios in the coding guidelines that would allow the visit to be 
attributed to cannabis but the primary diagnosis would not be a cannabis code. These 
guidelines include two or more conditions that meet the definition for primary diagnosis or two or 
more comparative or contrasting conditions that allow for either diagnosis to be sequenced 
first.180 Nevertheless, our finding suggest cannabis codes in primary position perform well at 
predicting cannabis attribution and should be considered in developing a ICD-10-CM code case 
definition for ED visits attributable to cannabis. 
The findings from co-occurring codes of outcomes related to cannabis did not show any 
codes of motor vehicle collisions or withdrawal symptom codes with cannabis codes. The lack of 
motor vehicle collision codes is interesting considering there were 10 motor vehicle collision 
diagnoses identified in the manual records review. Also, findings from the Colorado Department 
of Public Safety demonstrate the number of fatal car crashes involving drivers testing positive 
for cannabinoids increased from 55 (11.4% of fatal crashes) in 2013 to 125 (20.6%) 2016.181 It is 
possible the sample was underpowered to detect motor vehicle collision codes with cannabis 
abuse, dependence, or use codes or that coding for cannabis is not being captured in ED visits 
for a motor vehicle collision attributed to cannabis intoxication. A second explanation may be 
that symptom codes or injury codes may have been assigned instead of the motor vehicle 
codes we examined in this study. A third explanation could be that the drivers testing positive in 
fatal crashes may have not been intoxicated but were regular cannabis users and tested 
positive from chronic use. The absence of codes of withdrawal symptoms with cannabis codes 
may be from a small sample size. The prevalence of diagnosed cannabis use disorder among 
US adults ranges from 2.7%-3.2% and the prevalence of cannabis withdrawal syndrome among 
US adults that frequently uses were estimated at 0.4%.182–184 Cannabis attributed withdrawal 
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symptoms are nonspecific like anxiety, hostility, difficulty sleeping, and mood disorders and 
could be receiving codes related to these symptoms and not withdrawal symptoms.180  
Co-occurring codes of cyclic vomiting and cannabis abuse, dependence, or use codes 
improved the PPV of cannabis abuse, dependence, or use codes. This finding supports 
numerous case reports and studies in the literature describing cannabinoid hyperemesis as an 
emerging outcome related to increased cannabis use in communities.119–123,153,154,185,186 Although 
the range of PPVs for cyclic vomiting codes with cannabis abuse, dependence, or use codes 
was low (42%-80%), they should be considered in future development of a case definition for 
ED visits attributed to cannabis. Other outcomes that improved the PPV of cannabis abuse, 
dependence, or use codes were codes of psychotic symptoms and altered mental status. This 
finding supports associations described between psychosis and cannabis 
use52,54,55,57,59,138,160,187–192 and relationships between mental health conditions and increased 
screening for substance use.193 It is likely that patients with mental health evaluations and 
diagnoses have more thorough questioning around substance abuse habits and therefore would 
be more likely to identify characteristics determining the visit attributed to cannabis.194 
Limitations 
These data are limited in that they are subject to patient reporting use of cannabis to 
healthcare providers and/or providers identifying cannabis use. With Colorado’s history of 
cannabis legalization, we expect that reporting bias was minimized in this sample, though it is 
possible that ED visits who should have received a cannabis code did not as a result of 
reporting bias or screening bias. 
There are no standardized clinical definitions for adverse health conditions caused by 
cannabis. Furthermore, research on high potency cannabis and concentrates sold in legal state 
markets is limited due to the schedule I status of cannabis federally. Some conditions like 
cannabinoid hyperemesis have been described in literature119–123,153,154 but others like cannabis 
induce psychosis remain vague and difficult to diagnose.203,204 For this reason, our chart 
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abstractions in this study may be biased. We attempted to mitigate this bias by using a medical 
toxicologist to arbitrate questionable ED discharges and by minimizing discharges counted as 
attributable when an attending physician did not document cannabis as a contributing factor to 
the visits. Though our approach was conservative in assigning attribution to cannabis, some ED 
visits may have been misclassified as not attributable to cannabis due to lack of standard 
clinical guidelines for cannabis adverse health conditions. This may have biased our findings by 
lowering PPVs. 
The attending ED physician determined cannabis attribution in 77.2% of true positives. 
For the 273 (29.1%) of ED visits attributed to cannabis that were admitted it was not always 
documented if the attending ED physician and inpatient physician agreed on cannabis 
attribution. During the chart abstraction process once cannabis attribution was established by 
the attending ED physician no more abstraction was required even if the patient was admitted 
and therefore agreement with the inpatient physician was not always captured. An additional 
review of the inpatient records for agreement between the two physicians would strengthen the 
determination of attributable to cannabis. 
It was determined a priori that at least 1,200 ED visits would need at least one cannabis 
ICD-10-CM code from January 1, 2016 to December 31, 2016 to detect PPVs as high as 93% 
with 95% confidence, 80% power, at a 1% prevalence, and with sensitivities and specificities as 
low as 88% and 85% respectively. Our sample included 2,528 ED visits with at least one 
cannabis ICD-10-CM code. While we were likely powered to detect high PPVs with at least one 
cannabis code, we may have been underpowered to detect high PPVs in the individual 
cannabis chapters cannabis abuse, cannabis dependence, cannabis use, and poisoning by 
cannabis codes.  
These findings were reflective of practices in a large, urban, academic hospital in a state 
with legal retail cannabis and may not be generalizable to other emergency departments in 
dissimilar settings. However, the ICD-10-CM coding system is intended to be a standardized 
63 
 
system that will yield similar results across hospital systems. It is used in national surveillance of 
other conditions including opioid overdoses and therefore we expect similar results would be 
found in similar emergency departments as the one evaluated in this study.162,195 
Conclusions 
When cannabis codes in the primary diagnosis are included in a case definition with 
cannabis poisoning and intoxication codes, 23% of the ED visits attributed to cannabis would be 
captured at high positive predictive values ranging from 89%-96%. There may be characteristics 
within the discharge record that may improve the PPV of the cannabis abuse, dependence, and 
use codes as well as the sensitivity of these codes to capture ED visits attributed to cannabis. 







FINDING NEGATIVE PREDICTIVE VALUE OF CANNABIS ICD-10-CM CODES IN 
EMERGENCY DEPARTMENT DISCHARGES WITH NOVEL TEXT ANALYTICS  
Abstract 
Introduction: The positive predictive values (PPVs) of cannabis ICD-10-CM codes are 
poor. To date the negative predictive value (NPV) of these codes have not been estimated. This 
is a critical step to calculate sensitivity and specificity of cannabis ICD-10-CM codes but it can 
be difficult and costly to review all records for false negatives. We aimed to develop a novel text 
mining approach to capture emergency department (ED) visits most likely to be false negatives 
and review them for cannabis attribution. 
Methods: All emergency department visits at the University of Colorado Hospital without 
cannabis ICD-10-CM codes between January 1, 2016 and December 31, 2016 were included. 
We searched the chief complaint, lab records, nurse’s notes, physician notes, and history and 
physical for cannabis text strings. We limited records to those indicating recent cannabis use or 
intoxication. We prioritized cannabis text strings for likelihood of being attributed to cannabis to 
manually review a random sample of electronic medical records. ED visits without cannabis 
ICD-10-CM codes were the predicted negative condition. The true negative condition was 
verified by the determination of not attributed to cannabis by records review of a random 
sample. We described cannabis text strings and calculate NPV for cannabis ICD-10-CM codes. 
Results: There were 10,361 (10.8%) ED visits with cannabis text strings and no 
cannabis ICD-10-CM codes. Among those, 2,738 (26.4%) ED visits had text indicating recent 
cannabis use or intoxication and 2,238 (81.7%) ED visits had recent cannabis use/intoxication 
and diagnoses of outcomes known to be associated with cannabis in the literature. There were 
2,238 ED visits eligible for false negative review and a random sample of 691(30.9%) ED visits 
were reviewed for cannabis attribution. There were 236 ED records determined to be false 
negatives. We then estimated 580.5 false negatives across the sample of all ED visits without 
65 
 
cannabis ICD-10-CM codes in 2016 and when combined with the true positives from Chapter II 
(TP=942) a false negative rate was estimated at 38.1%. The absence of cannabis ICD-10-CM 
codes accurately predicted 99.4% (95% CI: 99.4%-99.5%) of the ED visits as not attributable to 
cannabis. 
Conclusions: Using text analytics to prioritize records for potential to be attributed to 
cannabis was efficient at finding and estimating false negatives. The absence of cannabis codes 
accurately predicted 99.4% of ED visits not attributable to cannabis. However, the false negative 
rate of the sample was 38.1%. More research is needed to identify novel methods to detected 
ED visits attributable to cannabis.  
Introduction 
The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-
10-CM) expanded diagnosis codes from ~14,000 to ~68,000 and expanded cannabis codes 
from 10 to 53 codes.97,144 The newly added cannabis codes are more specific to cannabis 
poisonings, intoxication, and use. The positive predictive values (PPVs) of cannabis ICD-10-CM 
codes to predict cannabis attribution have been estimated in ED visits reported in syndromic 
surveillance by Marx et al.99They found PPVs of cannabis ICD-10-CM codes to be as high as 
60% and were improved by including keywords from triage notes. Further analysis of cannabis 
ICD-10-CM codes PPVs was performed in Chapters II and III of this project. We found that 
cannabis poisoning and intoxication codes identified up to 96% of ED visits attributed to 
cannabis, but were rarely coded. Cannabis abuse, dependence, and use codes comprised a 
majority of cannabis ICD-10-CM codes, but poorly identified ED visits attributed to cannabis 
(PPV=37%). Cannabis abuse, dependence, and use codes PPVs were improved by limiting to 
the primary diagnosis (95%) or when co-occurring with codes for cyclic vomiting (57%), 
psychotic symptoms (48%), or altered mental status (58%). PPVs help inform the development 
of an ICD-10-CM case definition for ED visits attributable to cannabis, however, to calculate 
sensitivity and specificity the negative predictive value is required. These four performance 
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statistics can be used to select the best combination of ICD-10-CM codes to predict cannabis 
attribution. To date, the number of false negatives or ED visits attributed to cannabis that did not 
receive a cannabis ICD-10-CM code has not been quantified. 
Estimating the number of false negatives will describe the extent that a case definition 
comprised of cannabis ICD-10-CM codes will underestimate the true number of ED visits 
attributed to cannabis. However, receiving a cannabis code is rare ranging between 1% to 2% 
of annual ED visits in Colorado, while not receiving a cannabis code is common.193,196 Advances 
in technology and electronic medical records have allowed for increases in medical data. These 
large datasets of medical records have now made manual reviews inefficient and costly. One 
method to improve the efficiency of estimating false negatives is to use text mining. The digital 
format and data systems of most medical records allows for text documented in the record to be 
searched. Novel text mining approaches have emerged as an efficient tool in research of large 
medical databases. Methods like natural language processing have been used to evaluate drug 
safely in large administrative datasets.197 Text mining has been applied to evaluate the accuracy 
of diagnostic codes for psychiatric conditions, to develop algorithms to identify smoking status in 
electronic medical records, and in developing case definitions for syndromic surveillance of real-
time ED visit chief complaints and diagnostic codes.140,198,199 Applying text mining techniques 
allows the records for review to be limited to those with the text of interest and should be more 
likely to be false negatives or attributed to cannabis.  
We leveraged a novel text mining approach to identify a sample of records without 
cannabis ICD-10-CM codes but cannabis text strings for manual records review. We used 
Practical Extraction and Report Language (PERL) regular expressions to prioritize cannabis text 
and sentiment in ED visits more likely to be false negatives.  We aimed to estimate the negative 
predictive value of ED visits without cannabis codes to determine visits not attributable to 
cannabis through reviewing a sample of electronic medical records selected from the novel text 
mining approach. Secondly, we aimed to describe the top 1.0% of terms from the cannabis text 
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strings and sentiment documented in true negative ED visits compared to false negative ED 
visits. 
Materials and Methods 
Study Design and Population 
We utilized a retrospective cohort study design and selected all ED visits discharged 
from January 1, 2016 00:00 to December 31, 2016 23:59 from the University of Colorado 
Hospital Emergency Department (UCHED) an urban, academic, Level 2 Trauma center. 
Records with a cannabis ICD-10-CM code in the up to 30 listed discharge diagnosis codes were 
excluded from the sample (Figure 9). We used encounter-level data instead of patient-level 
data, allowing individuals to have multiple visits to the ED during this time period.  
Figure 9. Sampling strategy for calculating negative predictive values for the absence of 
cannabis specific in predicting ED visits not partially attributable to cannabis. 
 
 
Cannabis Text Strings 
Mining for cannabis text strings was used to narrow the number of records without 
cannabis ICD-10-CM codes to be reviewed for cannabis attribution. This was done in three 
False Negatives (FN) 
NO Cannabis Text String 
True Negatives (TN) 
EMRs Screened for Cannabis Text Strings  
ED Visits from UCH (2016) without Cannabis 
ICD-10-CM Codes  










stages. 1) We used Structured Query Language (SQL) scripts run against EPIC electronic 
medical records (EMRs) software to mine chief complaint, physician or nurses’ notes, and 
laboratory records for crude cannabis text strings (Table 15). The script identified records with 
cannabis text strings in the above mentioned text fields. Upon identification of a cannabis text 
string, 100 words, or 100 space delimited terms, before and after the cannabis text string (or the 
beginning or end of the section) were pulled into a database to capture sentiment around the 
cannabis term. 2) We used text explorer in JMP Pro 14 (SAS Institute Inc., Cary, NC) to refine 
the cannabis text strings through categorizing terms and phrases with PERL regular 
expressions (regex).200,201 A regex with terms and phrases that included sentiment around the 
initial cannabis text strings and indicated recent cannabis consumption, exposures, or 
intoxication (Appendix G) was coupled with a regex of terms and phrases that were not related 
to recent cannabis consumption, exposure, or intoxication (Appendix H) to narrow the records to  
Table 15. Cannabis text strings to select ED visits for manual records review without 
Cannabis ICD-10-CM codes. 
Text Strings Included 
“ T40.7“ or “ T407“ 
“ F12” 
“ cannab” 
“ edible “ 
“ marijuana ” or “ mj ” 
“ THC ” or “ tetrahydrocannabinol ” or “ cannabinoids “ 
“smok” and “ pot “ 
“ brown“ and “ pot “ 
those with recent cannabis consumption, exposures, or intoxication. 3) After limiting the records 
to only those containing terms for cannabis consumption, exposure, or intoxication, records 
were further refined by excluded those with cannabis use but acute outcomes unrelated to 
cannabis (i.e. influenza, urinary tract infections, dental pain etc.) (Appendix I). We prioritized the 
remaining records into 5 different groups for manual review for cannabis attribution using the 
decision tree in Figure 10. These cases included Case 1) cannabis consumption, exposure, or 
intoxication only with acute cannabis related outcomes from Table 16 (Appendix J), Case 2) 
69 
 
cannabis consumption, exposure, or intoxication only (Appendix K), Case 3) self-
medicating/medical cannabis or chronic conditions with co-use of prescription drugs (Appendix 
L), Case 4) cannabis related conditions with co-substance use (Appendix M), and Case 5) non-
specific cannabis terms or misfits (Appendix N) that did not prioritized into another regex.  
Predicted Not Attributed to Cannabis  
All ED visits included in this study were predicted to be not attributable to cannabis 
based on the absence of the following cannabis codes: cannabis abuse (F12.1), cannabis 
dependence (F12.2), cannabis use, unspecified (F12.9), and cannabis poisoning (T40.7).  
Verification of Not Attributed to Cannabis 
ED visits without cannabis ICD-10-CM codes or cannabis text strings were assumed to 
be true negatives and were not reviewed for verification of not attributed to cannabis (Figure 
10). All records in case 1) cannabis consumption, exposure, or intoxication only with acute 
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Figure 10. Decision tree for prioritizing records with cannabis text strings for manual 
records review for cannabis attribution.
 
Table 16. Case definitions for priority in manual records reviews for false negatives. 
Case Priority or 




Included ED visits with cannabis use terms and no other substance use 
terms and included terms of acute cannabis related outcomes 
Case 2 
Included cannabis use terms and no other substance use terms, but may 
have not indicating additional terms of outcomes 
Case 3 
Included terms indicating self-medicating or medical cannabis use or terms 
for chronic conditions with co-use of prescription drugs and cannabis 
Case 4 
Included terms for cannabis use, outcomes related to cananbis, and co-
substance use 
Case 5 
Included terms for non-specific cannabis terms that could not be classified 






Reason for ED visits associated with 
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cannabis or chronic 
conditions with co-use of 
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illness or injury not 
related 
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cannabis related outcomes were reviewed for verification of not attributable to cannabis. A 
random sample of at least 25% of each of the remaining four cannabis cases was reviewed for 
verification of not attributable to cannabis (Figure 11). Partial attribution to cannabis was 
determined through manual review of electronic medical records (EMRs) by a trained 
abstracter. ED visits without cannabis coding, but with cannabis text were determined at least 
partially attributable to cannabis if at least one of the following criteria were met: 1) the ED 
physician identified cannabis as likely precipitating or contributing to the condition bringing the 
patient to the ED, 2) the patient was admitted to the hospital, and the inpatient provider 
identified cannabis as likely precipitating or contributing to the condition, or 3) the urine 
toxicology screen was positive for delta-9-tetrahydrocannabinol AND there was a temporally 
related cannabis exposure documented in the medical record (~24 hours) with a condition 
known to be associated with cannabis use. Conditions know to be associated with cannabis use 
included unintentional marijuana exposures20,24,152, cannabis poisonings or overdoses, motor 
vehicle collision103–106, injury due to impairment, cyclic vomiting119–123,153,154, chronic bronchitis 
with cough/wheeze/sputum130,131,133,136,157–159, psychotic symptoms or disorders54,57,59,138,160, 
acute panic attack107,108, and withdrawal symptoms. Both urine toxicology screening and 
documentation of temporal cannabis use were necessary in these cases otherwise, the visit was 
considered not attributable to cannabis (Table 17). Assessment of cannabis use was included in 
the drug use section of the standard nursing assessment questionnaire performed on every 
patient seen in the UCHED. If none of the three criteria were met for cannabis attribution, then 
the visit was determined NOT attributable to cannabis. The chart abstraction form for false and 






Table 17. Criteria to determine partially attributed to marijuana within the electronic 
medical record (EMR). 
Criteria  
1) ED physician identified marijuana as likely precipitating or contributing to the condition 
bringing the patient to the ED 
OR  
2) If the patient was admitted to the hospital, and the inpatient provider identified marijuana 
as likely precipitating or contributing to the condition 
OR  
3) The urine toxicology screen was positive for delta-9-tetrahydrocannabinol AND there was 
a temporally related marijuana exposure documented in a condition known to be 
associated with marijuana use 
Outcomes related to 
marijuana use 
Unintentional marijuana exposures20,24,152 
Marijuana poisonings or overdoses 
Motor vehicle collision103–106 
Injury due to impairment 
Cyclic vomiting119–123,153,154 
Chronic bronchitis with cough/wheeze/ sputum 
130,131,133,136,157–159 
Mental health outcomes 
related to marijuana use 
Psychotic symptoms or disorders54,57,59,138,160 
Acute panic attack107,108 
Withdrawal symptoms (only marijuana use indicated) 
 
Demographics 
Age in years was recorded continuously. Gender (male/female) and race/ethnicity 
(White, non-Hispanic, African American/Black, Hispanic, non-Hispanic Other race, and missing 
race) were coded as categorical variables. Colorado resident status was determined using 
billing address and coded as resident or non-resident. Health insurance was grouped into 
Private and other insurance, public insurance (including Medicare or Medicaid), VA insurance, 
indigent, and missing insurance. 
Visit Characteristics 
To account for patients with more than one ED discharge in 2016, the median number of 
visits per patient (in 2016) was calculated and dichotomized into one visit vs. more than one visit 
in 2016. Mean and standard deviation of length of stay was calculated as number of hours in ED 
and separately days in inpatient care for those admitted from the emergency department. Visit 
disposition was classified as discharge to home, admitted, left against medical advice (against 
medical advice (AMA), including left without being seen, and left before visit complete (LBVC)), 
73 
 
other, and missing. In the reviewed sample, clinical diagnoses were categorized into Altered 
mental status cardiovascular, dermatologic, gastrointestinal, intoxication, motor vehicle collision, 
neurologic, psychiatric, respiratory, trauma, and other. ED visits may have had more than one 
clinical diagnosis. 
Statistical Analysis 
To examine representativeness of the random 25% sample, demographics and clinical 
characteristics for the entire sample (all ED visits without cannabis ICD-10-CM codes) were 
compared to the random sample reviewed for cannabis attribution. Demographics and clinical 
characteristics were also examined for ED visits determined as false negatives from the random 
sample of reviews compared to the ED visit determined as true negatives without cannabis 
codes or cannabis text strings. A Pearson chi squared test was used for categorical 
comparisons and an ANOVA for continuous comparisons using SAS version 9.4 (SAS Institute 
Inc., Cary, NC). We calculated the negative predictive value (NPV) for the absence of all 
cannabis ICD-10-CM codes’ ability to predict attribution to cannabis using Equation 4.1. We 
calculated binomial 95% confidence intervals (95% CI) using the Clopper-Pearson exact 
method for the NPV using the binomial option in SAS FREQ procedure. The percent of false 
negatives in each random sample reviewed was used to estimate the total number of ED visit 
attributed to cannabis in that case category. The percent of false negatives was multiplied by 
the total number of ED visits in that case category to obtain an estimated number of false 
negatives or ED visits attributed to cannabis across the sample case category. The estimated 
ED visits attributable to cannabis in each case category were summed to represent the 
estimated total false negatives in the sample of ED visits in 2016. The total true negatives were 
estimated by subtracting the estimated false negatives from the total predicted negatives. Word 
clouds of the most frequent 1.0% of terms associated with the false negatives were compared to 
terms from the true negative ED visits using JMP Pro 14 (SAS Institute Inc., Cary, NC). We did 
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not group or modify terms to preserve the provider documentation. Non-descriptive clinical 
terms were removed from the word cloud analysis (Appendix O).  
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 4.1: 𝑁𝑃𝑉 = 𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 
Results 
Analytic Population 
There were 98,521 emergency department (ED) discharges at the UCH main campus 
emergency department in 2016. Of those, 95,993 (97.4%) did not have cannabis ICD-10-CM 
codes in the discharge diagnoses. ED visits were adults on average 42.3 years old (SE=18.2), 
41.5% white, 43.9% male, 95.2% Colorado residents, 60.0% had public insurance, and 81.9% 
were discharged to home. There were 4 (<0.01%) ED discharges missing sex, 513 (0.5%) 
missing race/ethnicity, 3,951 (4.1%) missing residence status, 15,578 (16.2%) missing health 
insurance and 690 (0.7%) missing disposition. On average, ED visits were 17.2 (SE=7.4) hours 
and inpatient visits 4.5 (SE=6.2) days. Median number of visits in 2016 per patient was 1.0 
(range=1-54) (Table 18). There were 2,238 (2.3%) that included cannabis terms indicating 
recent cannabis consumption, exposures, or intoxication in history and physical, chief complaint, 
physician or nurses’ notes, or laboratory records. ED visits included young adults on average 
35.2 years old, 45.5% White, 58.9% male, 92.8% Colorado residents, and 62.9% had public 
health insurance (Table 19).  
Random Sample Reviewed for False Negatives 
There were 146 (6.5%) ED visits that with terms in Case 1) cannabis consumption, 
exposure, or intoxication only with acute cannabis related outcomes, 583 (26.1%) in Case 2) 
cannabis consumption, exposure, or intoxication only, 137 (6.1%) in Case 3) self-
medicating/medical cannabis or chronic conditions with co-use of prescription drugs, 540 
(24.1%) in Case 4) cannabis related conditions with co-substance use, and 832 (37.2%) in Case 
5) non-specific cannabis terms or misfits. We reviewed all ED visits in Case 1, 146 (25.0%) in 
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Case 2, 33 (24.1%) in Case 3, 137 (25.4%) in Case 4, and 229 (27.5%) in Case 5 totaling to 
691 (30.9%) ED visits reviewed for false negatives. The demographics of the reviewed visits 
were similar to those with cannabis text (n=2,238) where majority were young adults (average 
34.5 years), White (43.8%), male (58.2%), Colorado residents (94.3), and had public insurance 
(64.0) (Table 19).  
In Case 1 there were 117 (80.1%) ED visits determined false negatives, or did not have a 
cannabis ICD-10-CM code but attributed to cannabis, 56 (38.4%) in Case 2, 7 (21.2%) in Case 
3, 24 (17.5%) in  Case 4, and 32 (14.0%) in Case 5. In total 236 (34.2%) ED visits were 
identified as false negatives in the random sample reviewed (Table 19). The demographics of 
the false negatives were on average 9.9 years younger, more were males (60.2% vs 43.6%), 
fewer patients had more than one ED visit in 2016 (13.1% vs 54.5%), on average the ED length 
of stay was 1.7 hours longer, and fewer were admitted to the hospital (8.1% vs 15.2%) 
compared to the assumed true negatives (records without cannabis text or cannabis ICD-10-CM 
codes) (Table 20). The majority (163, 69.1%) of ED visits identified as false negatives were 
determined attributable to cannabis by the ED physician (criteria 1). There were 49 (20.8%) 
determined attributable to cannabis from a positive urine toxicology for tetrahydrocannabinol 
(THC) (criteria 3), 14 (5.9%) determined attributable to cannabis by the inpatient physician 
(criteria 2), and 10 (4.2%) met multiple criteria for attribution to cannabis. There were 116 
(49.2%) of false negatives with gastrointestinal diagnoses, 85 (36.2%) psychiatric diagnoses, 52 
(22.0%) intoxications, 36 (15.3%) other diagnoses, 18 (7.7%) altered mental status diagnoses, 8 
(3.4%) cardiovascular diagnoses, 8 (3.4%) neurologic diagnoses, 8 (3.4%) with trauma, 2 






Table 18. Demographics of emergency department visits that did not have cannabis ICD-
10-CM codes but had cannabis text strings (subset of predicted negatives) at UCH in 
2016 compared to those of the 25% random sample reviewed for false negatives. 











Age, mean (SE) 42.3 (18.2) 35.2 (13.3) 34.5 (13.0) 
Male 42,176 (43.9) 1,318 (58.9) 403 (58.3) 
Race    
White, Non-Hispanic 39,849 (41.5) 1,015 (45.4) 304 (44.0) 
African American, 
Non-Hispanic 26,191 (27.3) 755 (33.7) 240 (34.7) 
Hispanic 22,601 (23.5) 365 (16.3) 115 (16.6) 
Other, Non-Hispanic 6,839 (7.1) 90 (4.0) 29 (4.2) 
Missing 513 (0.5) 13 (0.6) 3 (0.4) 
Resident Status    
Colorado Resident 91354 (95.2) 2,077 (92.8) 651 (94.2) 
Nonresident 688 (0.7) 26 (1.2) 6 (0.9) 
Missing 3,951 (4.1%) 135 (6.0) 34 (4.9) 
Health Insurance    
Private and other 20,174 (21.0) 383 (17.1) 117 (16.9) 
Public (Medicare or 
Medicaid) 57,602 (60.0) 1,408 (62.9) 442 (64.0) 
VA 632 (0.7) 18 (0.8) 6 (0.9) 
Indigent 2,007 (2.1) 32 (1.4) 9 (1.3) 
Missing 15,578 (16.2) 397 (17.7) 117 (16.9) 
More than one visit in 
2016 16,848 (27.9) 429 (19.2) 81 (11.7) 
Number of visits in 
2016, median (range) 1.0 (1-54) 1.0 (1-10) 1.0 (1-4) 
ED Length of Stay, 
mean (SE) (hours)a 17.2 (7.4) 18.6 (10.6) 18.2 (10.7) 
Hospital Length of Stay, 
mean (SE) (days)b 4.5 (6.2) 4.3 (5.9) 3.6 (3.5) 
Disposition    
Discharge to Home 78,644 (81.9) 1,797 (80.3) 564 (81.6) 
Admit 14,577 (15.2) 292 (13.1) 80 (11.6) 
AMA* 988 (1.0) 27 (1.2) 9 (1.3) 
Other 1,094 (1.1) 117 (5.2) 37 (5.4) 
Missing 690 (0.7 5 (0.2) 1 (0.1)   







Figure 9. Sampling strategy for reviewing ED visits without cannabis ICD-10-CM codes 




Table 19. Determination of 25% random samples of emergency department visits to be 
reviewed for false negatives. Visits did not have cannabis ICD-10-CM codes but had 











Negatives, N (%) 
Total sample size 98,521     
Predicted positive 2,528     











Case 1 146 117 146 80.1 117* 
Case 2 583 56 146 38.4 223.6 
Case 3 137 7 33 21.2 29.1 
Case 4 540 24 137 17.5 94.5 
Case 5 832 32 229 14.0 116.3 
Total  236 (34.2%) 691 (30.9%)   
Total estimated 
false negative  
 
  580.5 
Total estimated 
true negatives  
 
  95,412.5 
*All records in this category were reviewed and this number represent the total false negatives. 



























Case 1 False 
Negatives 
N=117 (80.1%) 
Case 2 False 
Negatives 
N=56 (38.4%) 
Case 3 False 
Negatives 
N=7 (21.2%) 
Case 4 False 
Negatives 
N=24 (17.5%) 





Table 20. Demographics of emergency department visits that did not have cannabis ICD-
10-CM codes at UCH in 2016 by true negatives and false negatives found in 25% random 
sample. 
 Attributed to Cannabis, N (%)  
 
Yes or False Negatives 
(N=236) 




Age, mean (SE) 32.6 (12.0) 42.5 (18.2) <0.05 
Male 142 (60.2) 40,858 (43.6) <0.05 
Race   <0.05 
White, Non-Hispanic 111 (47.0) 38,834 (41.4)  
African American, Non-Hispanic 81 (34.3) 25,436 (27.1)  
Hispanic 35 (14.8) 22,236 (23.7)  
Other, Non-Hispanic 9 (3.8) 6,749 (7.2)  
Missing 0.0 (0.0) 500 (0.5)  
Resident Status   <0.05 
Colorado Resident 219 (92.8) 89,277 (95.2)  
Nonresident 2 (0.9) 662 (0.7)  
Missing 15 (6.4) 3,816 (4.1)  
Health Insurance   <0.05 
Private or Other 37 (15.7) 19,791 (21.1)  
Public (Medicare or Medicaid) 145 (61.4) 56,194 (59.9)  
VA 3 (1.3) 614 (0.7)  
Indigent 3 (1.3) 1,975 (2.1)  
Missing 48 (20.3) 15,181 (16.2)  
More than one visit in 2016 31 (13.1) 51,108 (54.5) <0.05 
Number of visits in 2016, median 
(range) 1.0 (1-3) 2.0 (1-55) <0.05 
ED Length of Stay, mean (SE) 
(hours)a 18.9 (12.6) 17.2 (7.3) <0.05 
Hospital Length of Stay, mean 
(SE) (days)b 1.8 (1.3) 4.5 (6.2) 0.06 
Disposition   <0.05 
Discharge to Home 191 (80.9) 76,847 (82.0)  
Admit 19 (8.1) 14,285 (15.2)  
AMA* 0 (0.0) 961 (1.0)  
Other 26 (11.0) 977 (1.0)  
Missing 0 (0.0) 685 (0.7)  










Table 21. Criteria met to determine false negatives or emergency department visits 
attributed to cannabis without cannabis ICD-10-CM codes (N=236). 
Criteria Met for Attribution to cannabis N (%) 
1. ED physician identified cannabis as likely precipitating or contributing to the 
condition bringing the patient to the ED  163 (69.1) 
2. The patient was admitted to the hospital and the inpatient physician identified 
cannabis as likely precipitating or contributing to the condition  14 (5.9) 
3. The urine toxicology screen was positive AND there was a documented 
temporal (within ~24 hours) relationship between cannabis exposure and a 
condition or event known to be associated with cannabis 49 (20.8) 
4. Met multiple criteria 10 (4.2) 
Diagnosis  
Altered mental status 18 (7.7) 
Cardiovascular 8 (3.4) 
Dermatologic 2 (0.9) 
Gastrointestinal 116 (49.2) 
Intoxication 52 (22.0) 
Motor vehicle collision 1 (0.4) 
Neurologic 8 (3.4) 
Psychiatric 85 (36.2) 
Respiratory 12 (5.1) 
Trauma 8 (3.4) 
Other 36 (15.3) 
Cannabis Terms Word Clouds 
There were 6,301 unique terms pulled from ED visits determined to be true negatives 
through manual records review and 4,211 unique terms pulled from ED visits determined to be 
false negatives. We included the top 73 terms most frequently used in the reviewed sample 
which represented 1.2% of all terms extracted in true negatives and 1.7% of all terms extracted 
in false negatives. The top ten most frequent term in cannabis text and sentiment in false 
negative ED visits were pain (10.1%), vomiting (6.4%), use (5.6%), marijuana (5.5%), 
abdominal (5.4%), nausea (4.3%), negative (4.0%), male (3.9%), complaint (3.8%), and 
discharge (3.1%). Top ten terms in true negative ED visits included pain (17.6%), use (10.9%), 
negative (6.7%), medical (6.4%), social (6.3%), denies (5.5%), normal (5.5%), complaint (5.3%), 
male (5.3%), and marijuana (5.0%). Terms like vomiting (6.4% vs 3.2%), nausea (4.3% vs 
2.8%), hyperemesis (1.9% vs 0.3%), cyclic (1.5% vs 0.5%), cannabis (1.3% vs 0.6%), and 
ingestion (1.2% vs 0.6%) comprised larger proportions of terms in false negatives compared to 
true negatives. Terms like pain (17.6% vs 10.1%), use (10.9% vs 5.6%), negative (6.7% vs 
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4.0%), medical (6.4% vs 0.0%), social (6.3% vs 1.2%), denies (5.5% vs 2.6%), normal (5.5% vs 
3.1%), complaint (5.3% vs 3.8%), male (5.3% vs 3.9%), female (4.3% vs 2.4%), alcohol (4.1% 
vs 2.0%), smoking (3.8% vs 1.7%), chest (3.8% vs 1.3%), tobacco (3.3% vs 1.1%), drug (3.1% 
vs 0.8%), smoker (2.9% vs 1.0%) and smokeless (2.8% vs 0.9%) were present in larger 
proportions of terms in true negatives compared to false negatives (Table 22 & Figure 12).  
NPV Results 
In each random sample reviewed false negatives were estimated. All of Case 1 was 
reviewed and the false negatives were added to those estimated from the other random 
samples. We estimated 223.6, 28.2, 96.0, and 114.8 ED visits as false negatives for Cases 2, 3, 
4, and 5 respectively (Table 19). Over the sample with cannabis text (n=2,238) we estimated 
580.5 false negatives. We subtracted the estimated false negatives from the total predicted 
negative (n=95,993), or ED visits without cannabis ICD-10-CM codes, to calculate the estimated 
true negatives at 95,412.5 ED visits (Table 19). Based on these estimates, the absence of 
cannabis ICD-10-CM codes accurately predicted 99.4% (95% CI: 99.4%-99.5%) of the ED visits 
as not attributable to cannabis. 
Discussion 
Text mining electronic medical records allowed for an efficient review of a smaller 
sample of predicted negatives for identification of false negatives. This approach saved time 
and costs compared to a full manual record review. We found 34.2% of reviewed ED visits that 
did not have cannabis codes were attributed to cannabis or determined false negatives and we 
estimated there were 580.5 (0.6%) false negatives across the entire 2016 sample. Text 
analytics of the frequency of terms around cannabis terms indicated that there are differences 
between terms in false negatives and true negatives. Our findings showed that the negative 
predictive value for the absence of cannabis codes to predict not attributable to cannabis was 




Figure 10. Word clouds for terms used in ED visits determined to be false negatives 







A. True negatives 
B. False negatives 
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Table 22. Top terms in 100 strings before and after a cannabis term in ED visits without 
cannabis ICD-10-CM codes that were attributed to cannabis (false negatives) or not (true 
negatives) at UCH in 2016 (N=691). 



















abd 85 (2.0) 99 (1.6)  gastritis 38 (0.9) 22 (0.3) 
abdomen 45 (1.1) 44 (0.7)  gi 51 (1.2) 73 (1.2) 
abdominal 226 (5.4) 299 (4.7)  haldol 33 (0.8) 15 (0.2) 
abuse 66 (1.6) 150 (2.4)  hyperemesis 81 (1.9) 21 (0.3) 
acute 116 (2.8) 172 (2.7)  ingestion 51 (1.2) 40 (0.6) 
admission 46 (1.1) 81 (1.3)  intoxication 35 (0.8) 81 (1.3) 
admit 73 (1.7) 162 (2.6)  male 163 (3.9) 332 (5.3) 
alcohol 83 (2) 259 (4.1)  marijuana 230 (5.5) 317 (5) 
anxiety 96 (2.3) 150 (2.4)  medical 0 (0) 401 (6.4) 
asthma 33 (0.8) 103 (1.6)  mg 101 (2.4) 117 (1.9) 
biba 56 (1.3) 117 (1.9)  mild 38 (0.9) 48 (0.8) 
bipolar 46 (1.1) 64 (1.0)  mj 42 (1.0) 100 (1.6) 
breath 33 (0.8) 117 (1.9)  nausea 183 (4.3) 175 (2.8) 
cannabinoids 33 (0.8) 2 (0.0)  neg 17 (0.4) 107 (1.7) 
cannabis 53 (1.3) 28 (0.4)  negative 170 (4) 421 (6.7) 
cdu 66 (1.6) 0 (0.0)  ng 46 (1.1) 82 (1.3) 
chest 55 (1.3) 238 (3.8)  normal 130 (3.1) 347 (5.5) 
chills 42 (1) 97 (1.5)  pain 424 (10.1) 1107 (17.6) 
chronic 57 (1.4) 100 (1.6)  pancreatitis 44 (1) 43 (0.7) 
complaint 162 (3.8) 336 (5.3)  positive 95 (2.3) 194 (3.1) 
cough 35 (0.8) 93 (1.5)  psych 36 (0.9) 45 (0.7) 
counseled 36 (0.9) 38 (0.6)  resp 59 (1.4) 110 (1.7) 
cyclic 62 (1.5) 30 (0.5)  shortness 24 (0.6) 103 (1.6) 
daily 70 (1.7) 118 (1.9)  si 103 (2.4) 111 (1.8) 
denies 110 (2.6) 349 (5.5)  smokeless 39 (0.9) 178 (2.8) 
depression 57 (1.4) 107 (1.7)  smoker 42 (1) 183 (2.9) 
diarrhea 74 (1.8) 72 (1.1)  smoking 71 (1.7) 239 (3.8) 
discharge 132 (3.1) 143 (2.3)  sob 24 (0.6) 86 (1.4) 
drug 32 (0.8) 195 (3.1)  social 49 (1.2) 396 (6.3) 
discharged 44 (1) 63 (1.0)  substance 67 (1.6) 162 (2.6) 
distress 37 (0.9) 48 (0.8)  tobacco 45 (1.1) 210 (3.3) 
emesis 75 (1.8) 77 (1.2)  use 234 (5.6) 688 (10.9) 
ems 51 (1.2) 145 (2.3)  used 21 (0.5) 89 (1.4) 
epigastric 34 (0.8) 36 (0.6)  utox 44 (1) 63 (1) 
etoh 48 (1.1) 220 (3.5)  vomiting 270 (6.4) 201 (3.2) 
female 102 (2.4) 270 (4.3)  zofran 43 (1.0) 23 (0.4) 
fever 49 (1.2) 132 (2.1)     
There were unexpected terms pulled from the initial text mine of the electronic medical 
records for cannabis related text (Table 15). Terms that were searched like “pot” captured any 
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text around pots used for cooking and the term “brown-” intended to capture “brownies” also 
captured all persons with the last name of Brown. ED visits were captured that documented 
denying cannabis use with phrases like “denies marijuana use”, “denies use of marijuana”, “No 
THC”. Infrequent cannabis use was captured through phrases like “smoking marijuana twice 
since start of pregnancy” or “infrequent marijuana use”. A comprehensive list of cannabis terms 
excluded can be found in Appendix P. There were 10,361 ED visits with text matching our 
cannabis text string in Table 15 and 26.4% of ED visits indicated recent cannabis use, 
intoxication, or exposure. Therefore, we had to perform additional text analytics to only include 
ED visits with text indicating recent cannabis use, intoxication, or exposures. Unfortunately, this 
required additional analysis and manually building regular expressions from reading the text 
pulled from ED visit to create a systematic and reproducible method of excluded records that 
were not indicating recent cannabis use. This increased time spent cleaning the data may have 
negated the efficiency added by using text mining approaches. 
Text analytics revealed that ED visits documenting regular cannabis use like reporting 
alcohol or tobacco use do not receive cannabis ICD-10-CM codes. Cannabis terms like 
“Comment: MJ”, “Comment: marijuana”, or “history of marijuana use” were often included under 
a substance use screening section of the electronic medical record. Text analysis of cannabis 
terms in ED visits with cannabis ICD-10-CM codes should be performed to confirm this finding. 
If such documentation does not appear in ED visits with cannabis ICD-10-CM codes it would 
indicate that vague documentation of cannabis use or history of cannabis use does not receive 
cannabis ICD-10-CM codes. 
Although 0.6% of the sample of ED visits without cannabis ICD-10-CM codes were 
estimated false negatives or attributed to cannabis, the false negative rate was 38.1% of all ED 
visits attributed to cannabis in all 2016 ED visits. In other words 38.1% of ED visits attributed to 
cannabis were predicted negative from the lack of cannabis ICD-10-CM codes [data not 
shown].163 This finding highlights cannabis ICD-10-CM codes limited sensitivity to detect ED 
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visits attributable to cannabis. We described the percent of ED visits attributed to cannabis that 
were missed by relying on cannabis ICD-10-CM to capture ED visits attributed to cannabis. This 
should be considered when interpreting estimated rates of ED visits attributed to cannabis. More 
research is needed to find discharge data characteristics that could improve the sensitivity of 
cannabis ICD-10-CM codes.  
Regardless of the increased false negative rate of ED visits attributed to cannabis, the 
negative predictive value for the absence of cannabis codes was highly predictive to identify ED 
visits not attributed to cannabis. The absence of a cannabis code determined that the ED visit 
was not attributed to cannabis in 99.4% of ED visits without cannabis ICD-10-CM codes. This 
finding emphasizes that future research should focus on improving the positive predictive value 
and the sensitivity of cannabis ICD-10-CM codes and less on NPV and specificity of the codes. 
It was determined a priori that a sample of 97,000 ED visits without cannabis specific 
ICD-10-CM codes from January 1, 2016 to December 31, 2016 would be able to detect NPVs 
for the absence of cannabis codes as high as 99% and as low as 0.02% with 95% confidence, 
80% power, at a 90% prevalence of no marijuana codes, and with sensitivities and specificities 
as low as 85% and 80% respectively (Appendix Q). Our study included 93,755 ED visits without 
cannabis ICD-10-CM codes, however, a sample of at least 10,000 ED visits without cannabis 
ICD-10-CM codes would meet the same criteria. This study was not underpowered to calculated 
99% NPVs. 
Limitations 
We assumed ED visits without cannabis ICD-10-CM codes and without cannabis text 
were true negatives. We did not confirm this with medical records reviews. It is possible ED 
visits included misspelling of cannabis terms and were counted as true negatives. We 
hypothesized that the occurrence of this scenario would be minimal and not affect the findings in 
this study. Additionally, we did not review all 2,238 ED visits without cannabis ICD-10-CM codes 
but with cannabis text for recent cannabis use. Instead we reviewed a random sample which 
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was used to estimate the number of false negatives across the entire sample of ED visits in 
2016. It is possible that we over- or underestimated the number of false negatives because we 
did not review the entire sample of 2016 ED visits.  
The text included in the text analytics was 100 space delimited character strings before 
and after the cannabis term to capture sentiment around the documentation of cannabis use. It 
is possible sentiment was included elsewhere in the record and not captured in this text. It is 
also possible for terms in the text to be reported more than once. Therefore, comparisons of the 
frequency of terms between the false negatives and true negatives could be biased by over 
documentation of similar terms in the same record. Results from the text analytics were 
intended to be hypothesis generating for future studies into sentiment being used to 
characterize cannabis text as attributed to cannabis or not. 
These data are limited in that they are subject to patient reporting use of cannabis to 
healthcare providers and/or providers screening for cannabis use. With Colorado’s history of 
cannabis legalization, we expect that reporting bias was minimized in this sample. Though it is 
possible that ED visits who should have received a cannabis text or codes did not as a result of 
reporting bias or screening bias and were misclassified into the true negatives. 
These findings were reflective of practices in a large, urban, academic hospital and may 
not be generalizable to other emergency departments in dissimilar settings. These findings also 
may not be generalizable to emergency departments in other states without the history of 
cannabis legalization and de-stigmatization as Colorado. However, the ICD-10-CM coding 
system is intended to be a standardized system that will yield similar results across hospital 
systems. It is used in national surveillance of other conditions including opioid overdoses and 
therefore we expect similar results would be found in similar emergency departments as the one 






The absence of cannabis codes strongly predicts ED visits not attributable to cannabis. 
Over one third of the ED visits attributed to cannabis in the 2016 sample were false negatives 
which would not be captured using a case definition limited to cannabis ICD-10-CM codes. This 
finding coupled with the results from text analytics of cannabis terms highlights the potential for 
exploring cannabis text to be included in a case definition for cannabis attribution. More 





DISCUSSION, LIMITATIONS, AND CONCLUSIONS 
Discussion 
We found cannabis ICD-10-CM codes positively identified ED visits partially attributable 
to cannabis between 31%-89% of the time. Cannabis intoxication and poisoning ICD-10-CM 
codes had the highest probabilities of predicting ED discharges attributed to cannabis, but these 
codes were rare and captured only 8.9% of ED visits partially attributed to cannabis in 2016. We 
found that the PPVs for the cannabis abuse, use, and dependence codes were improved by 
incorporating additional information from the discharge diagnosis like: limiting to ED visits with a 
cannabis code and no additional substance codes; limiting to cannabis codes as the primary 
diagnosis; and limiting to ED visits with co-occurring cyclic vomiting, psychotic symptoms, or 
altered mental status codes. When cannabis codes appeared in the primary diagnosis, the 
PPVs were improved to 95%, however, they only captured 5.0% of total ED visits partially 
attributed to cannabis in 2016. The characteristics to improve PPVs of cannabis codes were 
examined individually and combinations or more complex algorithms were not examined.   
The text mining and prioritizing approach used to identify false negatives or ED visits 
partially attributed to cannabis without cannabis ICD-10-CM codes was time and cost efficient 
compared to the traditional records review of a random sample. There were 691 records 
prioritized for electronic record reviews that were used to estimate the number of false negative 
across a sample of 95,993 ED visits without cannabis ICD-10-CM codes. Relying on cannabis 
ICD-10-CM codes alone missed 38.1% of the total ED visits partially attributed to cannabis in 
2016. Those false negatives comprised 0.6% of all ED visits in 2016. The absence of cannabis 
ICD-10-CM codes correctly identified ED visits as not attributed to cannabis 99.4% of the time.  
This project elucidated some common criticism of using cannabis ICD-10-CM coding to 
capture ED visits attributed to cannabis. The criticism that counting ED visits with cannabis 
codes and not patients with cannabis codes overestimates rates because cannabis users are 
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more likely to have multiple repeat ED visits was not supported by these findings. The number 
of repeat ED visits among patients in 2016 were similar in ED visits with cannabis codes that 
were partially attributed to cannabis and those that were not. Patients with ED visits without 
cannabis codes and not attributed to cannabis had a higher percentage (54.5%) of repeat ED 
visit in 2016 compared to patients with ED visits without cannabis codes that were partially 
attributed to cannabis (13.1%). The data were limited to repeat ED visits within 2016, thus it is 
possible that persons with ED visits that had a cannabis codes may have had an additional ED 
visits in 2015 or 2017.  
Another common criticism that cannabis codes capture reported past history of cannabis 
or infrequent cannabis was not supported by these findings. There were 10,361 ED visits 
without cannabis ICD-10-CM codes that were identified as having a cannabis text string in the 
record. Some of these records were captured because from terms like the last name “Brown” 
when the term “brownie” was intended or when a cooking pot was involved but the term “pot” as 
in a colloquial name for cannabis was intended. However, we identified at least 148 different 
terms and phrases across this sample that described historical, distant, or nonspecific cannabis 
use that did not received a cannabis ICD-10-CM (Appendix O). We also identified 2,738 records 
that included terms or phrases for recent cannabis use or a positive toxicology for cannabis that 
did not receive a cannabis ICD-10-CM code. The large percent of false negatives (38.1%) 
identified in this project indicate that is more likely that cannabis codes underestimate ED visits 
attributed to cannabis use.  
The PPVs for cannabis ICD-10-CM codes in this analysis were lower than those 
described in syndromic surveillance systems by DeYoung et al. (2017) and Marx et al. (2019). 
Though cannabis poisoning codes performed with the highest PPV in this study (PPV=89.0%) 
as well as those in both syndromic surveillance studies (PPV=100.0%). It is possible that these 
differences were due to differences in sample size in this study (N=2,528) compared to 
DeYoung et al. (N=698) and Marx et al. (N=190). The differences could also be due to 
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differences in data structure between ED visits included in discharge datasets and those 
included in syndromic surveillance.98,99 Close et al. (2019) also found higher PPVs (range: 
64.5%-100.0%) for cannabis ICD-10-CM codes in hospitalizations confirmed to involve cannabis 
through positive toxicology screens for THC in trauma records compared to these findings 
(range: 31%-89%).100 This study may have had lower PPVs due to more rigorous and 
conservative efforts in determining ED visits as partially attributable to cannabis. These efforts 
may have misclassified ED visits as not attributable, when in fact they were due to cannabis. 
It is possible that high PPVs while capturing a large number of ED visits attributed to 
cannabis may not be possible with cannabis ICD-10-CM codes alone or within administrative 
ED discharge data. Similar results were described by Close et al. (2019) were cannabis 
poisoning codes performed well at predicting a hospitalization involving cannabis (PPV=100%), 
but had low sensitivity (Sen=0.29%) in capturing hospitalizations involving cannabis across the 
sample. Despite this limitation, monitoring ED visits with cannabis ICD-10-CM codes may be a 
reliable indicator to track trends in the impacts of cannabis legalization. Close et al. (2019) came 
to a similar conclusion for using cannabis ICD-10-CM coding within hospitalizations.100  
This study was the first to complete a traditional performance evaluation of cannabis 
ICD-10-CM codes that included a robust electronic records review with a double review for inter-
rater reliability and a comprehensive clinical criteria for determination of cannabis attribution. It 
is the first study to evaluate ED visit that were attributed to cannabis but did not receive a 
cannabis ICD-10-CM codes. It is also the first study to provide positive and negative predictive 
values for cannabis ICD-10-CM codes within ED visit administrative discharge data. Estimates 
from this work can inform public health with estimates of potentially how many ED visits 
attributed to cannabis may be missed with cannabis coding. Additionally, the novel method 
applied for false negative reviews provides public health with a time- and cost-efficient 
methodology for effectively evaluating the performance of administrative case definitions. This 
approach provides a novel solution to quickly and effectively complete false negative reviews 
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which would allow for the calculation of sensitivity and specificity of number administrative case 
definitions applied in public health surveillance of administrative discharge data. 
Next Steps in Research of an Administrative Case Definition for Cannabis Attribution 
This project provides foundation for further exploration of the cannabis ICD-10-CM 
codes in an administrative case definition to measure public health impacts of cannabis 
legalization. It achieved the specific goal of providing performance measures (PPVs and NPVs) 
of cannabis ICD-10-CM codes. However, more research is needed to achieve the goal of a 
standardized administrative case definition for ED visits attributed to cannabis.  
This study focused on separate methods for improving the PPVs of cannabis codes, but 
did not evaluate combination of these methods or algorithms that may improve PPVs. More 
research should be done on the supporting information in ED visits discharge data and how 
combinations of that information affects the performance of cannabis ICD-10-CM codes. These 
findings should then be incorporated into a final administrative case definition that maximizes 
the sensitivity and specificity for identifying ED visits attributable to cannabis. 
If other supporting characteristics in the administrative ED visits data cannot improve 
PPVs for cannabis codes then alternative data sources that capture sentiment around cannabis 
terms should be considered. Researchers should evaluate richer data sources like syndromic 
surveillance through the National Syndromic Surveillance program. This data includes chief 
complaint text along with diagnostic codes which could be leveraged to improve the 
performance of cannabis codes. 
It is possible that “attributed cannabis” is too broad of a clinical definition to develop a 
surveillance indicator for adverse health effects of cannabis. Researcher should consider 
splitting the cannabis codes into two surveillance indicators that measure acute and chronic 
health impacts from cannabis legalization separately. Acute impacts could be measured by ED 
visits due to cannabis poisonings or intoxication. While, a separate indicator that uses cannabis 
abuse, dependence, or use codes to identify ED visits where cannabis contributed to the visit 
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but may not be the underlying cause for the visit could measure more chronic impacts. 
Researchers would need to examine the performance of these separate indicators with updated 
clinical determinations for an acute versus chronic cannabis health event.    
Due to the complexity of cannabis use and the outcomes related to use, it is possible 
that an administrative case definition that relies on cannabis ICD-10-CM cannot achieve high 
enough performance to reliably identify the true number of ED visits attributed to cannabis. In 
the case where the goal is to estimate the true number of adverse health events due to 
cannabis, public health or researchers should explore other routes for accurately measuring ED 
visits attributable to cannabis. One option may be estimating the true number by performing 
annual manual records reviews for true positives and false negatives in a random samples of 
ED visits to estimate over or under counting and then adjust rates according. Another more 
accurate, but costly option may include establishing a clinical definition for healthcare 
encounters due to cannabis and requiring reporting of that condition to health departments. 
Once a case definition is identified it should be internally validated and externally 
validated across multiple ED visits datasets. A case definition that performs with similar 
sensitivity and specificity internally and externally would be a reliable indicator to use for 
surveillance of the public health impacts of cannabis legalization. Once a case definition has 
been validated work should begin to incorporate it into nationally recommended surveillance 
indicators.  
Limitations 
This study was based on ICD codes which have opportunity for measurement errors. 
Discharge diagnosis codes are intended for healthcare billing purposes and not for public health 
surveillance. Documented measurement errors in this data source can be both from interactions 
between patient and provider and interpretations of paperwork by coders. The quality of patient 
detail collected by providers, communication from the patient, and the clinical experience or 
knowledge of condition by the provider affect what is documented in the record. Then the 
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coder’s experiences and training affect how the documentation is coded.202 Additionally, it has 
been documented that changes in cannabis legalization has affected cannabis ICD coding.100  
Both internal and external factors can influence discharge coding in ED visits and these should 
be considered with using ICD codes for public health surveillance. 
With Colorado’s history of cannabis legalization, we expect that reporting bias was 
minimized in this sample. Though it is possible that ED visits may have not received a cannabis 
codes as a result of a patient not reporting cannabis use or a provider not screening for 
cannabis use. It is possible that ED visits that should have received cannabis text or codes did 
not as a result of reporting bias or screening bias and were misclassified into the true negatives. 
There are not standardized clinical definitions for adverse health conditions caused by 
cannabis. Furthermore, research on high potency cannabis and concentrates sold in Colorado’s 
markets is limited due to the Schedule I status of cannabis federally. Some conditions like 
cannabinoid hyperemesis have been described in literature119–123,153,154 but others like cannabis 
induced psychosis remain vague and difficult to clinically diagnose especially with other 
substances are involved.203,204 For this reason, the chart abstractions for determination of partial 
attribution of cannabis in this study may be biased. Every effort was take to minimize this bias 
by using a medical toxicologist to arbitrate questionable ED discharges and by requiring positive 
toxicology results for cannabis with a documented temporal relationship and an outcome related 
to cannabis use in discharges when an attending physician did not document cannabis as a 
contributing factor to the visits. It is possible that this conservative approach may have 
misclassified some ED visits as not attributable to cannabis due to lack of standard clinical 
guidelines for cannabis adverse health conditions. This may have biased our findings by 
lowering the PPVs. Additionally, in the manual records reviews it was not required to document 
corroboration between attending emergency and inpatient physicians when a patient was 
admitted. Often once an attending emergency physician determined cannabis as participating in 
the cause of the ED visit, not addition review of the inpatient physician’s opinion was done. A 
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further review to measure concordance of the opinions of the two physicians would strengthen 
the determination of attributable to cannabis. 
A large percent (85.6%) of ED discharges attributed to cannabis received a cannabis 
use, abuse, or dependence code. Many of these codes did not include symptoms coding and 
were coded more generally like cannabis abuse uncomplicated (F12.10) instead of Cannabis 
abuse with psychotic disorder with delusions (F12.150). Sensitivity analyses showed that 
cannabis coding indicating symptoms (i.e. with delirium, with perceptual disturbance, with 
psychotic disorder) improved the PPVs of these codes. However, this study was underpowered 
to provide reliable PPV estimates for these codes and they were collapse together into larger 
categories. Further research on a larger sample of ED discharges should examine the 
improvement of PPVs in cannabis use, abuse, and dependence codes described with 
symptoms (6th character) compared to more general coding.  
We assumed ED visits without cannabis ICD-10-CM codes and without cannabis text 
were true negatives. We did not confirm this with a manual records review of every predicted 
negative ED visits due to the large amount of time a review of 95,993 ED visits would require. 
Instead only a random sample of ED visits with text indicating recent cannabis use or positive 
toxicology screens for cannabis were reviewed. It is possible ED visits included misspelling of 
cannabis terms and were counted as true negatives. We hypothesized that the occurrence of 
this scenario would minimally impact the findings in this study. Additionally, we did not review all 
2,238 ED visits without cannabis ICD-10-CM codes but with cannabis text for recent cannabis 
use or positive toxicology screens for cannabis. Instead we reviewed a random sample which 
was used to estimate the number of false negatives across the entire sample of ED visits in 
2016. It is possible that we over- or underestimated the number of false negatives because we 
did not review the entire sample of 2016 ED visits.  
The text included in the text analytics was 100 space delimited character strings before 
and after the cannabis term to capture sentiment around the documentation of cannabis use. It 
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is possible sentiment was included elsewhere in the record and not captured in this text. It is 
also possible for terms in the text to be reported more than once. Therefore, comparisons of the 
frequency of terms between the false negatives and true negatives could be biased by over 
documentation of similar terms in the same record. Results from the text analytics were 
intended to be hypothesis generating for future studies into sentiment being used to 
characterize cannabis text as attributed to cannabis or not. 
These findings were reflective of practices in a large, urban, academic hospital in a state 
with legal retail cannabis and may not be generalizable to other emergency departments in 
dissimilar settings. However, the ICD-10-CM coding system is intended to be a standardized 
system that will yield similar results across hospital systems. It is used in national surveillance of 
other conditions including opioid overdoses and therefore we expect similar results would be 
found in similar emergency departments as the one evaluated in this study.162,195  
Conclusions 
The expansion of the cannabis codes under ICD-10-CM has improved their ability to be 
used in surveillance of administrative ED and hospital discharge datasets. This study assessed 
the positive and negative predictive values of cannabis ICD-10-CM codes in identifying ED visits 
partially attributable to cannabis. The study found that cannabis poisoning and intoxication 
codes performed well at positive identifying ED visits partially attributed to cannabis, but did not 
capture a large amount of ED visits attributed to cannabis. Cannabis codes in the primary 
diagnosis position also performed well at positively predicting ED visits partially attributed to 
cannabis, but also did not capture a large amount of ED visits attributed to cannabis. Combining 
these two captured 10.0% of all ED visits partially attributed to cannabis in the sample. For this 
reason, cannabis ICD-10-CM codes alone may not be ideal in determining the true number of 
ED visits attributed to cannabis. However, combinations or algorithms of cannabis ICD-10-CM 
codes that leverage additional data within the ED discharge data may be able to maximize 
performance of an administrative case definition that would be useful in measuring trends over 
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A. SEARCH TERMS FOR LITERATURE REVIEW OF CANNABIS ICD-10-CM PERFOMANCE 
 ((((("Sensitivity and Specificity"[MeSH Terms] OR (((("Sensitivity and Specificity"[MeSH Terms] 
OR ("sensitivity"[All Fields] AND "specificity"[All Fields])) OR "Sensitivity and Specificity"[All 
Fields]) OR ("specificity"[All Fields] AND "sensitivity"[All Fields])) OR "specificity and 
sensitivity"[All Fields])) OR ((((((((("hypersensitivity"[MeSH Terms] OR "hypersensitivity"[All 
Fields]) OR "sensitive"[All Fields]) OR "sensitively"[All Fields]) OR "sensitives"[All Fields]) OR 
"sensitivities"[All Fields]) OR "Sensitivity and Specificity"[MeSH Terms]) OR ("sensitivity"[All 
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Fields] AND "specificity"[All Fields])) OR "Sensitivity and Specificity"[All Fields]) OR 
"sensitivity"[All Fields])) OR ((((((((((("Sensitivity and Specificity"[MeSH Terms] OR 
("sensitivity"[All Fields] AND "specificity"[All Fields])) OR "Sensitivity and Specificity"[All Fields]) 
OR "specificity"[All Fields]) OR "specific"[All Fields]) OR "specifically"[All Fields]) OR 
"specification"[All Fields]) OR "specifications"[All Fields]) OR "specificities"[All Fields]) OR 
"specifics"[All Fields]) OR "specifities"[All Fields]) OR "specifity"[All Fields])) OR "Predictive 
Value of Tests"[MeSH Terms]) AND 
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((("Cannabis"[MeSH Terms] OR (("Cannabis"[MeSH 
Terms] OR "Cannabis"[All Fields]) OR "cannabi"[All Fields])) OR "Hemp Plant"[All Fields]) OR 
"Hemp Plants"[All Fields]) OR "plant hemp"[All Fields]) OR "plants hemp"[All Fields]) OR 
"Cannabis indica"[All Fields]) OR ((("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR 
"cannabi"[All Fields]) AND (("indica"[All Fields] OR "indica s"[All Fields]) OR "indicas"[All 
Fields]))) OR "indica cannabis"[All Fields]) OR ((("indica"[All Fields] OR "indica s"[All Fields]) OR 
"indicas"[All Fields]) AND (("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR 
"cannabi"[All Fields]))) OR (("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR 
"marihuana"[All Fields])) OR "Marihuanas"[All Fields]) OR ((("Cannabis"[MeSH Terms] OR 
"Cannabis"[All Fields]) OR "marijuana"[All Fields]) OR "marijuana s"[All Fields])) OR 
(("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR "ganja"[All Fields])) OR 
("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields])) OR (("Cannabis"[MeSH Terms] OR 
"Cannabis"[All Fields]) OR "hashish"[All Fields])) OR ("Cannabis"[MeSH Terms] OR 
"Cannabis"[All Fields])) OR (("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR 
"hemp"[All Fields])) OR (("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR "hemps"[All 
Fields])) OR (("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR "bhang"[All Fields])) OR 
("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields])) OR "Cannabis sativa"[All Fields]) OR 
((("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR "cannabi"[All Fields]) AND 
(("sativa"[All Fields] OR "sativae"[All Fields]) OR "sativas"[All Fields]))) OR "sativa cannabis"[All 
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Fields]) OR ((("sativa"[All Fields] OR "sativae"[All Fields]) OR "sativas"[All Fields]) AND 
(("Cannabis"[MeSH Terms] OR "Cannabis"[All Fields]) OR "cannabi"[All Fields]))) OR "Medical 
Marijuana"[MeSH Terms]) OR "marijuana medical"[All Fields]) OR "Medicinal Marijuana"[All 
Fields]) OR "marijuana medicinal"[All Fields]) OR "Medicinal Cannabis"[All Fields]) OR 
"cannabis medicinal"[All Fields]) OR "Marijuana Treatment"[All Fields]) OR "treatment 
marijuana"[All Fields]) OR "Medical Cannabis"[All Fields]) OR "cannabis medical"[All Fields]) 
OR (("marijuana smoking"[MeSH Terms] OR ("marijuana"[All Fields] AND "smoking"[All Fields])) 
OR "marijuana smoking"[All Fields])) AND "Mesh"[All Fields]) OR "smoking marijuana"[All 
Fields]) OR "Marihuana Smoking"[All Fields]) OR "smoking marihuana"[All Fields]) OR "Hashish 
Smoking"[All Fields]) OR "smoking hashish"[All Fields]) OR "Cannabis Smoking"[All Fields]) OR 
"smoking cannabis"[All Fields]) OR "Marijuana Abuse"[MeSH Terms]) OR "abuse marijuana"[All 
Fields]) OR "Marihuana Abuse"[All Fields]) OR ((("Marijuana Abuse"[MeSH Terms] OR 
("marijuana"[All Fields] AND "abuse"[All Fields])) OR "Marijuana Abuse"[All Fields]) OR 
("abuse"[All Fields] AND "marihuana"[All Fields]))) OR "Hashish Abuse"[All Fields]) OR 
((("Marijuana Abuse"[MeSH Terms] OR ("marijuana"[All Fields] AND "abuse"[All Fields])) OR 
"Marijuana Abuse"[All Fields]) OR ("abuse"[All Fields] AND "hashish"[All Fields]))) OR "cannabis 
related disorder"[All Fields]) OR "cannabis related disorder"[All Fields]) OR "disorder cannabis 
related"[All Fields]) OR "Cannabis Abuse"[All Fields]) OR "abuse cannabis"[All Fields]) OR 
"Cannabis Dependence"[All Fields]) OR "dependence cannabis"[All Fields]) OR "Marijuana 
Dependence"[All Fields]) OR "dependence marijuana"[All Fields])) AND ((((("international 
classification of diseases"[MeSH Terms] OR (("international"[All Fields] AND "classification"[All 
Fields]) AND "diseases"[All Fields])) OR "international classification of diseases"[All Fields]) OR 
"icd 10 cm"[All Fields]) OR ((("international classification of diseases"[MeSH Terms] OR 
(("international"[All Fields] AND "classification"[All Fields]) AND "diseases"[All Fields])) OR 
"international classification of diseases"[All Fields]) OR "icd10"[All Fields])) OR ((("international 
classification of diseases"[MeSH Terms] OR (("international"[All Fields] AND "classification"[All 
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Fields]) AND "diseases"[All Fields])) OR "international classification of diseases"[All Fields]) OR 
"icd 10"[All Fields])) 
Translations 
Specificity and Sensitivity: "sensitivity and specificity"[MeSH Terms] OR ("sensitivity"[All 
Fields] AND "specificity"[All Fields]) OR "sensitivity and specificity"[All Fields] OR 
("specificity"[All Fields] AND "sensitivity"[All Fields]) OR "specificity and sensitivity"[All Fields] 
Sensitivity: "hypersensitivity"[MeSH Terms] OR "hypersensitivity"[All Fields] OR "sensitive"[All 
Fields] OR "sensitively"[All Fields] OR "sensitives"[All Fields] OR "sensitivities"[All Fields] OR 
"sensitivity and specificity"[MeSH Terms] OR ("sensitivity"[All Fields] AND "specificity"[All 
Fields]) OR "sensitivity and specificity"[All Fields] OR "sensitivity"[All Fields] 
Specificity: "sensitivity and specificity"[MeSH Terms] OR ("sensitivity"[All Fields] AND 
"specificity"[All Fields]) OR "sensitivity and specificity"[All Fields] OR "specificity"[All Fields] OR 
"specific"[All Fields] OR "specifically"[All Fields] OR "specification"[All Fields] OR 
"specifications"[All Fields] OR "specificities"[All Fields] OR "specifics"[All Fields] OR 
"specifities"[All Fields] OR "specifity"[All Fields] 
Cannabi: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "cannabi"[All Fields] OR 
"cannabis's"[All Fields] 
Marihuana: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "marihuana"[All Fields] 
Marijuana: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "marijuana"[All Fields] OR 
"marijuana's"[All Fields] 
Ganja: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "ganja"[All Fields] 
Ganjas: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "ganjas"[All Fields] 
Hashish: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "hashish"[All Fields] 
Hashishs: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "hashishs"[All Fields] 
Hemp: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "hemp"[All Fields] 
Hemps: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "hemps"[All Fields] 
123 
 
Bhang: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "bhang"[All Fields] 
Bhangs: "cannabis"[MeSH Terms] OR "cannabis"[All Fields] OR "bhangs"[All Fields] 
Marijuana Smoking: "marijuana smoking"[MeSH Terms] OR ("marijuana"[All Fields] AND 
"smoking"[All Fields]) OR "marijuana smoking"[All Fields] 
ICD-10-CM: "international classification of diseases"[MeSH Terms] OR ("international"[All 
Fields] AND "classification"[All Fields] AND "diseases"[All Fields]) OR "international 
classification of diseases"[All Fields] OR "icd 10 cm"[All Fields] 
ICD10: "international classification of diseases"[MeSH Terms] OR ("international"[All Fields] 
AND "classification"[All Fields] AND "diseases"[All Fields]) OR "international classification of 
diseases"[All Fields] OR "icd10"[All Fields] 
ICD-10: "international classification of diseases"[MeSH Terms] OR ("international"[All Fields] 
AND "classification"[All Fields] AND "diseases"[All Fields]) OR "international classification of 





B. CHART ABSTRACTION FORM FOR REVIEW FOR FALSE AND TRUE POSITIVES 
# Variable / Field Name 
Field Label 
Field Note 
Field Attributes (Field Type, Validation, Choices, 
Calculations, etc.) 
Instrument:Demographics(demographics)  
1 pid Participant ID text 
2 mrn MRN text (number), Identifier 
3 csn_id CSN ID text (number) 
4 date_of_visit Date of visit text (datetime_mdy), Identifier 
5 state State radio 
0 Colorado 
1 Other state 
 
6 state_other_specify 
Show the field ONLY if: 
[state] = '1' 
Other, specify: text 
7 zip Zipcode text (zipcode), Identifier 
8 dob DOB text (date_mdy), Identifier 
9 age_at_visit Age 
Age at visit date 
text (number) 





11 race Race radio 
1 American Indian and Alaska Native 
2 Asian 
3 Black or African American 
4 Native Hawaiian or Other Pacific Islander 
5 White 
6 More than one race 
7 Unknown or not reported 
8 Other 
 
12 race_other_specify Other, specify: text 
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Show the field ONLY if: 
[race] = '8' 
13 ethnicity Ethnicity radio 
1 Hispanic or Latino 
0 Not Hispanic or Latino 
2 Unknown or not reported 
 
14 coded_benefit_plan_group Coded benefit 
plan group 
radio 
1 Private insurance 





7 Not listed 
8 Indigent 
 
15 uncoded_benefit_plan_group Benefit plan 
group 
text 
16 ra_initials RA Initials text 









Instrument:Visit Details(visit_details)  
18 rereviewer_initials PRA Re-
Reviewer Initials 
text 
19 csn_2 CSN text 
20 include_in_data Include in 
dataset? 
If coded as 0/no, 
information was 
not reviewed by 
Monte and should 
not be included in 
this dataset. This 
information was 







and have no MJ 
ICD code(s). 





22 visit_number Visit number text (integer, Min: 0) 





3 Left without being seen 
4 Left against medical advice 
5 CDU admit (ED observation) 
6 ICU (MICU, SICU, BICU, CICU, or other ICU) 
7 Transfer to psych 
8 Other 
0 Check dispo in EMR 
 
24 dispo_other_specify 
Show the field ONLY if: 
[coded_dispo_from_ed] = '8' 
Other, specify: text 
25 chief_complaint Chief complaint 




26 discharge_diagnosis Discharge 
diagnosis 
The final primary 
discharge diagnosis 
listed in Epic. 
text 
27 discharge_date_ed Discharge date 
& time from the 
ED 
text (datetime_mdy), Identifier 
28 discharge_date_hosp Discharge date 
& time from the 
hospital 
text (datetime_mdy), Identifier 
29 icd_9_code ICD 9 code text 
30 icd_10_code ICD 10 code(s) text 
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31 icd_n How many MJ 
ICD codes were 
in the chart? 
text 
32 icd_01 
Show the field ONLY if: 
[icd_n] > 0 
First ICD code text 
33 icd_02 
Show the field ONLY if: 





Show the field ONLY if: 
[icd_n] > 2 
Third ICD code text 
35 icd_04 
Show the field ONLY if: 
[icd_n] > 3 
Fourth ICD code text 
36 icd_05 
Show the field ONLY if: 
[icd_n] > 4 
Fifth ICD code text 
37 icd_06 
Show the field ONLY if: 
[icd_n] > 5 
Sixth ICD code text 
38 icd_07 
Show the field ONLY if: 





Show the field ONLY if: 
[icd_n] > 7 
Eighth ICD code text 
40 icd_09 
Show the field ONLY if: 
[icd_n] > 8 
Ninth ICD code text 
41 icd_10 
Show the field ONLY if: 
[icd_n] > 9 
Tenth ICD code text 
42 ed_visit_mj_related ED visit MJ 
related 
Visit at least 
partially 
attributable to 
cannabis if one or 
more of the 
following criteria 









cannabis as likely 
precipitating or 
contributing to the 
condition bringing 
the patient to the 
ED, 2) the patient 
was admitted to 
the hospital and 
the inpatient 
physician identified 
cannabis as likely 
precipitating or 
contributing to the 
condition, and/or 
3) the urine 
toxicology screen 
was positive AND 





exposure and a 
condition or event 
known to be 










spice, etc. Only 
products naturally 
derived from the 
cannabis plant. 
43 visit_mj_related_data_def 
Show the field ONLY if: 
[ed_visit_mj_related] = '1' 
If yes, which 
part of the data 
definition best 
fits the visit 
reason (choose 
all that apply)? 




spice, etc. Only 
products naturally 
derived from the 
cannabis plant. 
checkbox 








patient to the ED 
2 visit_mj_related_data_def___2 The patient was 
admitted to the 
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3 visit_mj_related_data_def___3 The UTox 
screen was 
positive AND 







exposure and a 
condition or 
event known to 
be associated 





Show the field ONLY if: 
[ed_visit_mj_related] = '0' 
If no, why? notes 
45 reason_to_mj 
Show the field ONLY if: 
[ed_visit_mj_related] = '1' 
Reason to 
marijuana 
The reason this 
visit was coded as 
at least partially 
attributable to 
cannabis use. 
Check all that 
apply. 
checkbox 
1 reason_to_mj___1 Psychiatric 
2 reason_to_mj___2 Gastrointestinal 
3 reason_to_mj___3 Cardiovascular 
4 reason_to_mj___4 Respiratory 
5 reason_to_mj___5 Intoxication 
6 reason_to_mj___6 Motor vehicle collision 
7 reason_to_mj___7 Trauma 
8 reason_to_mj___8 Dermatologic 
9 reason_to_mj___9 Neurologic 
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10 reason_to_mj___10 Altered mental status 
11 reason_to_mj___11 Other 
12 reason_to_mj___12 Visit not related to MJ 
 
46 reason_to_mj_other_specify 
Show the field ONLY if: 
[reason_to_mj(11)] = '1' 
Other, specify: text 
47 psychiatric_type 
Show the field ONLY if: 




>1 month. Acute 
psych reason: no 







Show the field ONLY if: 







1 chronic_psych_reason___1 Chronic depression 
2 chronic_psych_reason___2 Chronic anxiety 
3 chronic_psych_reason___3 Chronic psychosis 
4 chronic_psych_reason___4 PTSD 
5 chronic_psych_reason___5 Schizophrenia 
6 chronic_psych_reason___6 Other chronic 
psychiatric disease 
7 chronic_psych_reason___7 Acute exacerbation 




Show the field ONLY if: 
[chronic_psych_reason(6)] = '1' 
Other, specify: text 
50 acute_psych_reason 
Show the field ONLY if: 




reason: no prior 
history of any 
psychiatric disease 
checkbox 
1 acute_psych_reason___1 Acute panic attack 
2 acute_psych_reason___2 Acute anxiety 
3 acute_psych_reason___3 Acute depression 
4 acute_psych_reason___4 Acute psychosis 
5 acute_psych_reason___5 Other acute 
psychiatric disease 
6 acute_psych_reason___6 Suicidal ideation 





Show the field ONLY if: 
[acute_psych_reason(5)] = '1' 
Other, specify: text 
52 gastro_type 
Show the field ONLY if: 





deemed by MD in 
ED or by definition 
of >=3 visits for 
vomiting resulting 
in a visit to a 





within 1 year. 
radio 




Show the field ONLY if: 
[gastro_type] = '0' 
Other, specify: text 
54 intoxication_type 
Show the field ONLY if: 





for the visit is due 




1 Single drug (MJ only) 
2 Alcohol and MJ 
3 Polydrug use (without alcohol) 
4 Polydrug use and alcohol 
 




56 edible Edible exposure 








edible agents. If not 
documented, filled 






57 vaporized Vaporized 
exposure 









includes terms like, 
"vape, vapor, 
electronic 
cigarette." If not 
documented, filled 
in as 0 (No). 
2 Unknown 
 









outcome as a direct 
result of work in 
the marijuana 
industry (e.g., a 
"marijuana grow" 




be found anywhere 
in the chart, that is, 
in the triage note, 





2 Not documented or unknown 
 
59 mj_occupational_visit 
Show the field ONLY if: 





outcome from an 
exposure to a 
marijuana-related 
occupation = an 
emergency 
department visit 
for an adverse 
health event 
directly resulting 





and could range 

















to MJ pollen, injury 
from trimming 
marijuana buds or 
plants, etc. 
60 utox_mj Urine Tox 
screen 
Other drugs listed 
in the incident 
record or in the 





synthetic drugs of 
abuse (ex: mamba), 
or any other illicit 






2 Not performed 
 
61 positive_tox_mj 
Show the field ONLY if: 
[utox_mj] = '1' 
What was the 
tox screen 
positive for and 
what other 
drugs of abuse 
were found in 
the chart? 
checkbox 
1 positive_tox_mj___1 Opioids 
2 positive_tox_mj___2 Benzodiazepines 
3 positive_tox_mj___3 THC/ marijuana 
4 positive_tox_mj___4 Barbiturates 
5 positive_tox_mj___5 Methamphetamine/ 
amphetamines 
6 positive_tox_mj___6 Cocaine 
7 positive_tox_mj___7 Other 
 
62 alcohol_use Alcohol use 
Alcohol use 
coincident with the 






63 pregnant Pregnant 
The patient is 
currently pregnant. 
Either stated in the 
medical record or 








64 ed_los ED length of 
stay (hours) 
text 
65 hospital_los Hospital length 
of stay (days) 
text 









Instrument:Alcohol Info(alcohol_info)  
67 arrival_creatinine Arrival 
creatinine 
text 
68 arrival_potassium Arrival 
potassium 
text 
69 arrival_bicarb Arrival bicarb text 
70 arrival_lactate Arrival lactate text 




72 arrival_troponin Arrival troponin text 


















2 Not performed 
 
77 positive_tox_etoh 
Show the field ONLY if: 
[utox_etoh] = '1' 




1 positive_tox_etoh___1 Opioids 
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2 positive_tox_etoh___2 Benzodiazepines 
3 positive_tox_etoh___3 THC/ marijuana 
4 positive_tox_etoh___4 Barbiturates 
5 positive_tox_etoh___5 Methamphetamine/ 
amphetamines 
6 positive_tox_etoh___6 Cocaine 
7 positive_tox_etoh___7 Other 
 
78 patient_admit_hospital Was the patient 







Show the field ONLY if: 
[patient_admit_hospital] = '1' 
24-hr creatinine text 
80 potassium_24 
Show the field ONLY if: 





Show the field ONLY if: 
[patient_admit_hospital] = '1' 
24-hr bicarb text 
82 lactate_24 
Show the field ONLY if: 
[patient_admit_hospital] = '1' 
24-hr lactate text 
83 coded_audit_c AUDIT C radio 
1 AUDIT C >= 4 
0 AUDIT C < 4 
2 No AUDIT C 
 








Show the field ONLY if: 
[presence_of_etoh_icd10] = '1' 
If yes, which 
codes? (Fill in) 
text 
86 code_etoh_icd10_codes 
Show the field ONLY if: 
[presence_of_etoh_icd10] = '1' 
If yes, which 
codes? 
checkbox 
1 code_etoh_icd10_codes___1 F10.1-10.9 
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2 code_etoh_icd10_codes___2 K70.0, K70.1, 
K70.4 
3 code_etoh_icd10_codes___3 K85.2 
4 code_etoh_icd10_codes___4 E51.2 
5 code_etoh_icd10_codes___5 K29.2 
6 code_etoh_icd10_codes___6 X45 
7 code_etoh_icd10_codes___7 X65 
 
87 concern_for_etoh Concern for 
EtOH abuse in 






88 notes_etoh_abuse Notes on 
concern for 
EtOH abuse 
PRA impression of 
EtOH abuse from 
chart. 
notes 









Show the field ONLY if: 
[cardiac_cath] = '1' 
If yes, which 
ICD-10 code(s)? 
checkbox 
1 cath_icd10_codes___1 72662 
2 cath_icd10_codes___2 72663 
 


















Show the field ONLY if: 
[intubation_or_nippv] = '1' 
If yes, which 
ICD-10 code(s)? 
checkbox 
1 intubation_icd10_codes___1 72977 
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2 intubation_icd10_codes___2 72982 
3 intubation_icd10_codes___3 72987 
4 intubation_icd10_codes___4 72998 
5 intubation_icd10_codes___5 72999 
6 intubation_icd10_codes___6 73000 
 









Instrument:Monte comment(monte_comment)  
95 monte_agree Monte agree? checkbox 
1 monte_agree___1 Yes 
0 monte_agree___0 No 
2 monte_agree___2 See comment 
 
96 monte_comment Monte 
comment 
notes 
97 pra_comment PRA comment notes 













C. CANNABIS ICD-10-CM CODES 
Short description of cannabis ICD-10-CM codes evaluated for positive predictive values to predict ED visits 
partially attributable to cannabis. 
Cannabis ICD-10-CM 
Codes Codes Description 
 
F12.1 Cannabis Abuse Unspecified 
F12.10 Uncomplicated 
F12.12 With intoxication 
F12.120-F12.129 Uncomplicated, with delirium, with perceptual disturbance, unspecified 
F12.15 With psychotic disorder 
F12.150-F12.159 With delusions, with hallucinations, unspecified 
F12.18 With other cannabis-induced disorder  
F12.180-F12.188 Cannabis-induced anxiety disorder, cannabis-induced disorder 
F12.19 With unspecified cannabis-induced disorder 
 
F12.2 Cannabis Dependence Unspecified 
F12.20 Uncomplicated 
F12.21 In remission 
F12.22 With intoxication  
F12.220-F12.229 Uncomplicated, with delirium, with perceptual disturbance, unspecified 
F12.25 With psychotic disorder  
F12.250-F12.259 With delusions, with hallucinations, unspecified 
F12.28 With other cannabis-induced disorder  
F12.280-F12.288 Cannabis-induced anxiety disorder, other cannabis-induced disorder 
F12.29 With unspecified cannabis-induced disorder 
 
F12.9 Cannabis Use Unspecified 
F12.90  Unspecified uncomplicated 
F12.92 Unspecified with intoxication  
F12.920- F12.929 Uncomplicated, with delirium, with perceptual disturbance, or unspecified 
F12.95 Unspecified with psychotic disorder  
F12.950-F12.959 With delusions, with hallucinations, unspecified 
F12.98 Unspecified with other cannabis-induced disorder  
F12.980-F12.988 With anxiety disorder, with cannabis-induced disorder 




Poisoning by cannabis (derivatives), accidental (unintentional) (Initial encounter, subsequent 
encounter, sequela) 
T40.7X2(A,D,S) 
Poisoning by cannabis (derivatives), intentional self-harm (Initial encounter, subsequent 
encounter, sequela) 
T40.7X3(A,D,S) Poisoning by cannabis (derivatives), assault (Initial encounter, subsequent encounter, sequela) 
T40.7X4(A,D,S) 
Poisoning by cannabis (derivatives), undetermined (Initial encounter, subsequent encounter, 
sequela) 
T40.7X5(A,D,S) Adverse effect of cannabis (derivatives) (Initial encounter, subsequent encounter, sequela) 






D. SAS MACRO FOR KOSINSKI (2013) GENERALIZED SCORE STATISTIC 
Macro pv_SS 
/* 
SAS macro pv_SS: Calculates Test Statistic to compare predicted values (pv) 
of a diagnostic test based on generalized score statistic and weighted 
generalized score statistic proposed by Andrzej S.Kosinki(2013) 
Author: Lovedeep Gondara 
This program is free software; you can redistribute it and/or modify it. 
This program is distributed in the hope that it will be useful, but WITHOUT 
ANY WARRANTY. 
Please forward any comments to: lgond2@uis.edu 
*/ 
%macro pv_SS(data=, test1=, test2=, dis=, method=); 
/* 
data --- Name of SAS dataset that should contain information for test1, 
test2 and gold standard result(True result) 
test1 --- Name of variable which has information for first test (0=negative, 
1=positive) 
test2 --- Name of variable which has information for second test (0=negative, 
1=positive) 
dis --- Name of variable with information for true result (0=negative, 
1=positive) 
method= Name of method to be used for compuation of test statitstic 
(gs=generalized score statistic, wgs=weighted generalized score statistic) 
*/ 
/*typical macro call*/ 
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/* %pv_WGS(data=data_set_name, test1=first_test, test2=second_test, 
dis=true_result)*/ 
/*** Using PROC FREQ to get output tables with percentages for both test 
types 
so that the PPV and NPV can be extracted ***/ 
proc freq data=&data noprint; 
table &test1*&dis / outpct out=&test1 sparse ; 
table &test2*&dis / outpct out=&test2 sparse; 
table &test1*&test2*&dis / outpct out=test sparse ; 
run; 


















set &test1 &test2 test; 
pv=pct_row/100; 
run; 
/*** Getting counts and sums and storing them in macro variables to be used 
in calculations ***/ 
proc sql noprint; 
select pv into :ppv1 from pv where &test1=1 and &&dis=1 and t=1; 
select pv into :ppv2 from pv where &test2=1 and &&dis=1 and t=2; 
select pv into :npv1 from pv where &test1=0 and &&dis=0 and t=1; 
select pv into :npv2 from pv where &test2=0 and &&dis=0 and t=2; 
select count into :td from pv where &test1=1 and &test2=1 and &&dis=1 
and t=3 ; 
select count into :tnd from pv where &test1=1 and &test2=1 and &dis=0 
and t=3; 
select count into :ntd from pv where &test1=0 and &test2=0 and &dis=0 
and t=3 ; 
select count into :ntnd from pv where &test1=0 and &test2=0 and &dis=1 
and t=3; 
select sum(count) into :di1 from pv where not missing(&test1) and 
&dis=1 and &test1=1 and t ne 3; 
select sum(count) into :di2 from pv where not missing(&test2) and 
&dis=1 and &test2=1 and t ne 3; 
select sum(count) into :dj1 from pv where not missing(&test1) and 
&dis=0 and &test1=0 and t ne 3; 
select sum(count) into :dj2 from pv where not missing(&test2) and 
&dis=0 and &test2=0 and t ne 3; 
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select sum(count) into :d2 from pv where not missing(&test2) and 
&test2=1 and t ne 3; 
select sum(count) into :d1 from pv where not missing(&test1) and 
&test1=1 and t ne 3; 
select sum(count) into :nd2 from pv where not missing(&test2) and 
&test2=0 and t ne 3; 
select sum(count) into :nd1 from pv where not missing(&test1) and 
&test1=0 and t ne 3; 
select sum(count) into :d2i from pv where not missing(&test2) and 
&test2=0 and t ne 3; 
select sum(count) into :d1i from pv where not missing(&test1) and 
&test1=0 and t ne 3; 
select sum(count) into :d1c from pv where not missing(&test1) and 
&test1=1 and &dis=0 and t ne 3; 
select sum(count) into :d2c from pv where not missing(&test2) and 
&test2=1 and &dis=0 and t ne 3; 
select sum(count) into :dj1c from pv where not missing(&test1) and 
&test1=0 and &dis=1 and t ne 3; 
select sum(count) into :dj2c from pv where not missing(&test2) and 
&test2=0 and &dis=1 and t ne 3; 
quit; 




























cppv=(td*((1-ppvp)**2) + tnd*(ppvp**2))/tt; 
nppv=((ntnd*(npvp**2)) + (ntd*(1-npvp)**2))/ntt; 
%if &method=wgs %then %do; 
Sp=abs((difppv**2)/((ppvp*(1-ppvp) - 2*cppv)*((1/d1)+(1/d2)))); 


















%if &method=gs %then %let title=Method: Generalized Score Statistic; 
%if &method=wgs %then %let title=Method: Weighted Generalized Score 
Statistic; 
/*** Printing results ***/ 
proc print data=pv_WGS noobs label; 
var ppv1 ppv2 Sp pvp npv1 npv2 Sn pvn; 
label ppv1="PPV &test1" ppv2="PPV &test2" npv1="NPV &test1" npv2="NPV 






/*** Garbage collection ***/ 







E. POWER SIMULATIONS FOR POSITIVE PREDICTIVE VALUE CALCULATIONS 
Power for O1.1: In 2014, there were 1,210 (1.2%) ED visits that received a marijuana 
ICD-9-CM code. Therefore, we would expect at least 1,200 ED visits with at least one marijuana 
ICD-10-CM code from January 1, 2016 to December 31, 2016. We will be able to detect PPVs 
as high as 93% with 95% confidence, 80% power, at a 1% prevalence, and with sensitivities 
and specificities as low as 88% and 85% respectively (Figure 10). 
 
 
Power for O2.1: In 2014, there were 96,688 (98.7%) ED visits without a marijuana ICD-9-CM 
code. Therefore, we would expect 97,000 ED visits without marijuana ICD-10-CM codes from 
January 1, 2016 to December 31, 2016. In this sample we will be able to detect PPVs for non-
marijuana codes as high as 99% with 95% confidence, 80% power, at a 90% prevalence of no 







F. NON-CANNABIS ICD-10-CM CODES EVALUATED 
Table A2. Short description of codes for outcomes related to cannabis examined with cannabis ICD-10-
CM codes for positive predictive values to predict ED visits partially attributable to cannabis. 
ICD-10-CM Codes Codes Description 
V87, V88, V89 Motor vehicle collision  
S00-T32 Injury 
G43.A, -0, -1, R11 Cyclic vomiting  
G45.8, -.9 Ischemic Stroke in individuals younger than 55 years old  
J40-J42, R05, R06.2, 
R09.3 Chronic bronchitis with cough/wheeze/sputum  
F22, F23, F28, F29, 
F30.2, F31.2, F32.3, 
F33.3 Psychotic symptoms or disorders  
F41.0 Acute panic attack  
F19.93 Withdrawal symptoms (only marijuana use indicated)  






G. PERL REGULAR EXPRESSIONS FOR TERMS AND PHRASES INDICATING RECENT 

































































































































































































































































































H. PERL REGULAR EXPRESSIONS FOR TERMS AND PHRASES WITH CANNABIS TEXT 








































































































I. CANNABIS CONSUMPTION, EXPOSURE, OR INTOXICATION WITH ACUTE ILLNESS OR 


















































































































































































































































































































J. CASE 1: CANNABIS CONSUMPTION, EXPOSURE, OR INTOXICATION ONLY WITH 















































































































































































































































































































































































































































































































































































































































































































L. CASE 3: SELF-MEDICATING/MEDICAL CANNABIS USE OR CHRONIC CONDITIONS 



















































































































































































































































































































































































































































































































































O. CHART ABSTRACTION FORM FOR REVIEW FOR FALSE AND TRUE NEGATIVES 
# Variable / Field Name 
Field Label 
Field Note 
Field Attributes (Field Type, Validation, Choices, 
Calculations, etc.) 
Instrument:Visit Information(visit_information)  
1 record_id Record ID text 
2 falseneg_review False negative? 






3 pat_mrn_id Medical record 
number 
Link Dataset 3 to 
the master Dataset 
1 and to link 
patients with 
multiple visits. 
text (integer), Identifier 
4 pat_enc_csn_id Patient 
Encounter Case 
ID 
To track the 
emergency 
department visits 
and the chief 
complaints for 
individual patients 
and to link multiple 
datasets. 
text (integer), Identifier 

































29 New Hampshire 
30 New Jersey 
31 New Mexico 
32 New York 
33 North Carolina 





39 Rhode Island 
40 South Carolina 














6 age_at_visit Age at visit text (integer) 




8 race Race text 
9 ethnicity Ethnicity radio 
1 Hispanic or Latino 
0 Not Hispanic or Latino 
2 Unknown 
 









11 uncoded_benefit_plan_group Benefit plan 
group 
text 
















name from Excel 
file) 
text 
14 chief_complaint Chief complaint text 
15 discharge_diagnosis Discharge 
diagnosis 
text 
16 discharge_date_ed Discharge date 
and time from 
the ED 
text (datetime_mdy), Identifier 
17 discharge_date_hosp Discharge date 
and time from 
the hospital 
text (datetime_mdy), Identifier 
18 mj_string_char The cannabis 
text string that 
was present 
The specific string 
of text from Table 
1. in the data 
request that 




19 ed_los ED length of 
stay (hours) 
text 
20 hospital_los Hospital length 
of stay (days) 
text 




















23 ed_placserv Place of service 
for ED patients 
radio 
1 Emergency Room 
2 Outpatient Surgery 
3 Observation Only 
4 Other Outpatient for ASC Patients 
 




through the ED 
text 
25 ed_ppayer ED Primary 
Payer 
text 
26 hosp_ppayer Inpatient 
Primary Payer 
text 
27 ed_sourcadm ED Source of 
Admission 
text (integer) 
28 hosp_sourcadm Hospital Source 
of Admission 
text (integer) 




30 visit_number Visit number text (integer) 






32 noteid Michael Info text 




34 notetext Note Text notes 
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35 ed_visit_mj_related ED visit MJ 
related 
Visit at least 
partially 
attributable to 
cannabis if one or 
more of the 
following criteria 
were met: 1) the ED 
physician identified 
cannabis as likely 
precipitating or 
contributing to the 
condition bringing 
the patient to the 
ED, 2) the patient 
was admitted to 
the hospital and 
the inpatient 
physician identified 
cannabis as likely 
precipitating or 
contributing to the 
condition, and/or 
3) the urine 
toxicology screen 
was positive AND 





exposure and a 
condition or event 
known to be 










spice, etc. Only 
products naturally 







Show the field ONLY if: 
[ed_visit_mj_related] = '1' 
If yes, which 
part of the data 
definition best 
fits the reason 
checkbox 





(choose all that 
apply)? 




spice, etc. Only 
products naturally 







patient to the 
ED 
2 visit_mj_related_data_def___2 The patient was 
admitted to the 









3 visit_mj_related_data_def___3 The UTox 
screen was 
positive AND 







exposure and a 
condition or 
event known to 
be associated 





Show the field ONLY if: 
[ed_visit_mj_related] = '0' 
If no, why? notes 
38 reason_to_mj Reason to 
marijuana 
The reason this 
visit was coded as 




1 reason_to_mj___1 Psychiatric 
2 reason_to_mj___2 Gastrointestinal 
3 reason_to_mj___3 Cardiovascular 
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Check all that 
apply. 
4 reason_to_mj___4 Respiratory 
5 reason_to_mj___5 Intoxication 
6 reason_to_mj___6 Motor vehicle collision 
7 reason_to_mj___7 Trauma 
8 reason_to_mj___8 Dermatologic 
9 reason_to_mj___9 Neurologic 
10 reason_to_mj___10 Altered mental status 
11 reason_to_mj___11 Other 
 
39 reason_to_mj_other_specify 
Show the field ONLY if: 
[reason_to_mj(11)] = '1' 
Other, specify: text 
40 psychiatric_type 
Show the field ONLY if: 




>1 month. Acute 
psych reason: no 







Show the field ONLY if: 




1 chronic_psych_reason___1 Chronic depression 
2 chronic_psych_reason___2 Chronic anxiety 
3 chronic_psych_reason___3 Chronic psychosis 
4 chronic_psych_reason___4 PTSD 
5 chronic_psych_reason___5 Schizophrenia 
6 chronic_psych_reason___6 Other chronic 
psychiatric disease 
7 chronic_psych_reason___7 Acute exacerbation 
of a chronic 
psychiatric disease 
8 chronic_psych_reason___8 Suicidal ideation 
9 chronic_psych_reason___9 Suicide attampt 
 
42 chron_psych_other_specify 
Show the field ONLY if: 
[chronic_psych_reason(6)] = '1' 
Other, specify: text 
43 acute_psych_reason 
Show the field ONLY if: 








reason: no prior 
history of any 
psychiatric disease 
2 acute_psych_reason___2 Acute anxiety 
3 acute_psych_reason___3 Acute depression 
4 acute_psych_reason___4 Acute psychosis 
5 acute_psych_reason___5 Other acute 
psychiatric disease 
6 acute_psych_reason___6 Suicidal ideation 
7 acute_psych_reason___7 Suicide attempt 
 
44 acute_psych_other_specify 
Show the field ONLY if: 
[acute_psych_reason(5)] = '1' 
Other, specify: text 
45 gastro_type 
Show the field ONLY if: 





deemed by MD in 
ED or by definition 
of >=3 visits for 
vomiting resulting 
in a visit to a 





within 1 year. 
radio 




Show the field ONLY if: 
[gastro_type] = '0' 
Other, specify: text 
47 intoxication_type 
Show the field ONLY if: 





for the visit is due 




1 Single drug (MJ only) 
2 Alcohol and MJ 
3 Polydrug use (without alcohol) 
4 Polydrug use and alcohol 
 




49 edible Edible exposure 













edible agents. If not 
documented, filled 
in as 0 (No). 
2 Unknown 
 
50 vaporized Vaporized 
exposure 




includes terms like, 
"vape, vapor, 
electronic 
cigarette." If not 
documented, filled 















outcome as a direct 
result of work in 
the marijuana 
industry (e.g., a 
"marijuana grow" 




be found anywhere 
in the chart, that is, 
in the triage note, 





2 Not documented or unknown 
 
52 mj_occupational_visit 
Show the field ONLY if: 





outcome from an 
exposure to a 
marijuana-related 
occupation = an 
emergency 
department visit 















and could range 










to MJ pollen, injury 
from trimming 
marijuana buds or 
plants, etc. 
53 self_medicating Was patient 
self-medicating 
with the MJ 
they were noted 






54 utox_mj Urine Tox 
screen 
Other drugs listed 
in the incident 
record or in the 





synthetic drugs of 
abuse (ex: mamba), 
or any other illicit 






2 Not performed 
 
55 positive_tox_mj 
Show the field ONLY if: 
[utox_mj] = '1' 
What was the 
tox screen 
positive for and 
what other 
drugs of abuse 
were found in 
the chart? 
checkbox 
1 positive_tox_mj___1 Opioids 
2 positive_tox_mj___2 Benzodiazepines 
3 positive_tox_mj___3 THC/ marijuana 
4 positive_tox_mj___4 Barbiturates 
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5 positive_tox_mj___5 Methamphetamine/ 
amphetamines 
6 positive_tox_mj___6 Cocaine 
7 positive_tox_mj___7 Other 
 
56 alcohol_use Alcohol use 
Alcohol use 
coincident with the 






57 pregnant Pregnant 
The patient is 
currently pregnant. 
Either stated in the 
medical record or 






58 chart_review_initials Chart review 
initials 
text 




60 monte_comments Monte 
comments: 
notes 










62 dx1 Diagnosis code 
1 
text 
63 dx2 Diagnosis code 
2 
text 
64 dx3 Diagnosis code 
3 
text 
65 dx4 Diagnosis code 
4 
text 





67 dx6 Diagnosis code 
6 
text 
68 dx7 Diagnosis code 
7 
text 
69 dx8 Diagnosis code 
8 
text 
70 dx9 Diagnosis code 
9 
text 
71 dx10 Diagnosis code 
10 
text 
72 dx11 Diagnosis code 
11 
text 
73 dx12 Diagnosis code 
12 
text 
74 dx13 Diagnosis code 
13 
text 
75 dx14 Diagnosis code 
14 
text 
76 dx15 Diagnosis code 
15 
text 
77 dx16 Diagnosis code 
16 
text 
78 dx17 Diagnosis code 
17 
text 
79 dx18 Diagnosis code 
18 
text 
80 dx19 Diagnosis code 
19 
text 
81 dx20 Diagnosis code 
20 
text 
82 dx21 Diagnosis code 
21 
text 
83 dx22 Diagnosis code 
22 
text 
84 dx23 Diagnosis code 
23 
text 





86 dx25 Diagnosis code 
25 
text 
87 dx26 Diagnosis code 
26 
text 
88 dx27 Diagnosis code 
27 
text 
89 dx28 Diagnosis code 
28 
text 
90 dx29 Diagnosis code 
29 
text 
91 dx30 Diagnosis code 
30 
text 









Instrument:CPT Codes(cpt_codes)  
93 cpt1 CPT Code 1 text 
94 cpt2 CPT Code 2 text 
95 cpt3 CPT Code 3 text 
96 cpt4 CPT Code 4 text 
97 cpt5 CPT Code 5 text 
98 cpt6 CPT Code 6 text 
99 cpt7 CPT Code 7 text 
100 cpt8 CPT Code 8 text 
101 cpt9 CPT Code 9 text 
102 cpt10 CPT Code 10 text 
103 cpt11 CPT Code 11 text 
104 cpt12 CPT Code 12 text 
105 cpt13 CPT Code 13 text 
106 cpt14 CPT Code 14 text 
107 cpt15 CPT Code 15 text 
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Instrument:POA Codes(poa_codes)  
109 poa1 POA 1 text 
110 poa2 POA 2 text 
111 poa3 POA 3 text 
112 poa4 POA 4 text 
113 poa5 POA 5 text 
114 poa6 POA 6 text 
115 poa7 POA 7 text 
116 poa8 POA 8 text 
117 poa9 POA 9 text 
118 poa10 POA 10 text 
119 poa11 POA 11 text 
120 poa12 POA 12 text 
121 poa13 POA 13 text 
122 poa14 POA 14 text 
123 poa15 POA 15 text 
124 poa16 POA 16 text 
125 poa17 POA 17 text 
126 poa18 POA 18 text 
127 poa19 POA 19 text 
128 poa20 POA 20 text 
129 poa21 POA 21 text 
130 poa22 POA 22 text 
131 poa23 POA 23 text 
132 poa24 POA 24 text 
133 poa25 POA 25 text 
134 poa26 POA 26 text 
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135 poa27 POA 27 text 
136 poa28 POA 28 text 
137 poa29 POA 29 text 
138 poa30 POA 30 text 













P. TERMS EXCLUDED IN THE WORD CLOUD ANALYSIS 
A. True negatives: 
a, a1c, a&o, a&ox1, a&ox2, a&ox3, a&ox4, aaox2, aaox3, aaox4, aaron, ab, abby, about, 
above, activity, additional, after, again, against, age, ago, agree, agrees, all, also, am, an, and, 
any, are, aren't, as, assessment, associated, at, attending, attestation, back, be, because, been, 
before, being, below, between, blood, both, bp, briefly, but, by, c, can, cannot, can't, care, cdu, 
change, chem, chief, children, clinic, clinical, code, comment, comments, complete, 
components, concern, concerns, conjunction, considered, constitutional, consult, consults, 
could, couldn't, course, current, currently, d, date, day, days, ddx, decision, details, diagnosis, 
did, didn't, discussed, disease, disorder, disposition, do, documentation, documented, does, 
doesn't, doing, don't, down, dr, during, dx, e, each, ed, education, ekg, else, encounter, 
endorses, episode, episodes, evaluation, every, exam, exams, except, f, family, father, few, file, 
findings, follow, following, for, found, from, full, further, get, gets, given, got, h, h&p, had, hadn't, 
hand, has, hasn't, have, haven't, having, hc, he, health, he'd, he'll, hent, her, here, here's, hers, 
herself, he's, him, himself, his, history, home, hospital, hour, hours, how, however, how's, hpi, 
hx, i, ï, i'd, if, i'll, illness, i'm, imaging, impression, in, include, includes, information, intact, 
interpreted, into, is, isn't, it, its, it's, itself, i've, kg, known, l, labs, last, laterality, left, let's, likely, 
limited, m, main, marital, md, mdm, me, medications, meds, mine, ml, more, most, mother, 
mustn't, my, myself, n, name, narrative, need, never, new, no, non, none, nor, not, notable, 
note, noted, number, o, observation, occupational, of, off, on, once, only, onset, or, other, ought, 
our, ours, ourselves, out, over, own, p, pa, packs, past, patient, pcp, pending, per, performed, 
personally, pertinent, physical, physician, plan, please, pmh, pmhx, post, pre, precautions, 
presence, present, presentation, presenting, presents, primary, prior, problem, problems, 
procedure, provided, provider, psl, pt, pulse, qualitative, questions, r, re, recent, recommended, 
relation, reported, reports, request, resident, results, return, review, reviewed, right, s, same, 
screening, scribe, see, seen, sexual, shan't, she, she'd, she'll, she's, shift, should, shouldn't, 
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significant, signs, similar, since, single, so, soft, some, spo2, spouse, started, states, status, 
studies, such, surgery, surgical, symptoms, systems, t, taking, temp, than, that, that's, the, their, 
theirs, them, themselves, then, there, there's, these, they, they'd, they'll, they're, they've, this, 
those, through, time, to, today, too, topics, treatment, two, types, u, under, understanding, 
unknown, until, up, urine, v, value, very, visit, vitals, vs, w, was, wasn't, we, we'd, week, weeks, 
well, we'll, were, we're, weren't, we've, what, what's, when, whenever, when's, where, where's, 
whether, which, while, who, whoever, whom, whomever, who's, why, why's, will, with, within, 
without, won't, work, would, wouldn't, x, y o, year, years, yes, yesterday, yo, you, you'd, you'll, 
your, you're, yours, yourself, yourselves, you've 
 
B. False negatives 
a, a&o, a&ox3, a&ox4, aaox3, aaox4, about, above, additional, addressed, after, again, against, 
ago, agree, agrees, all, also, am, an, and, any, appearing, appears, are, aren't, as, assessment, 
associated, at, attempt, attending, attestation, available, be, because, been, before, being, 
below, better, between, blood, both, bp, briefly, but, by, c, can, cannot, can't, care, cbc, change, 
changes, chem, chief, choice, clear, clinic, clinical, code, comment, comments, complete, 
components, concern, concerns, condition, conditions, conjunction, considered, constitutional, 
consult, consults, continue, control, could, couldn't, course, ct, current, currently, d, date, day, 
days, ddx, decision, department, details, developed, diagnoses, diagnosis, did, didn't, diff, 
differential, diffuse, discussed, disease, disorder, dispo, disposition, do, documentation, 
documented, does, doesn't, doing, don't, doubt, down, dr, due, during, e, each, ecg, ed, ekg, 
else, emergency, encounter, endorses, episode, episodes, eval, evaluated, evaluation, every, 
evidence, exam, examined, exams, except, expectant, f, falsely, family, feeling, feels, few, file, 
findings, follow, following, for, found, from, full, fully, further, get, gets, given, got, h, h&p, had, 
hadn't, has, hasn't, have, haven't, having, hc, he, health, he'd, he'll, help, her, here, here's, hers, 
herself, he's, him, himself, his, history, hold, home, hospital, hours, how, however, how's, hpi, 
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hx, i, ï, i'd, if, i'll, illness, i'm, imaging, impression, improved, in, include, includes, including, 
information, initial, injection, interpreted, into, is, isn't, it, its, it's, itself, i've, k, kg, l, labs, last, lb, 
left, let's, level, like, likely, limited, limits, lipase, long, loss, low, m, may, md, mdm, me, medical, 
medication, medications, mine, ml, months, more, morning, most, mother, multiple, mustn't, my, 
myself, n, need, needed, never, new, no, non, none, nor, not, notable, note, noted, now, o, 
observation, observed, obtained, of, off, on, once, one, only, onset, op, optimize, or, orders, 
other, otherwise, ought, our, ours, ourselves, out, outpatient, over, own, p, panel, past, patient, 
patient's, pcp, pending, per, performed, personally, pertinent, physical, physician, placed, 
placement, plan, please, pmh, pmhx, po, poct, possible, post, pre, precautions, presence, 
present, presentation, presented, presenting, presents, previous, primary, prior, prn, problem, 
procedure, procedures, prognosis, provided, provider, psl, pt, pulse, questions, r, rad, rate, re, 
recent, recently, recommended, records, related, reported, reports, resident, result, results, 
return, review, reviewed, right, s, same, sanitary, screen, screening, scribe, scribing, see, seen, 
self, services, setting, several, shan't, she, she'd, she'll, she's, shift, should, shouldn't, signed, 
significant, signs, similar, since, so, soft, some, specialist, spo2, stable, staff, states, status, 
studies, such, surgical, suspect, sx, symptoms, syndrome, systems, take, taking, temp, term, 
testing, than, that, that's, the, their, theirs, them, themselves, then, therapeutic, there, there's, 
these, they, they'd, they'll, they're, they've, this, those, through, time, times, to, today, too, 
topics, treatment, ttp, u, under, understanding, until, up, urine, v, value, verbalized, very, visit, 
vital, vitals, vs, w, was, washed, wasn't, we, we'd, week, weeks, well, we'll, were, we're, weren't, 
we've, what, what's, when, whenever, when's, where, where's, whether, which, while, who, 
whoever, whom, whomever, who's, why, why's, will, with, within, without, wnl, won't, work, 
would, wouldn't, wt, x, y, year, years, yes, yesterday, yo, you, you'd, you'll, your, you're, yours, 
yourself, yourselves, you've  
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Q. POWER SIMULATIONS FOR NEGATIVE PREDICTIVE VALUES CALCULATIONS 
Power for O3.1: In 2014, there were 96,688 (98.7%) ED visits without a marijuana ICD-9-CM 
code. Therefore, we would expect 97,000 ED visits without marijuana specific ICD-10-CM codes 
from January 1, 2016 to December 31, 2016. In this sample we will be able to detect NPVs for 
the absence of marijuana codes as high as 99% and as low as 0.02% with 95% confidence, 80% 
power, at a 90% prevalence of no marijuana codes, and with sensitivities and specificities as low 











































• 29 duplicated records removed 
 
No cannabis text string or 
cannabis codes  
N=85,632 (%) 
12,619 discharged outside 2016 
1,225 without discharge codes 
8 Double reviewed, records will less 








UCH ED visits with reviews (N=112,365) 








No recent cannabis 
use 
N=7,623 (%) 
Records with cannabis use or positive urine drug screen 
N=2,738 (%) 
Cannabis text string 





Cannabis code and text string 
N= 1,044 (%) 
 
Cannabis text string, NO code 
N=10,361 (%) 
 
Records to be reviewed for false negatives 
N=2,236 (%) 
Cannabis code only 
N= 1,484 (%) 
 
Reviewed for Cannabis Attribution 
ED visits (2012-2017) 
N=15,039 
N=502 
No cannabis text string or 
cannabis codes  
N=93,255 (%) 
Assumed true negatives 
N=93,757 (%) 
All UCH ED visits (from~2016) 
N=99,995 
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